Entomopoxvirus expression system

ABSTRACT

The subject invention pertains to novel Entomopoxvirus (EPV) polynucleotide sequences free from association with other viral sequences with which they are naturally associated, recombinant polynucleotide vectors containing the sequences, recombinant viruses containing the sequences, and host cells infected with the recombinant viruses are provided herein, as well as methods for use thereof in the expression of heterologous proteins in both insect and mammalian host cells.

This invention was made with Government support under Grant No. R01 AI15722-12 awarded by the National Institutes of Health and NIH Training Grant T32 AI-07110. The Government has certain rights in this invention.

CROSS-REFERENCE TO A RELATED APPLICATION

This application is a continuation-in-part of application Ser. No. 08/107,755, filed Nov. 22, 1993, now U.S. Pat. No. 5,721,352, which was the national stage of PCT application Ser. No. PCT/US92/00855, filed Feb. 12, 1992. This application is also a continuation-in-part of application Ser. No. 07/991,867, filed Dec. 07, 1992, now U.S. Pat. No. 5,476,781, which was a continuation-in-part of PCT application PCT/US92/00855, filed Feb. 12, 1992, which is a continuation-in-part of U.S. application Ser. No. 07/827,685, filed Jan. 30, 1992, now abandoned which is a continuation-in-part of U.S. application Ser. No. 07/657,584, filed Feb. 19, 1991, now abandoned.

FIELD OF THE INVENTION

This invention relates generally to the field of recombinantly-produced proteins and specifically to novel, recombinant Entomopoxvirus genes, proteins, protein regulatory sequences and their uses in expressing heterologous genes in transformed hosts.

BACKGROUND OF THE INVENTION

Poxviruses are taxonomically classified into the family Chordopoxvirinae, whose members infect vertebrate hosts, e.g., the Orthopoxvirus vaccinia, or into the family Entomopoxvirinae. Very little is known about members of the Entomopoxvirinae family other than the insect host range of individual members. One species of Entomopoxvirus (EPV) is the Amsacta moorei Entomopoxvirus (AmEPV), which was first isolated from larvae of the red hairy caterpillar Amsacta moorei (Roberts and Granados 1968! J. Invertebr. Pathol. 12:141-143). AmEPV is the type species of genus B of EPVs and is one of three known EPVs which will replicate in cultured insect cells (R. R. Granados et al. 1976! "Replication of Amsacta moorei Entomopoxvirus and Autographa califomica Nuclear Polyhedrosis Virus in Hemocyte Cell Lines from Estigmene acrea," in Invertebrate Tissue Culture Applications in Medicine, Biology, and Agriculture, E. Kurstak and K. Maramorosch (ed.), Academic Press, New York, pp. 379-389; T. Hukuhara et al. 1990! J. Invertebr. Pathol. 56:222-232; and Sato, T. 1989! "Establishment of Eight Cell Lines from Neonate Larvae of Torticids (Lepidoptera), and Their Several Characteristics Including Susceptibility to Insect Viruses," in Invertebrate Cell Systems Applications, J. Mitsuhashi (ed.), Vol. II, CRC Press, Inc., Boca Raton, Florida, pp. 187-198).

AmEPV is one of the few insect poxviruses which can replicate in insect cell culture; AmEPV is unable to replicate in vertebrate cell lines. The AmEPV doublestranded DNA genome is about 225 kb and is unusually A+T rich (18.5% G+C) (W. Langridge, H. R., et al. 1977! Virology 76:616-620). Recently, a series of restriction maps for AmEPV were published (Hall, R. L., et al. 1990! Arch. Virol. 110:77-90). No DNA homology to vaccinia has been detected (Langridge, W. H. 1983! J. Invertebr. Pathol. 42:77-82; Langridge, W. H. 1984! J. Invertebr. Pathol. 43:41-46).

The viral replication cycle of AmEPV resembles that of other poxviruses except for the appearance of occluded virus late in infection. For AmEPV, once a cell is infected, both occluded and extracellular virus particles are generated. The mature occlusion body particle, which is responsible for environmentally protecting the virion during infection, consists of virus embedded within a crystalline matrix consisting primarily of a single protein, spheroidin. Spheroidin, the major structural protein of AmEPV, has been reported to be 110 kDa in molecular weight and to consist of a high percentage of charged and sulfur-containing amino acids (Langridge and Roberts 1982! J. Invertebr. Pathol. 39:346-353).

Another insect virus is the baculovirus. Like baculoviruses, a characteristic feature of entomopoxviruses is the amalgamation of virions within environmentally stable occlusion bodies. It is this occluded form of the virus that is primarily responsible for dissemination to other insects. While the major protein (polyhedrin) of baculovirus occlusions is quite similar between viruses, it has been reported that the major occlusion body protein (spheroidin) of two group B entomopoxviruses, Amsacta moorei (AmEPV) and Choristoneura biennis (CbEPV) is quite different both in terms of amino acid sequence and coding capacity of the corresponding spheroidin genes (115 and 47 kDa for AmEPV and CbEPV, respectively).

The entomopoxviruses and the role of occlusion bodies have recently been reviewed by Arif and Kurstak (Arif, B. M., E. Kurstak, E. 1991! "The entomopoxviruses," In Viruses of Invertebrates (E. Kurstak, Ed.), pp. 179-195, Marcel Dekker, Inc., New York) and Goodwin et al. (Goodwin, R. H., R. J. Milner, C. D. Beaton 1991! "Entomopoxvirinae," In Atlas of Invertebrate Viruses (J. R. Adams and J. R. Bonami, Eds.), pp. 259-285, CRC Press, Inc., Boca Raton ). The gene which encodes the AmEPV spheroidin, a 115 kDa protein, has been identified and sequenced (Hall, R. L., R. W. Moyer 1991! J. Virol. 65, 6516-6527; Banville, M., F. Dumas, F., S. Trifiro, B. Arif, C. Richardson 1992! J. Gen. Virol. 73, 559-566). The AmEPV gene was also mapped and found to be located at the 3' end of a nucleoside triphosphate phosphohydrolase gene (NPH I or NTPase I, Hall and Moyer 1991!, supra). The spheroidin gene of Choristoneura biennis entomopoxvirus (CbEPV) has been reported to be derived from a gene capable of encoding a 47 kDa protein (Yuen, L., J. Dionne, B. Arif, C. Richardson 1990! Virology 175:427-433.). A comparison of the sequence of the two spheroidins shows no relationship between the two encoded proteins.

We have investigated the spheroidin genes of Choristoneura biennis, Choristoneura fumiferana, and Amsacta moorei viruses. Our results indicate, in contrast to published results, that the initial Choristoneura EPV spheroidin assignment is likely incorrect and that the Choristoneura spheroidin is instead a highly conserved homolog of the AmEPV spheroidin.

The use of viruses and virus proteins in eukaryotic host-vector systems has been the subject of a considerable amount of investigation and speculation. Many existing viral vector systems suffer from significant disadvantages and limitations which diminish their utility. For example, a number of eukaryotic viral vectors are either tumorigenic or oncogenic in mammalian systems, creating the potential for serious health and safety problems associated with resultant gene products and accidental infections. Further, in some eukaryotic host-viral vector systems, the gene product itself exhibits antiviral activity, thereby decreasing the yield of that protein.

In the case of simple viruses, the amount of exogenous DNA which can be packaged into a simple virus is limited. This limitation becomes a particularly acute problem when the genes used are eukaryotic. Because eukaryotic genes usually contain intervening sequences, they are too large to fit into simple viruses. Further, because they have many restriction sites, it is more difficult to insert exogenous DNA into complex viruses at specific locations.

Vaccinia virus has recently been developed as an eukaryotic cloning and expression vector (Mackett, M., et al. 1985! DNA Cloning, Vol. II, ed. D. M. Glover, Oxford: IRL Press, pp. 191-212; Panicali, D., et al. 1982! Proc. Natl. Acad. Sci. USA, 88:5364-5368). Numerous viral antigens have been expressed using vaccinia virus vectors (Paoletti, E., et al. 1984! Proc. Natl. Acad. Sci. USA 81:193-197; Piccine, A., et al. 1986! BioEssays 5:248-252) including, among others, HBsAg, rabies G protein and the gp120/gp41 of human immunodeficiency virus (HIV). Regulatory sequences from the spruce budworm EPV have been used previously with vaccinia (Yuen, L., et al. 1990! Virology 175:427-433).

Additionally, studies with vaccinia virus have demonstrated that poxviruses have several advantageous features as vaccine vectors. These include the ability of poxvirus-based vaccines to stimulate both cell-mediated and humoral immunity, minimal cost to mass produce vaccine and the stability of the lyophilized vaccine without refrigeration, ease of administration under non-sterile conditions, and the ability to insert at least 25,000 base pairs of foreign DNA into an infectious recombinant, thereby permitting the simultaneous expression of many antigens from one recombinant.

There exists a need in the art for additional viral compositions and methods for use in expressing heterologous genes in selected host cells, and in performing other research and production techniques associated therewith. In addition, it is noted that the host range of entomopoxviruses is restricted to specific insect hosts which differ from the host range of the baculovirus. Thus, for environmental control of certain pests provision of recombinant entomopoxviruses is desirable.

BRIEF SUMMARY OF THE INVENTION

This invention pertains to novel vectors useful for producing proteins via the expression of an heterologous gene in a novel expression system. More particularly, this invention relates to methods for incorporating a selected heterologous gene (also referred to as exogenous DNA) into a poxvirus genome to produce a recombinant expression vector capable of expression of the selected gene in a host cell.

The expression systems described herein utilize novel structural and/or regulatory DNA elements from Entomopoxvirus genomes. For example, according to the subject invention, the entomopoxvirus spheroidin gene and/or the thymidine kinase gene can be used as the location for the insertion of exogenous DNA. These Entomopoxvirus genes have been discovered to be attractive sites for insertion of heterologous genes because it is possible to transfer the strongly expressed spheroidin gene, or the thymidine kinase gene, as an expression cassette, not only in insect cells, but for use in vertebrate poxviruses such as vaccinia and swinepox virus.

Another aspect of the subject invention pertains to the use of the entomopoxvirus spheroidin or thymidine kinase gene regulatory sequences in other virus vector systems to enhance the performance of those systems. Thus, the subject invention further pertains to the use of regulatory elements from entomopoxvirus to construct novel chimeric vaccines and expression systems which are functional across genera of mammalian poxviruses.

As one aspect, the invention provides novel Entomopoxvirus polynucleotide sequences, free from other viral sequences with which the Entomopoxvirus sequences are associated in nature. Specifically, the subject invention provides nucleotide sequences of Entomopoxvirus spheroidin and thymidine kinase genes, including flanking sequences and regulatory sequences. In particular embodiments, the spheroidin DNA sequence is that which occurs in the Choristoneura biennis, Choristoneura fumiferana, or Amsacta moorei Entomopoxviruses. Also specifically exemplified is the Amsacta moorei Entomopoxvirus thymidine kinase nucleotide sequence. As explained more fully herein, fragments and variants of the exemplified sequences are within the scope of the subject invention. Fragments and variants can be any sequence having substantial homology with the exemplified sequences so long as the fragment or variant retains the utility of the exemplified sequence. One specific type of variant pertains to spheroidin or tk genes from Entomopoxviruses other than those specifically exemplified herein. As described herein, for example, the current inventors have discovered that the spheroidin genes are highly conserved among different species of Entomopoxvirus. Specifically exemplified herein are three different Entomopoxviruse spheroidin genes having a high degree of homology. Other such spheroidin variants or tk variants from other Entomopoxviruses could be readily located and used by the ordinarily skilled artisan having the benefit of the subject application.

As another aspect, the present invention provides recombinant polynucleotide sequences comprising a sequence encoding an Entomopoxvirus spheroidin protein and/or its regulatory sequences, or a variant or fragment of the spheroidin sequence, linked to a second polynucleotide sequence encoding a heterologous gene. One embodiment of such a polynucleotide sequence provides a spheroidin promoter sequence operably linked to a heterologous gene to direct the expression of the heterologous gene in a selected host cell. Another embodiment provides a sequence encoding a spheroidin protein linked to the heterologous gene in a manner permitting expression of a fusion protein. Still another embodiment provides the heterologous gene inserted into a site in a spheroidin gene so that the heterologous gene is flanked on both termini by spheroidin sequences.

Yet a further aspect of the invention provides a recombinant polynucleotide sequence encoding an Entomopoxvirus tk gene and/or its regulatory sequences, or a variant or fragment thereof, linked to a second polynucleotide sequence encoding a heterologous gene. One embodiment of this polynucleotide sequence provides the tk promoter sequence operably linked to the heterologous gene to direct the expression of the heterologous gene in a selected host cell. Another embodiment provides the sequence encoding the tk protein linked to the heterologous gene in a manner permitting expression of a fusion protein. Still another embodiment provides the heterologous gene inserted into a site in the tk gene so that the heterologous gene is flanked on both termini by tk sequences.

Another aspect of the invention pertains to Entomopoxvirus spheroidin polypeptides, fragments thereof, or analogs thereof, optionally fused to a heterologous protein or peptide. Also provided is an Entomopoxvirus tk polypeptide, fragments thereof, or analogs thereof, optionally linked to a heterologous protein or peptide.

Yet another aspect of the invention is provided by recombinant polynucleotide molecules which comprise one or more of the polynucleotide sequences described above. This molecule may be an expression vector or shuttle vector. The molecule may also contain viral sequences originating from a virus other than the Entomopoxvirus which contributed a spheroidin or tk polynucleotide sequence, e.g., vaccinia.

In another aspect, the present invention provides a recombinant virus comprising a polynucleotide sequence as described above. Also provided are host cells infected with one or more of the described recombinant viruses.

The present invention also provides a method for producing a selected polypeptide comprising culturing a selected host cell infected with a recombinant virus, as described above, and recovering said polypeptide from the culture medium.

In another aspect, the invention provides a method for screening recombinant host cells for insertion of heterologous genes comprising infecting the cells with a recombinant virus containing a polynucleotide molecule comprising the selected heterologous gene sequence linked to an incomplete spheroidin or tk polynucleotide sequence or inserted into and interrupting the coding sequences thereof so that the heterologous gene is flanked at each termini by an Entomopoxvirus spheroidin or tk polynucleotide sequence. The absence of occlusion bodies formed by the expression of a spheroidin protein in the spheroidin-containing cell indicates the integration of the heterologous gene. Alternatively, the absence of the thymidine kinase function, i.e., resistance to methotrexate or a nucleotide analogue of methotrexate, formed by the integration of the inactive thymidine kinase sequence indicates the insertion of the heterologous gene.

In another aspect, the invention provides a shuttle vector system that facilitates expression of heterologous genes in insect or mammalian cells.

Other aspects and advantages of the present invention are described further in the following detailed description of embodiments of the present invention.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO. 1 is the DNA sequence of the Amsacta moorei Entomopoxvirus spheroidin gene and flanking sequences.

SEQ ID NO. 2 is the amino acid sequence encoded by the G1L ORF.

SEQ ID NO. 3 is the amino acid sequence encoded by the G2R ORF.

SEQ ID NO. 4 is the amino acid sequence encoded by the G3L ORF.

SEQ ID NO. 5 is the amino acid sequence encoded by the G4R ORF.

SEQ ID NO. 6 is the deduced amino acid sequence of the spheroidin protein.

SEQ ID NO. 7 is the amino acid sequence encoded by the G6L ORF.

SEQ ID NO. 8 is the DNA sequence of the Amsacta moorei Entomopoxvirus thymidine kinase (tk) gene and flanking sequences.

SEQ ID NO. 9 is a small peptide of 66 amino acids potentially encoded by ORF Q1.

SEQ ID NO. 10 is the amino acid sequence encoded by the Q3 ORF.

SEQ ID NO. 11 is the deduced amino acid sequence of the tk protein.

SEQ ID NO. 12 is the synthetic oligonucleotide designated RM58.

SEQ ID NO. 13 is the synthetic oligonucleotide designated RM82.

SEQ ID NO. 14 is the synthetic oligonucleotide designated RM83.

SEQ ID NO. 15 is the synthetic oligonucleotide designated RM92.

SEQ ID NO. 16 is the synthetic oligonucleotide designated RM118.

SEQ ID NO. 17 is the synthetic oligonucleotide designated RM165.

SEQ ID NO. 18 is the synthetic oligonucleotide designated RM03.

SEQ ID NO. 19 is the synthetic oligonucleotide designated RM04.

SEQ ID NO. 20 is the synthetic oligonucleotide designated RM129.

SEQ ID NO. 21 is the spheroidin gene coding sequence spanning nucleotides #3080 through #6091 of SEQ ID NO. 1.

SEQ ID NO. 22 is a fragment of the spheroidin gene spanning nucleotides #2781 through 3191 of SEQ ID NO. 1 which is likely to contain the promoter sequence.

SEQ ID NO. 23 is the G2R ORF.

SEQ ID NO. 24 is the G4R ORF.

SEQ ID NO. 25 is the G1L ORF.

SEQ ID NO. 26 is the G3L ORF.

SEQ ID NO. 27 is the G6L ORF.

SEQ ID NO. 28 is the tk gene coding sequence spanning nucleotides #234 through #782 of SEQ ID NO. 8. SEQ II) NO. 29 is a fragment of the tk gene spanning nucleotides #783 through #851 of SEQ ID NO. 8.

SEQ ID NO. 30 is a fragment spanning nucleotides #750 through #890 of

SEQ ID NO. 8 which is likely to contain the promoter sequence.

SEQ ID NO. 31 is the Q1 ORF.

SEQ ID NO. 32 is the Q3 OFR.

SEQ ID NO. 33 is a fragment included within the sequence spanning nucleotides #2274 through #6182 of SEQ ID NO. 1 containing the entire spheroidin open reading frame and some flanking sequences.

SEQ ID NO. 34 is a polypeptide cleavage product according to the subject invention.

SEQ ID NO. 35 is a polypeptide cleavage product according to the subject invention.

SEQ ID NO. 36 is a polypeptide cleavage product according to the subject invention.

SEQ ID NO. 37 is the peptide sequence encoded by the RM58 probe.

SEQ ID NO. 38 is a nucleotide fragment spanning nucleotides #4883 through #4957 of SEQ ID NO. 1.

SEQ ID NO. 39 is a nucleotide fragment spanning nucleotides #3962 through #4012 of SEQ ID NO. 1.

SEQ ID NO. 40 is a nucleotide fragment spanning nucleotides #4628 through #4651 of SEQ ID NO. 1.

SEQ ID NO. 41 is the AmEPV NPHI nucleotide sequence shown in FIG. 7.

SEQ ID NO. 42 is the AmEPV NPHI amino acid sequence from FIG. 7. This sequence is in the order opposite that shown in the Figure.

SEQ ID NO. 43 is the CbEPV nucleotide sequence shown in part A of FIG. 6.

SEQ ID NO. 44 is the CbEPV amino acid sequence shown in part B of FIG. 6.

SEQ ID NO. 45 is the CfEPV nucleotide sequence shown in part A of FIG. 6.

SEQ ID NO. 46 is the CfEPV amino acid sequence shown in part B of FIG. 6.

SEQ ID NO. 47 is the CbEPV amino acid sequence corresponding to amino acids 211 to 221 of AmEPV.

SEQ ID NO. 48 is the CbEPV amino acid sequence corresponding to amino acids 682 to 691 of AmEPV.

SEQ ID NO. 49 is the CbEPV amino acid sequence corresponding to amino acids 726-736 of AmEPV.

SEQ ID NO. 50 is the sequence of RM206.

SEQ ID NO. 51 is the sequence of RM212.

SEQ ID NO. 52 is the sequence of RM58.

SEQ ID NO. 53 is the sequence of RM75.

SEQ ID NO. 54 is the sequence of RM76.

SEQ ID NO. 55 is the sequence of RM78.

SEQ ID NO. 56 is the sequence of RM79.

SEQ ID NO. 57 is the sequence of RM82.

SEQ ID NO. 58 is the sequence of RM83.

SEQ ID NO. 59 is the sequence of RM87.

SEQ ID NO. 60 is the sequence of RM91.

SEQ ID NO. 61 is the sequence of RM92.

SEQ ID NO. 62 is the sequence of RM93.

SEQ ID NO. 63 is the sequence of RM95.

SEQ ID NO. 64 is the sequence of RM118.

SEQ ID NO. 65 is the sequence of RM169.

SEQ ID NO. 66 is the sequence of RM170.

SEQ ID NO. 67 is the sequence of RM282.

SEQ ID NO. 68 is the sequence of RM283.

SEQ ID NO. 69 is the sequence of pTk1.

SEQ ID NO. 70 is the sequence of pTk2.

SEQ ID NO. 71 is the sequence of pTk3.

SEQ ID NO. 72 is the sequence of pTk4.

SEQ ID NO. 73 is the sequence of pU.

SEQ ID NO. 74 is the sequence of pU2.

SEQ ID NO. 75 is the sequence of pU20.

SEQ ID NO. 76 is the sequence of PD1.

SEQ ID NO. 77 is the sequence of PD2.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a physical map of AmEPV illustrating restriction fragments thereof and showing the spheroidin gene just to the right of site #29 in the HindIII-G fragment.

FIGS. 2A-2P provide the AmEPV DNA sequence of the Amsacta moorei Entomopoxvirus spheroidin gene and flanking sequences (SEQ ID NO. 1), the deduced amino acid sequences of the spheroidin protein (SEQ ID NO. 6), and five additional open reading frames (ORFs). The complete sequence of the G6 ORF is not shown in this figure but is provided in SEQ ID NO. 1.

FIGS. 3A-3D provide the DNA sequence of the Amsacta moorei Entomopoxvirus thymidine kinase (tk) gene and flanking sequences (SEQ ID NO. 8), the deduced amino acid sequences of the tk protein (SEQ ID NO. 11), and two additional ORFs.

FIG. 4 is a schematic map of an AmEPV fragment illustrating the orientation of the spheroidin ORF on the physical map and indicating homologies.

FIG. 5 shows the location of the AmEPV spheroidin specific oligonucleotide primers used in PCR to identify an AmEPV spheroidin-like gene in Choristoneura EPV DNAs. The arrowheads over the numbers in the diagram represent oligonucleotide primers. The arrowhead base shows the approximate starting point of the primer, and the 5' to 3' direction is shown by the direction of the arrowhead. Primers from the upper line were paired with various primers from the lower line as shown in Table 2 for PCR reactions. The sequences of the primers are shown in Table 2.

FIGS. 6A, 6B and 6C show sequences of corresponding regions of the spheroidin-like gene of CbEPV and CfEPV and the spheroidin of AmEPV. FIG. 6A shows the AmEPV spheroidin sequence and PCR product sequences derived from CbEPV and CfEPV DNA using RM58 as the sequencing primer for the 1 kb PCR products resulting from the AmEPV spheroidin specific primer pair RM58-RM118 (Table 2) and either CbEPV or CfEPV DNA. The alignment of the Choristoneura EPV sequences with bases 4044-4278 of AmEPV spheroidin is shown. The predicted amino acid sequences from the sequences shown in FIG. 6A are shown in FIG. 6B. Identity is shown by vertical lines and two degrees of conserved changes are indicated by periods and colons. FIG. 6C shows CbEPV spheroidin amino acid sequences derived from protein microsequencing of 3 lys-c endoprotease fragments. Corresponding AmEPV spheroidin sequence and amino acid position numbers are shown.

FIGS. 7A and 7B shows the sequence of the 5' end of the AmEPV NPH I gene including the deduced amino acids. The base numbers represent the extension of the sequence shown in FIG. 2, which includes the partial AmEPV NPH I (NTPase I) gene. The sequence in FIG. 1 ends at base 6768. The base numbers correspond to those in FIG. 8.

FIG. 8 shows the spheroidin and NPH I gene orientations in AmEPV, and the locations of primers used in PCR reactions. The arrowheads over the numbers in the figure represent oligonucleotide primers. The arrowhead base shows the approximate starting point of the oligo and 5' to 3' is shown by the direction of the arrowhead. RM83 and RM161 are AmEPV spheroidin specific primers. Primer RM212 is from the 3' end of the CbEPV NPH I gene and RM206 is just downstream of the CbEPV NPH I gene but within the published CbEPV sequence (Yuen et al. 1991!, supra).

FIG. 9 shows the scheme for providing pYLATILacZ.

FIG. 10 shows the Southern blot of EcoRI digested AmEPV recombinant.

FIG. 11 shows the experiment to further characterize entomopxovirus spheroidin promoter.

FIG. 12 shows the bi-functional vector for making other recombinant entomopoxvirus or vaccinia virus constructs.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel Entomopoxvirus (EPV) polynucleotide sequences free from association with other viral sequences with which they are naturally associated. Recombinant polynucleotide vectors comprising the sequences, recombinant viruses comprising the sequences, and host cells infected with the recombinant viruses are also disclosed herein. These compositions are useful in methods of the invention for the expression of heterologous genes and production of selected proteins in both insect and mammalian host cells.

Novel polynucleotide sequences of the invention encode EPV spheroidin genes and/or flanking sequences, including sequences which provide regulatory signals for the expression of the gene. The invention also provides novel polynucleotide sequences encoding an EPV thymidine kinase (tk) gene and/or its flanking sequences. The polynucleotide sequences of this invention may be either RNA or DNA sequences. More preferably, the polynucleotide sequences of this invention are DNA sequences.

Specifically disclosed by the present invention are spheroidin polynucleotide sequences obtainable from the Amsacta moorei Entomopoxvirus (AmEPV), Choristoneura biennis Entomopoxvirus (CbEPV), and Choristoneura fumiferana Entomopoxvirus (CfEPV). Also specifically exemplified is a tk polynucleotide sequence obtained from AmEPV. While these species are exemplified for practice of the methods and compositions of this invention, utilizing the techniques described herein, substantially homologous sequences may be obtained by one of ordinary skill in the art from other Entomopoxvirus species.

The AmEPV spheroidin DNA sequence, including flanking and regulatory sequences, is reported in FIG. 2 as spanning nucleotides #1 through 6768 (SEQ ID NO. 1). Within this sequence, the spheroidin gene coding sequence spans nucleotides #3080 through #6091 (SEQ ID NO. 21). A fragment which contains the promoter sequences spans nucleotides #2781 through #3199 (SEQ ID NO. 22). More specifically, we show herein that the spheroidin promoter extends beyond the ATG translational start codon and that the promoter is a powerful transcriptional initiator of foreign gene expression. Other regions of that sequence have also been identified as putative coding regions for other structural or regulatory genes associated with spheroidin. These other fragments of interest include the following sequences: the G2R ORF, which is nucleotides #1472 through #2151 (SEQ ID NO. 23) encoding the amino acid sequence shown in SEQ ID NO. 3; the G4 ORF, which is nucleotides #2502 through #2987 (SEQ ID NO. 24) encoding the amino acid sequence shown in SEQ ID NO. 5; and the following sequences transcribed left to right on FIGS. 2A-2P: the G1L ORF, which is nucleotides #65 through #1459 (SEQ ID NO. 25) encoding the amino acid sequence shown in SEQ ID NO. 2; the G3L ORF, which is nucleotides #2239 through #2475 (SEQ ID NO. 26) encoding the amino acid sequence shown in SEQ ID NO. 4; and the G6 ORF, which includes nucleotides #6277 through #6768 (SEQ ID NO. 27) encoding the amino acid sequence shown in SEQ ID NO. 7. These ORFs are identified in FIGS. 2A-2P. It should be noted that the full length of the G6 ORF extends beyond nucleotide #6768, is shown in SEQ ID NO. 1 and FIGS. 7A and 7B, and is discussed more fully below.

The AmEPV ORF G4R (SEQ ID NO. 24) which encodes G4R (SEQ ID NO. 5) is immediately upstream of the spheroidin gene has significant homology to the capripoxvirus HM3 ORF. A homolog of the HM3 ORF is found in vaccinia virus just upstream of a truncated version of the cowpox virus ATI gene. Therefore, the microenvironments in this region are similar in the two viruses. Two other ORFs relate to counterparts in vaccinia virus. These ORFs include the I7 ORF of the vaccinia virus HindIII-I fragment (17) (Schmitt, J. F. C., et al. 1988! J. Virol. 62:1889-1897) which relates to the AmEPV G1L ORF (SEQ ID NO. 25) and the NTPase I (NPH I) ORF of the HindIII-D fragment which relates to the AmEPV G6L ORF (SEQ ID NO. 27) (Broyles, S. S., et al. 1987! J. Virol. 61:1738-1742; and Rodriguez, J. F., et al. 1986! Proc. Nall. Acad. Sci. USA 83:9566-9570). The genomic location of the AmEPV ORFs compared with that of the vaccinia virus ORFs suggests that the arrangement of essential "core genes," which are centrally located and colinear in many, if not all, of the vertebrate poxviruses on a more macroscopic scale, is quite different in the insect virus.

As set out in detail in the accompanying examples below, the spheroidin gene of AmEPV was identified through direct microsequencing of the protein, and the results were used for the design of oligonucleotide probes. Transcription of the spheroidin gene is inhibited by cycloheximide, suggesting it is a late gene. Consistent with this prediction are the observations that spheroidin transcripts were initiated within a TAAATG motif (See FIGS. 2A-2P, nucleotide #3077-3082) and that there is a 5' poly(A) sequence, both characteristic of late transcripts.

The isolation and sequencing of the CbEPV and CfEPV spheroidin genes are also described in detail below.

The AmEPV thymidine kinase (tk) DNA sequence, including flanking and regulatory sequences, is reported in FIGS. 3A-3D, as spanning nucleotides #1 through #1511 (SEQ ID NO. 8). Within this sequence, the tk gene coding sequence spans nucleotides #234 through #782 (SEQ ID NO. 28) (transcribed right to left on FIGS. 3A-3D). Another fragment of interest may include nucleotides #783 through #851 (SEQ ID NO. 29) of that sequence or fragments thereof. A fragment likely to contain the promoter regions spans nucleotides #750 through #890 (SEQ ID NO. 30). Other regions of that sequence have also been identified as putative coding regions for other structural or regulatory genes associated with tk. These other fragments of interest include the following sequences (transcribed left to right on FIGS. 3A-3D: ORF Ql, which is nucleotides #18 through #218 (SEQ ID NO. 31) encoding the amino acid sequence shown in SEQ ID NO. 10); and ORF Q3, which is nucleotides #852 through #1511 (SEQ ID NO. 32) encoding the amino acid sequence shown in SEQ ID NO. 10.

The location of the AmEPV tk gene maps in the EcoRI-Q fragment near the left end of the physical map of the AmEPV genome (FIG. 1) (see also, Hall, R. L., et al. 1990! Arch. Virol. 110:77-90, incorporated herein by reference). Because of the orientation of the gene within the AmEPV genome, transcription of the gene is likely to occur toward the terminus. There are believed to be similar tk genes, or variations thereof, in other systems, including mammalian systems. As set out in detail in the examples below, the tk gene of AmEPV was identified through direct microsequencing of the protein, and the results were used for the design of oligonucleotide probes.

The term "polynucleotide sequences" when used with reference to the invention can include the entire EPV spheroidin or tk genes with regulatory sequences flanking the coding sequences. The illustrated AmEPV sequences are also encompassed by that term. Also included in the definition are fragments of the coding sequences with flanking regulatory sequences. The definition also encompasses the regulatory sequences only, e.g., the promoter sequences, transcription sites, termination sequences, and other regulatory sequences.

Sequences of the invention may also include all or portions of the spheroidin or tk genes linked in frame to a heterologous gene sequence. Additionally, polynucleotide sequences of the invention may include sequences of the spheroidin or tk genes into which have been inserted a foreign or heterologous gene sequence, so that the EPV sequences flank the heterologous gene sequence.

Polynucleotide sequences of this invention also include sequences which are capable of hybridizing to the sequences of FIGS. 2A-2P and 3A-3D, under stringent conditions. Also sequences capable of hybridizing to the sequences of FIGS. 2A-2P and 3A-3D under non stringent conditions may fall within this definition providing that the biological or regulatory characteristics of the sequences of FIGS. 2A-2P and 3A-3D, respectively, are retained. Examples of stringent and non-stringent conditions of hybridization are conventional (see, e.g., Sambrook et al. 1989! Molecular Cloning. A Laboratory Manual, 2d edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

Similarly, polynucleotide sequences of this invention also include variants, including allelic variations (naturally-occurring base changes in the EPV species population which may or may not result in an amino acid change) of DNA sequences encoding the spheroidin or tk protein sequences or other ORFs or regulatory sequences illustrated in FIGS. 2A-2P and 3A-3D. Similarly, DNA sequences which encode spheroidin or tk proteins of the invention but which differ in codon sequence due to the degeneracies of the genetic code or variations in the DNA sequences which are caused by point mutations or by induced modifications to, for example, enhance a biological property or the usefulness of a desired polynucleotide sequence encoded thereby are also encompassed in the invention.

Utilizing the sequence data in FIGS. 2A-2P or 3A-3D, as well as the denoted characteristics of spheroidin or thymidine kinase, it is within the skill of the art to obtain other DNA sequences encoding these polypeptides. For example, the structural gene may be manipulated by varying individual nucleotides, while retaining the same amino acid(s), or varying the nucleotides, so as to modify the amino acids, without loss of utility. Nucleotides may be substituted, inserted, or deleted by known techniques, including, for example, in vitro mutagenesis and primer repair.

The structural gene may be truncated at its 3-terninus and/or its terminus. It may also be desirable to ligate a portion of the polypeptide sequence to a heterologous coding sequence, and thus to create a fusion peptide.

The polynucleotide sequences of the present invention may be prepared by a variety of techniques well known to those skilled in the art. The sequences may be prepared synthetically or can be derived from viral RNA or from available cDNA-containing plasmids by chemical and genetic engineering techniques or combinations thereof which are standard in the art.

The Entomopoxvirus proteins-spheroidin, thymidine kinase and their respective regulatory sequences, as described herein-may be encoded by polynucleotide sequences that differ in sequence from the sequences of FIGS. 2A-2P and 3A-3D due to, for example, natural allelic or species variations. Thus, the terms spheroidin or tk polypeptides also refer to any of the naturally occurring sequences and various analogs, e.g., processed or truncated sequences or fragments, including the mature spheroidin or tk polypeptides and mutant or modified polypeptides or fragments that retain the same utility and preferably have homology to FIGS. 2A-2P or 3A-3D, respectively, of at least 75%, more preferably 90%, and most preferably 95%.

Another aspect of the present invention is provided by the proteins encoded by the EPV spheroidin and tk polynucleotide sequences. Putative amino acid sequences of the two EPV proteins as well as additional putative proteins encoded by the ORFs of these sequences which are identified in FIGS. 2A-2P and 3A-3D, respectively. EPV spheroidin has no significant amino acid homology to any previously reported protein, including the polyhedrin protein of baculovirus. We have found that both spheroidin and tk are nonessential proteins, which makes them desirable as sites for insertion of exogenous DNA.

Comparison of the AmEPV tk amino acid sequence with other tk genes reveals that the AmEPV tk gene is not highly related to any of the vertebrate poxvirus tk genes (43.4 to 45.7%). The relatedness of the vertebrate tk proteins to AmEPV is still lower (39.3 to 41.0%), while African Swine Fever (ASF) showed the least homology of all the tk proteins tested (31.4%). Although ASF has many similarities to poxviruses, and both ASF and AmEPV infect vertebrate hosts, the tk genes indicate little commonality and/or indication of common origin stemming from invertebrate hosts.

The spheroidin and thymidine kinase polypeptide sequences may include isolated naturally-occurring spheroidin or tk amino acid sequences identified herein or deliberately modified sequences which maintain the biological or regulatory functions, or other utility, of the AmEPV polypeptides, respectively identified in FIGS. 2A-2P and 3A-3D. Therefore, provided that the utilities of these polypeptides are retained in whole or part despite such modifications, this invention encompasses the use of all amino acid sequences disclosed herein as well as variants thereof retaining spheroidin or tk utility. Similarly, proteins or functions encoded by the other spheroidin or tk ORFs may include sequences containing amino acid modifications but which retain their regulatory or other biological functions, or other utility.

Examples of such modifications include polypeptides with amino acid variations from the natural amino acid sequence of Entomopoxvirus spheroidin or thyrnidine kinase; in particular, conservative amino acid replacements. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into four families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid will not have a major effect on biological activity, especially if the replacement does not involve an amino acid at an active site of the polypeptides.

As used herein, the term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. The phrase "polypeptide and variants thereof" includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The proteins or polypeptides of the present invention may be expressed in host cells and purified from the cells or media by conventional means (Sambrook et al., supra).

This invention also relates to novel viral recombinant polynucleotide molecules or vectors, which permit the expression of heterologous genes in a selected host cell. Such a polynucleotide vector of the invention comprises the polynucleotide sequence encoding all or a portion of the spheroidin or tk gene, the RNA polymerase from a selected poxvirus, and the polynucleotide sequence encoding a desired heterologous gene. Preferably, the sequence includes the regulatory region, and most preferably, the promoter region, of either the EPV spheroidin or tk gene. In addition, the source of the polymerase is not limited to EPV; rather, any poxvirus RNA polymerase may be utilized.

Therefore, the viral vectors may contain other viral elements contributed by another poxvirus, either vertebrate or invertebrate, with the only EPV sequences being provided by the presence of the EPV spheroidin or tk gene sequences, or fragments thereof. Numerous conventional expression viral vectors and expression systems are known in the art. Particularly desirable vectors systems are those of vertebrate or invertebrate poxviruses. The Entomopoxvirus spheroidin and tk gene regulatory sequences may be used in other virus vector systems which contain a poxvirus RNA polymerase to enhance the performance of those systems, e.g., in vaccinia vectors. Methods for the construction of expression systems, in general, and the components thereof, including expression vectors and transformed host cells, are within the art. See, generally, methods described in standard texts, such as Sambrook et al., supra. The present invention is therefore not limited to any particular viral expression system or vector into which a polynucleotide sequence of this invention may be inserted, provided that the vector or system contains a poxvirus RNA polymerase.

The vectors of the invention provide a helper independent vector system, that is, the presence or absence of a functional spheroidin or tk gene in a poxvirus contributing elements to the vector, e.g., contributing the RNA polymerase, does not affect the usefulness of the resulting recombinant viral vector. Because both spheroidin and tk are non-essential genes, the viral vectors of this invention do not require the presence of any other viral proteins, which in helper-dependent systems are contributed by additional viruses to co-infect the selected host cell.

Selected host cells which, upon infection by the viral vectors will permit expression of the heterologous gene, include insect and mammalian cells. Specifically, if the viral vector comprises the EPV spheroidin or tk gene sequences of the invention inserted into any member of the family Entomopoxvirinae, e.g., EPVs of any species, the host cell will be limited to cells of insects normally infected by EPVs. If the viral vector comprises the EPV spheroidin or tk gene sequences of the invention inserted into a vertebrate poxvirus, such as vaccinia or swinepox, the host cells may be selected from among the mammalian species normally infected by the wild-type vertebrate poxvirus. Most desirably, such mammalian cells may include human cells, rodent cells and primate cells, all known and available to one of skill in the art.

According to one aspect of the subject invention, therefore, vectors of the present invention may utilize a fragment of the polynucleotide sequence of EPV spheroidin, particularly the promoter and ancillary regulatory sequences which are responsible for the naturally high levels of expression of the gene. Desirably, spheroidin sequences may be found within the sequence of FIGS. 2A-2P (SEQ ID NO. 1), more particularly within the region of nucleotides #2781 through 3199 (SEQ ID NO. 22). Smaller fragments within that region may also provide useful regulatory sequences. The desired spheroidin promoter sequence can be utilized to produce large quantities of a desired protein by placing it in operative association with a selected heterologous gene in viral expression vectors capable of functioning in either a vertebrate or invertebrate host cell.

As used herein, the term "operative association" defines the relationship between a regulatory sequence and a selected protein gene, such that the regulatory sequence is capable of directing the expression of the protein in the appropriate host cell. One of skill in the art is capable of operatively associating such sequences by resort to conventional techniques.

Where the spheroidin polynucleotide sequence in the vector contains all or a portion of the spheroidin coding sequence in association with, or linked to, the heterologous gene, the resulting protein expressed in the host cell may be a fusion protein consisting of all or a portion of the spheroidin protein and the heterologous protein. Where the spheroidin polynucleotide sequence in the vector does not contain sufficient coding sequence for the expression of a spheroidin protein or peptide fragment, the heterologous protein may be produced alone.

In an analogous manner, the promoter and regulatory sequences of tk (FIGS. 3A-3D SEQ ID NO. 8) may be employed in the construction of an expression vector to drive expression of a heterologous protein, or a fusion protein, in a selected known expression system. These tk regulatory sequences are desirably obtained from the sequence of FIGS. 3A-3D (SEQ ID NO. 8), particularly in the fragment occurring between nucleotide #750 through 890 (SEQ ID NO. 30). Smaller fragments within that region may also provide useful regulatory sequences.

An advantage of the use of the novel EPV spheroidin or tk promoter sequences of this invention is that these regulatory sequences are capable of operating in a vertebrate poxvirus (e.g., vaccinia)-mammalian cell expression vector system. For example, the strong spheroidin promoter can be incorporated into the vaccinia virus system through homologous recombination. Unlike the promoter for the baculovirus polyhedrin gene, the promoter for the EPV spheroidin gene can be utilized directly in the vaccinia or swinepox virus expression vector.

To construct a vector according to the present invention, the spheroidin or tk polynucleotide sequence may be isolated and purified from a selected Entomopoxvirus, e.g., AmEPV, and digested with appropriate restriction endonuclease enzymes to produce a fragment comprising all or part of the spheroidin or tk gene. Alternatively such a fragment may be chemically synthesized.

Still alternatively, the desired AmEPV sequences may be obtained from bacterial cultures containing the plasmids pRH512, pMEGtk-1 or pRH7. The construction of the plasmid pRH512 is described in the examples below. This plasmid contains the 4.51 kb BglII fragment AmEPV DNA sequence inserted into a BamHI site in the conventional vector pUC9. The plasmid pRH7 was constructed by digesting AmEPV genomic DNA, obtained as described in Example 1, with Bsp12861, and the resulting fragments with HaeII. T4 DNA polymerase is employed to blunt end the AmEPV DNA and the fragment containing the spheroidin gene is ligated to the large fragment of a SmaI digested pUC9 fragment. This fragment contains the entire spheroidin open reading frame and some flanking sequence, included within the nucleotide sequence spanning #2274-6182 (SEQ ID NO. 33) of FIGS. 2A-2P. The construction of plasmid pMEGtk-1 comprising the regulatory sequences of the tk gene as well as the structural gene is described below in the Example 8. It was constructed by inserting the EcoRI-Q fragment of AmEPV into the conventional vector pUC18.

Bacterial cultures containing plasmids pRH512, pMEG tk-1, and pRH7 have been deposited in the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md., USA. The deposited cultures are as follows:

    ______________________________________     Culture        Accession No.                               Deposit Date     ______________________________________     E. coli SURE strain                    ATCC 68532 February 26, 1991     (Stratagene) pMEG-tk1     E. coli SURE strain                    ATCC 68533 February 26, 1991     (Stratagene) pRH512     E. coli SURE strain                    ATCC 68902 January 28, 1992     (Stratagene) pRH7     ______________________________________

The plasmids can be obtained from the deposited bacterial cultures by use of standard procedures, for example, using cleared lysate-isopycnic density gradient procedures, and the like.

These ATCC deposits were made under conditions that assure that access to the cultures will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademark to be entitled thereto under 37 CFR 1.14 and 35 USC 122. The deposits will be available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government action.

Further, the subject culture deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., they will be stored with all the care necessary to keep them viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of a deposit, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the cultures. The depositor acknowledges the duty to replace the deposit(s) should the depository be unable to furnish a sample when requested, due to the condition of a deposit. All restrictions on the availability to the public of the subject culture deposits will be irrevocably removed upon the granting of a patent disclosing them.

The molecular biology procedures referred to herein in describing construction of the vectors of this invention are standard, well-known procedures. The various methods employed in the preparation of the plasmid vectors and transformation or infection of host organisms are well-known in the art. These procedures are all described in, for example, Sambrook et al., cited above. Thus, it is within the skill of those in the genetic engineering art to extract DNA from microbial cells, perform restriction enzyme digestions, electrophorese DNA fragments, tail and anneal plasmid and insert DNA, ligate DNA, transform cells, prepare plasmid DNA, electrophorese proteins, and sequence DNA.

Because the AmEPV genome has no known unique restriction sites into which selected genes may be effectively introduced in a site-specific manner so as to be under the control of the spheroidin or tk promoter sequences, such restriction sites must be introduced into desired sites in the selected EPV polynucleotide sequence. For example, the unique BstB1 site located at nucleotide #3172 downstream from the start of the spheroidin gene is the closest site to genetically engineer a usable insertion sequence for cloning. Therefore, restriction sites closer to the initiating Met of the spheroidin gene must be deliberately inserted.

Methods for the insertion of restriction sites are known to those of skill in the art and include, the use of an intermediate shuttle vector, e.g., by cloning the EPV sequence into the site of an appropriate cloning vehicle. It will be recognized by those skilled in the art that any suitable cloning vehicle may be utilized provided that the spheroidin or tk gene and flanking viral DNA may be functionally incorporated.

A spheroidin shuttle vector may be constructed to include elements of the spheroidin structural gene, a cloning site located or introduced in the gene to enable the selected heterologous gene to be properly inserted into the viral genome adjacent to, and under the control of, the spheroidin promoter, and flanking viral DNA linked to either side of the spheroidin gene to facilitate insertion of the spheroidin-foreign gene-flanking sequence into another expression vector. The presence of flanking viral DNA also facilitates recombination with the wild type Entomopoxvirus, allowing the transfer of a selected gene into a replicating viral genome.

The shuttle vectors may thereafter be modified for insertion of a selected gene by deleting some or all of the sequences encoding for spheroidin or tk synthesis near the respective transcriptional start sites. Examples of such sites in spheroidin are nucleotides #3077 and 3080 and in tk includes nucleotide #809. Conventional procedures are available to delete spheroidin or tk coding sequences.

As an alternative to or in addition to the restriction site, a variety of synthetic or natural oligonucleotide linker sequences may be inserted at the site of the deletion. A polynucleotide linker sequence, which may be either a natural or synthetic oligonucleotide, may be inserted at the site of the deletion to allow the coupling of DNA segments at that site. One such linker sequence may provide an appropriate space between the two linked sequences, e.g., between the promoter sequence and the gene to be expressed. Alternatively, this linker sequence may encode, if desired, a polypeptide which is selectively cleavable or digestible by conventional chemical or enzymatic methods. For example, the selected cleavage site may be an enzymatic cleavage site, including sites for cleavage by a proteolytic enzyme, such as enterokinase, factor Xa, trypsin, collegenase and thrombin. Alternatively, the cleavage site in the linker may be a site capable of being cleaved upon exposure to a selected chemical, e.g. cyanogen bromide or hydroxylamine. The cleavage site, if inserted into a linker useful in the sequences of this invention, does not limit this invention. Any desired cleavage site, of which many are known in the art, may be used for this purpose. In another alternative, the linker sequence may encode one or a series of restriction sites.

It will be recognized by those skilled in the art who have the benefit of this disclosure that linker sequences bearing an appropriate restriction site need not be inserted in place of all or a portion of the spheroidin structural sequence, and that it would be possible to insert a linker in locations in the Entomopoxvirus genome such that both the sequence coding for the selected polypeptide and the spheroidin structural sequence would be expressed. For instance, the sequence coding for the selected polypeptide could be inserted into the tk gene in place of all or a portion of the tk structural sequence and under the transcriptional control of the tk promoter.

Polymerase chain reaction (PCR) techniques can also be used to introduce convenient restriction sites into the EPV DNA, as well as to amplify specific regions of the EPV DNA. These techniques are well known to those skilled in this art. See, for example, PCR Protocols. A Guide to Methods and Applications, M. A Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White, (1990).

By use of these techniques, a variety of alternative modified shuttle vectors into which a selected gene or portion thereof may be incorporated may be suitably utilized in the present invention. Specific examples of such constructs and their use in the production of recombinant entomopoxvirus and vaccinia viruses are provided herein.

As one embodiment of the invention, therefore, the polynucleotide sequence, described above, may be used as a shuttle vector to transfer a selected heterologous gene to a selected virus. In this embodiment, the polynucleotide sequence encoding the EPV spheroidin gene or EPV tk gene, or a fragment thereof, is linked to a heterologous gene. The polynucleotide sequence further contains a flanking region on either side of the spheroidin-heterologous gene or tk-heterologous gene to enable ready transfer into a selected virus. This resulting construct is termed a cassette. Such a flanking region may be derived from EPV, or alternatively, may be complementary to the target virus. For example, if it is desirable to insert a selected heterologous gene into a vaccinia virus to create a recombinant virus, one would utilize flanking regions complementary to the targeted vaccinia virus. Similarly if the heterologous gene is inserted within the EPV spheroidin or tk gene, so that the selected EPV regulatory sequence and heterologous gene are flanked by the EPV gene's own sequences, this cassette may be used for transfer into a wild type EPV having homologous sequences to the flanking sequences.

The insertion or linkage of the foreign gene into the tk or spheroidin sequences of the present invention or the linkage of flanking sequences foreign to the spheroidin or tk genes may be accomplished as described above. The vectors of the subject invention may use cDNA clones of foreign genes, because poxvirus genes contain no introns, presumably as a consequence of a totally cytoplasmic site of infection.

In accordance with standard cloning techniques, any selected gene may be inserted into the vector at an available restriction site to produce a recombinant shuttle vector. Virtually any gene of interest could be inserted into the vectors described herein in order to obtain high expression of the desired protein. The spheroidin gene product may be useful as a particulate biological carrier for foreign gene antigens. Thus, a foreign gene fused to the spheroidin gene may be useful as a method to produce a foreign protein attached to an effective vaccine carrier. Restriction sites in the fragment may thereafter be removed so as to produce a preferred spheroidin or tk shuttle vector, having one or more cleavage or cloning sites located in the 3' direction downstream from the spheroidin promoter sequence. Thus, the present invention is not limited by the selection of the heterologous gene.

Alternatively, a vector of this invention may comprise a heterologous gene which is inserted into all or a portion of the EPV spheroidin or tk protein encoding sequence to interrupt the protein's natural processing. However, when the vector is transferred to another virus which contains a wild-type spheroidin or tk gene, expression of the inserted heterologous gene is obtained. Thus, the Entomopoxvirus spheroidin gene (FIGS. 2A-2P; SEQ ID NO. 1) and/or the tk gene (FIGS. 3A-3D; SEQ ID NO. 8) can be used as the location for the insertion of exogenous (heterologous) DNA in any of the above-mentioned expression systems. A shuttle vector so constructed may be useful as a marker for research and production techniques for identifying the presence of successfully integrated heterologous genes into the selected expression system.

The tk gene is a particularly desirable site for insertion of a selected heterologous gene. Unlike spheroidin, tk is produced early in infection and in lesser quantities. Additionally, many poxviruses possess tk genes which may be sufficiently homologous to the EPV tk to provide easy recombination. For example, in vaccinia virus expression systems for mammalian cells, the vaccinia tk gene is a common insertion site. Therefore, the use of this gene is particularly desirable for construction of a shuttle vector to shuttle selected genes directly between vector systems. More specifically, a foreign gene may be desirably inserted into the EPV tk gene sequence between nucleotide #460 and #560 (See FIGS. 3A-3D).

Insertion of cassettes containing foreign genes into wild-type poxviruses can be accomplished by homologous recombination. The homologous recombination techniques used to insert the genes of interest into the viruses of the invention are well known to those skilled in the art. The shuttle vectors, when co-infected into host cells with a wild-type virus, transfer the cassette containing the selected gene into the virus by homologous recombination, thereby creating recombinant virus vectors.

Expression of a selected gene is accomplished by infecting susceptible host insect cells with the recombinant viral vector of this invention in an appropriate medium for growth. An EPV expression vector is propagated in insect cells or insects through replication and assembly of infectious virus particles. These infectious vectors can be used to produce the selected gene in suitable insect cells, thus facilitating the efficient expression of the selected DNA sequence in the infected cell. If the EPV spheroidin gene (or tk gene)-heterologous gene fragment is inserted into a vertebrate poxvirus by the same methods as described above, the recombinant virus may be used to infect mammalian cells and produce the heterologous protein in the mammalian cells.

For example, a gene inserted into the tk site of a vaccinia virus system could be transferred directly to the tk locus of an Entomopoxvirus vector of the subject invention or vice versa. This shuttling could be accomplished, for example, using homologous recombination. Similarly insertion of a selected gene into the spheroidin gene or tk gene in a viral vector permits the gene to be shuttled into other viruses having homologous spheroidin or tk sequences, respectively.

The following description illustrates an exemplary vector of this invention, employing the gene coding for human β-interferon (IFN-β) synthesis as the heterologous gene. A DNA fragment containing the IFN-β gene is prepared conventionally with restriction enzyme digested or blunt ended termini and cloned into a suitable site in the AmEPV spheroidin gene, into which a restriction site has been engineered by the methods described above.

The insertion of the IFN-β gene produces a hybrid or fused spheroidin-IFN-β gene capable of producing a fused polypeptide product if only a portion of the spheroidin gene was deleted as described above. If the entire spheroidin structural sequence was deleted, only interferon will be produced. Further, the hybrid gene may comprise the spheroidin promoter, the IFN-β protein coding sequences, and sequences encoding a portion of the polypeptide sequence of the spheroidin protein, provided all such coding sequences are not deleted from the particular shuttle vector utilized.

The resulting shuttle vector contains the AmEPV spheroidin gene sequence coupled to the IFN-β gene. The hybrid spheroidin-IFN-β gene of the recombinant shuttle vector is thereafter transferred into the genome of an appropriate Entomopoxvirus, such as the preferred Entomopoxvirus AmEPV, to produce a recombinant viral expression vector capable of expressing the gene encoding for β-interferon in a host insect cell. Transfer of the hybrid gene to a wild-type virus is accomplished by processes which are well known to those skilled in the art. For example, appropriate insect cells may be infected with the wild type Entomopoxvirus. These infected cells are then transfected with the shuttle vector of the subject invention. These procedures are described, for example, in DNA Cloning:A Practical Approach, Vol. II, Edited by D. M. Glover, Chapter 7, 1985. A person skilled in the art could choose appropriate insect cells to be used according to the subject invention. By way of example, salt marsh caterpillars and cultured gypsy moth cells can be used.

During replication of the AmEPV DNA after transfection, the hybrid gene is transferred to the wild-type AmEPV by homologous recombination between the recombinant shuttle vector and AmEPV DNA Accordingly, a mixture is produced comprising wild-type, nonrecombinant EPVs and recombinant EPVs capable of expressing the IFN-β gene.

While transfection is the preferred process for transfer of the hybrid gene into the EPV genome, it will be understood by those skilled in the art that other procedures may be suitably utilized so as to effect the insertion of the gene into the EPV genome and that recombination may be accomplished between the recombinant shuttle vector and other strains of EPV (or other poxviruses) so long as there is sufficient homology between the sequence of the hybrid gene and the corresponding sequence of the other strain to allow recombination to occur.

The preferred recombinant AmEPV expression vector, comprising a hybrid spheroidin-IFN-β gene incorporated into the AmEPV genome, can thereafter be selected from the mixture of nonrecombinant and recombinant Entomopoxviruses. The preferred, but by no means only, method of selection is by screening for plaques formed by host insect cells infected with viruses that do not produce viral occlusions. Selection may be performed in this manner because recombinant EPV viruses which contain the spheroidin or tk protein coding sequences interrupted by the heterologous gene are defective in the production of viral occlusions due to the insertional inactivation of the spheroidin gene.

Also, the selection procedure may involve the use of the β-galactosidase gene to facilitate color selection. This procedure involves the incorporation of the E. coli β-galactosidase gene into the shuttle vector and is well known to those skilled in the art. This technique may be of particular value if the exogenous DNA is inserted into the tk gene so that the spheroidin gene is still expressed. It will be recognized by those skilled in the art that alternative selection procedures may also be utilized in accordance with the present invention.

Accordingly, the DNA from a recombinant virus is thereafter purified and may be analyzed with appropriate restriction enzymes, or PCR technology, to confirm that the recombinant AmEPV vector has an insertion of the selected gene in the proper location.

The vectors and methods provided by the present invention are characterized by several advantages over known vectors and vector systems. Advantageously, such EPV viral vectors of the present invention are not oncogenic or tumorigenic in mammals. Also, the regulatory signals governing Amsacta moorei Entomopoxvirus (AmEPV) gene expressions are similar to those of vaccinia. Therefore, it is possible to transfer the strongly expressed spheroidin gene, or the thymidine kinase gene, as an expression cassette, not only in insect cells, but for use in vertebrate poxviruses such as vaccinia and swinepox virus.

Based on reported data with vaccinia, herpes and baculovirus vector systems, which suggest that up to 30 kb can be transferred without disrupting the vector viability, the normal limitation on the amount of exogenous DNA which can be packaged into a virus is not anticipated to be encountered when using the novel EPV vectors and methods of the subject invention.

Another advantage is that for the novel vectors of the subject invention, the transcription and translation of foreign proteins is totally cytoplasmic. Still another advantage lies in the expression power of the EPV spheroidin regulatory sequences, which when in operative association with a heterologous gene in a vector of this invention, can be used to produce high levels of heterologous protein expression in the selected host cell.

The EPV vectors of this invention and methods for employing them to express selected heterologous proteins in insect or mammalian cells, as described above, are characterized by the advantage of replication in insect cells, which avoids the use of mammalian viruses, thereby decreasing the possibility of contamination of the product with mammalian virus. The expression system of this invention is also a helper independent virus expression vector system. These two characteristics are shared by known baculovirus expression systems. However, as shown in Table 1, the EPV expression vector system (EEVS) using the vectors of this invention has some important distinguishing features compared to the baculovirus expression systems (BEVS).

                  TABLE 1     ______________________________________     Differences between EEVS and BEVS               EEVS        BEVS     ______________________________________     Site of replication:                 cytoplasm     nucleus     Virus family:                 Poxviridae    Baculoviridae     Sites for insertion of                 spheroidin &  polyhedrin & p10     foreign genes:                 thymidine                 kinase (tk)     Shuttle possibilities                 (Orthopoxviruses)                               No mammalian     between vertebrate and                 (Leporipoxviruses)                               counterparts.     insect systems:                 (Suipoxviruses)                               Baculovirus                 (Avipoxviruses)                               is not known to contain                               a tk gene. Polyhedrin is                               not found in mammalian                               systems.     ______________________________________

The present invention also provides a method for screening recombinant host cells for insertion of heterologous genes by use of the recombinant viral polynucleotide molecules of this invention. The viral molecules containing the selected heterologous gene sequence linked to the polynucleotide sequence encoding less than all of the Entomopoxvirus spheroidin protein. The heterologous gene may be linked to the spheroidin or tk regulatory sequences in the absence of the complete coding sequences, or it may be inserted into the spheroidin or tk gene coding sequences, thus disrupting the coding sequence. The cell infected with the recombinant vector is cultured under conditions suitable for expression of the heterologous protein, either unfused or as a fusion protein with a portion of the spheroidin sequence. The absence of occlusion bodies which would ordinarily be formed by the expression of the intact spheroidin protein indicates the integration of the heterologous gene.

If the viral vector similarly contained either incomplete or interrupted EPV tk encoding sequence, the absence of thymidine kinase function (e.g., resistance to methotrexate or an analogue thereof) formed by the integration of the inactive thymidine kinase sequence indicates the insertion of the heterologous gene.

Alternatively, if a parent virus is deleted of part of its tk or spheroidin gene, and is thereafter mixed with a viral vector containing intact tk or spheroidin fused to the foreign gene, recombinants would express the methotrexate resistance or produce occlusion bodies, respectively, thus indicating integration of the active tk or spheroidin genes and the foreign gene.

The above-described selection procedures provide effective and convenient means for selection of recombinant Entomopoxvirus expression vectors.

Another embodiment of the present invention involves using novel EPV expression systems of the subject invention for insect control. Control of insect pests can be accomplished by employing the vectors and methods of the invention as described above. For example, a gene coding for an selected insect toxin may be inserted into the viral expression vector under the control of the spheroidin or tk regulatory sequences or within either of the two genes for purposes of recombination into a selected virus having homologous flanking regions.

Genes which code for insect toxins are well known to those skilled in the art. An exemplary toxin gene isolated from Bacillus thuringiensis (B.t.) can be used according to the subject invention. B.t. genes are described, for example, in U.S. Pat. Nos. 4,775,131 and 4,865,981. Other known insect toxins may also be employed in this method.

The resulting EPV vector containing the toxin gene is applied to the target pest or its surroundings. Advantageously, the viral vector will infect the target pest, and large quantities of the toxin will be produced, thus resulting in the control of the pest. Particularly large quantities of the toxin protein can be produced if the regulatory sequences of the Entomopoxvirus spheroidin gene are used to express the toxin.

Alternatively, the spheroidin gene can be left intact and the toxin gene inserted into a different Entomopoxvirus gene such as the tk gene. In this construct, the toxin will be produced by the system and then effectively coated or encapsulated by the natural viral production of spheroidin. This system thus produces a toxin which will advantageously persist in the environment to prolong the availability to the target pest.

In addition to the novel Entomopoxvirus expression vectors and methods for their use described herein, the subject invention pertains to the use of novel regulatory elements from Entomopoxvirus to construct novel chimeric vaccinia and swinepox vaccines and expression systems which are functional across genera of mammalian poxviruses. The polynucleotide sequences of the invention can also be used with viral vaccines, e.g., known vaccinia virus vaccines, to enhance the effectiveness of these vaccines. Such vaccines have been described for use in controlling rabies and other infectious diseases in mammals. Specifically, it is anticipated that the introduction of the EPV spheroidin promoter sequences into known viral vectors which are used to express selected proteins in a mammalian host in vivo may enable the powerful spheroidin promoter to increase expression of the protein in the viral vaccine. This aspect of the invention provides a significant improvement over other expression systems, including the baculovirus expression system (BEVS).

The following examples illustrate the compositions and procedures, including the best mode, for practicing the invention. These examples, should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted. The restriction enzymes disclosed herein can be purchased from Bethesda Research Laboratories, Gaithersburg, Md., or New England Biolabs, Beverly, Mass. The enzymes are used according to the instructions provided by the supplier. Klenow fragment of DNA polymerase, T4 polynucleotide kinase, and T4 DNA ligase were obtained from New England Biolabs and Promega.

EXAMPLE 1 Preparation of AmEPV DNA

The replication of AmEPV has been described previously (Goodwin, R. H., et al. 1990! J. Invertebr. Pathol. 56:190-205). The gypsy moth (Lymantria dispar) cell line IPLB-LD-652 (Insect Pathology Laboratory, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, Md.) is maintained at 26 to 28° C. in EX-CELL 400 (JRH Biosciences, Lenexa, Kans.) supplemented with 10% fetal bovine serum, 100 U of penicillin, and 100 μg of streptomycin per ml. Other insect cell lines are well known to those skilled in the art and can be used according to the subject invention.

The AmEPV inoculum for cell culturing was from an AmEPV-infected, freeze-dried E. acrea larva stored at -70° C. (Hall, R. L., et al. 1990! Arch. Virol. 110:77-90). The larva was crushed and macerated in 5 ml of EX-CELL 400 (with penicillin and streptomycin but without fetal bovine serum) to which 0.003 g of cysteine-HCI had been added to prevent melanization. The debris was pelleted at 200× g for 5 minutes, and the supernatant was passed through a 0.45-μm-pore-size filter.

The gypsy moth cells were infected with AmEPV by addition of the inoculum to a preconfluent monolayer of cells (about 0.1 to 1 PFU per cell), with occasional agitation of the dish during the first day. Infected cells were harvested 5 to 6 days postinfection.

AmEPV DNA was prepared from the infected cells by one of two methods. The first method involved in situ digestion of infected cells embedded within agarose plugs, after which the released cellular and viral DNAs were separated by pulsed-field electrophoresis (Bio-Rad CHEF-II-DR system). IPLB-LD-652 cells were infected with first-cell-culture-passage AmEPV. Infected cells were harvested 6 days postinfection by centrifugation at 200× g for 5 minutes, rinsed, and resuspended in modified Hank's phosphate-buffered saline (PBS), which contained 15 g of glucose per liter, but no Ca²⁺ or Mg²⁺.

For embedding of the infected cells in agarose plugs, 1% SeaPlaque GTG agarose (prepared in modified Hank's PBS and equilibrated at 37° C.) was mixed 1:1 with infected cells to yield 5×10⁶ cells per ml in 0.5% agarose. Digestion to release DNA was done by gentle shaking of the inserts in 1% Sarkosyl-0.5 M EDTA-1 mg of proteinase K per ml at 50° C. for 2 days (Smith, C. L., et al. 1987! Methods Enzymol. 151:461-489). The CHEF-II-DR parameters for DNA separation were 180 V, a pulse ratio of 1, 50 initial and 90 second final pulse times, and a run time of 20 to 25 hours at 4° C. The separating gel was 1% SeaKem GTG agarose in 0.5× TBE buffer (Sambrook et al., supra). Viral DNA bands were visualized by ethidium bromide staining and electroeluted (Allington, W. B., et al. 1978! Anal. Biochem. 85:188-196). The recovered DNA was used for plasmid cloning following ethanol precipitation.

The second method of viral DNA preparation used the extracellular virus found in the infected-cell-culture supernatant. The supernatant from 10-day-postinfection cell cultures was clarified by centrifugation at 200× g for 5 minutes. Virus was collected from the supernatant by centrifugation at 12,000× g. Viral pellets were resuspended in 6 ml of 1× TE. DNase I and RNase A (10 and 20 μg/ml final concentrations, respectively) were added, and the mixture was incubated at 37° C. for 30 minutes. The mixture was heated to 50° C. for 15 minutes. SDS and proteinase K (1% and 200 μg/ml, respectively) were then added. The sample was incubated to 50° C. overnight and extracted three times with buffer-saturated phenol and once with SEVAG (Sambrook et al., supra). The DNA was ethanol precipitated and resuspended in 1× TE (pH 8).

For routine virus quantitation, 1 ml of an appropriate virus dilution (prepared in unsupplemented EX-CELL 400) was added to a preconfluent monolayer of cells in a 60 mm culture dish, with intermittent agitation over a 5 hour adsorption period at 26 to 28° C. The virus inoculum was removed, and 5 ml of a 0.75% SeaPlaque agarose (FMC BioProducts, Rockland, Me.) overlay prepared with 2× EX-CELL 400 and equilibrated at 37° C. was added to the monolayer. Plaques were visualized after 5 days of incubation at 26° C. by inspection with a stereomicroscope.

The DNA prepared according to either method was then cut with a variety of restriction endonuclease enzymes, e.g., BamHI, EcoRI, HindIII, PstI and XhoI, generating the various fragments which appear on the physical map of FIG. 1. Hereafter, reference to each restriction fragment will refer to the enzyme and the applicable letter, e.g., BamHI-A through BamHI-E, EcoRI-A through EcoRI-S, etc.

EXAMPLE 2 Production of Spheroidin Polypeptide

To localize the spheroidin gene, a purified preparation of occlusion bodies (OBs) from infected caterpillars was solubilized and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, J. K. 1970! Nature (London) 227:680-685) with a 4% acrylamide stacking gel and a 7.5% separating gel. The acrylamide used to prepare spheroidin for protein microsequencing was deionized with AG501X8 resin (Bio-Rad, Richmond, Calif.). The gels were polymerized overnight at 4° C. For sample preparation, 2× Laemrnli sample buffer consisting of 125 mM Tris-HCl (pH 6.8), 4% SDS (w/v), 10% β-mercaptoethanol (v/v), and 20% glycerol (v/v) was used.

OB suspension samples were diluted 1:1 with 2× Laemmli sample buffer and boiled for 5 minutes. Several lanes of an OB protein preparation were separated electrophoretically. The spheroidin protein (113 kDa) was the predominant protein of the purified OBs. Spheroidin within SDS-polyacrylamide gels was tested for glycosylation by periodic acid-Schiff staining (Zacharius, R. M., et al. 1969! Anal. Biochem. 30:149-152).

Following electrophoretic separation, several lanes in the unstained gel were transferred to an Immobilon polyvinylidene difluoride (PVDF) membrane with a Bio-Rad TransBlot apparatus at 90 V for 2 hours in a buffer consisting of 10 mM morpholinepropanesulfonic acid (pH 6.0) and 20% methanol. Spheroidin was visualized on the PVDF membrane by Coomassie blue staining.

The region of the PVDF membrane containing spheroidin was excised from the membrane, and direct protein microsequencing was done with an Applied Biosystems gas-phase sequencer. Microsequencing of the intact protein was unsuccessful, presumably because the N terminus of the protein was blocked.

Cyanogen bromide cleavage was performed on samples of spheroidin eluted from the PVDF membrane to generate internal peptide fragments for sequencing. Major polypeptides of 15, 9, 8, and 6.2 kDa were produced.

EXAMPLE 3 Sequencing, Hybridizations

All DNA sequencing was done by the dideoxy chain termination method (Sanger, F., et al. 1977! Proc. Natl. Acad. Sci. USA 74:5463-5467) with α-³⁵ S!dATP and Sequenase (US Biochemical, Cleveland, Ohio). Standard sequencing reactions with Sequenase were carried out in accordance with the instructions of the supplier, US Biochemical.

A reliable amino acid sequence was obtained from the 9, 8, and 6.2 kDa polypeptides produced as described in Example 2. The 8 and 9 kDa polypeptides represented overlapping partial CNBr cleavage products which together yielded the longest continuous amino acid sequence: Met-Ala-(Asn or Arg)-Asp-Leu-Val-Ser-Leu-Leu-Phe-Met-(Asn or Arg)-(?)-Tyr-Val-(Asn?)-Ile-Glu-Ile-Asn-Glu-Ala-Val-(?)(Glu?-)-(SEQ ID NO. 34). The amino acid sequence obtained from the 6.2 kDa fragmentwasMet-Lys-Ile-Thr-Ser-Ser-Thr-Glu-Val-Asp-Pro-Glu-Tyr-Val-(ThrorIle)-Ser-(Asn?) (SEQ ID NO. 35). A partial sequence for the 15 kDa fragment was also obtained: (Asn?)-Ala-Leu-Phe-(Phe?)(Asn?)-Val-Phe (SEQ ID NO. 36). The question marks in the above sequences indicated undetermined or unconfirmed amino acids. All sequences were ultimately located within the spheroidin gene sequence.

EXAMPLE 4 Plasmid pRH512

A BglII AmEPV DNA library was prepared by digesting the genomic AmEPV DNA with BglII according to manufacturer's instructions. Plasmid pUC9 (GIBCO; Bethesda Research Labs) was BamHI-digested and phosphatase-treated. The genomic BglII cut AmEPV was shotgun cloned into the BamHI site of pUC9. Escherichia coli SURE (Stratagene, La Jolla, Calif.) was transformed by electroporation with a Bio-Rad Gene Pulser following the instructions provided by the manufacturer with the shotgun ligation, containing a variety of recombinant plasmids. Mini-preparations of plasmids were made by a conventional alkaline lysis procedure (Sambrook et al., supra). These plasmids were cut with EcoRI-SalI to release the insert and run on a gel. The resulting plasmid DNA was southern blotted to a nylon membrane, producing a number of clones.

Among the fragments produced from the restriction enzyme digestions of the genomic DNA was a 4.4 BglII fragment and an EcoRI-D fragment. In order to locate a desirable clone from among those produced above, the sequence derived from the 6.2 kDa CNBr fragment was used to design a degenerate oligonucleotide for use as a hybridization probe to locate the spheroidin gene in a clone. The nucleotide sequence of this probe called RM58 (SEQ ID NO. 12) was GA5GT7GA6CC7GA5TA6GT, where 5 represents A or G, 6 represents C or T, and 7 represents A, G, C, or T. The peptide sequence of the probe was: Glu-Val-Asp-Pro-Glu-Tyr-Val (SEQ ID NO. 37).

The DNA probe was radiolabeled either with α-³² P!dCTP by the random oligonucleotide extension method (Feinberg, A. P., et al. 1983! Anal. Biochem. 132:613) or with γ-³² P!ATP and T4 polynucleotide kinase (Sambrook et al., supra). These same procedures were used for all other oligonucleotide probes described below. Both types of probes were purified by passage through spun columns of Sephadex G-50.

Southern transfer was done with Hybond-N (Amersham); the transferred DNA was fixed to the membrane by UV cross-linking. Southern hybridization was performed both with transferred DNA including the restriction fragments described above, as well as the BglII library of AmEPV DNA cloned into BamHI-digested plasmid pUC9 as described above. Hybridization with the oligonucleotide probe was done at 37 or 45° C. with BLOTTO (Sambrook et al., supra) and was followed by two washes at room temperature with 0.3 M NaCl-0.06 M Tris (pH 8)-2 mM EDTA for 5 minutes.

The RM58 probe (SEQ ID NO. 12) hybridized to the 4.4 kb BglII fragment and the EcoRI-D fragment of AmEPV DNA (See FIG. 1). A plasmid produced by the shotgun cloning, recombinant pRH512 (a BglII 4.56 kb fragment inserted into the BamHI site of pUC9 which contains about 1.5 kb of the 5' end of the spheroidin gene) was also identified by this hybridization with the RM58 oligonucleotide (SEQ ID NO. 12).

The 4.51 kb pRH512BglII insert was isolated, radiolabeled as described above, and hybridized back to various AmEPV genomic digests as follows. The DNA-DNA hybridization was done at 65° C. with BLOTTO (Sambrook et al., supra) and was followed by two washes at room temperature with 0.3 M NaCl-0.06 M Tris (pH 8)-2 mM EDTA for 5 minutes, two washes for 15 minutes each at 65° C. but with 0.4% SDS added, and two washes at room temperature with 0.03 M NaCl-0.06 M Tris (pH 8)-0.2 mM EDTA. Hybridization was observed to the BamHI-A, EcoRI-D, HindIII-G and -J, PstI-A, and XhoI-B fragments of AmEPV DNA. The results of these hybridizations indicated that the 4.51 kb fragment in pRH512 was substantially identical to the 4.4 kb fragment produced by BglII digestion of genomic DNA,

The 4.51 kb BglII insert of pRH512 was thereafter sequenced by two procedures. One is the double-stranded plasmid sequencing method (Hattori, M., et al. 1986! Anal Biochem. 152:232-238) performed with "miniprep" (Sambrook et al, supra) DNA and 1 pmol of universal, reverse, or custom-designed oligonucleotide primer in each sequencing reaction. Nested exonuclease II deletions (Henikoff, S. 1987! Methods EnzymoL 155:156-165) were used to sequence plasmid pRH512 according to this method. Deletions were made from the universal primer end. For making these deletions, the DNA was cut with EcoRI, filled in with α-thiophosphate dNTPs (Putney, S. D., et al. 1981! Proc. Natl. Acad. Sci. USA 78:7350-7354) by use of the Klenow fragment of E. coli DNA polymerase, cut with SmaI, and treated with exonuclease III. Samples were removed every 30 seconds, re-ligated, and used to transform E. coli SURE cells by electroporation. Sequencing reactions were carried out with the universal primer.

When a primer complementary to that sequence was prepared and used to sequence back through the RM58 binding site (bases 3983 to 4002), the generated sequence, when translated, yielded the amino acid sequence generated from microsequencing the 6.2 kDa CNBr polypeptide fragment.

A second sequencing method was performed using a combination of M12 shotgun sequencing with standard and universal and reverse M13 primers into M13 phage to permit single-stranded sequencing as follows. Plasmid pRH512 was sonicated to produce random fragments, repaired with bacteriophage T4 DNA polymerase, and these fragments were shotgun cloned into SmaI-cut M13mp19 (GIBCO). Plaque lifts were screened with a radiolabeled probe prepared from the 4.5 kb insert found in pRH512 to identify appropriate clones for shotgun single stranded sequencing (see, e.g., Sambrook et al, supra). Sequencing of the BglII insert of pRH512 isolated it to nucleotides #0 to 4505, thus extending the sequence 5' and 3' to the spheroidin gene (FIGS. 2A-2P).

EXAMPLE 5 Obtaining Additional AmEPV Sequence

A DraI AmEPV DNA library was prepared by digesting genomic DNA with DraI. These DraI fragments were shotgun cloned into SmaI-digested, phosphatase-treated vector M13mp19. Preparations of M13 virus and DNA were made by standard procedures (Sambrook et al., supra). Ligation and heat shock transformation procedures were performed conventionally (Sambrook et al., supra), resulting in the shotgun cloned fragments being transformed into the bacterial strain, E. coli UT481 (University of Tennessee) or the SURE strain.

Standard PCR (Innis et al., supra) with 400 ng of genomic AmEPV DNA as a template was used to prepare a probe to identify a 586 bp DraI clone from nitrocellulose filter replicas (plaque lifts) (Micron Separations, Inc.) of the M13 shotgun library of DraI-cut AmEPV fragments. This was done to isolate a clone spanning a central unsequenced region of the spheroidin gene. The standard PCR primers used for this reaction were RM92 (SEQ ID NO. 15) (GCCTGGTTGGGTAACACCTC) and RM118 (SEQ ID NO. 16) (CTGCTAGATTATCTACTCCG). This sequencing revealed that there was a single HindIII site at base 931 and that the 2' end of the spheroidin open reading frame (ORF) was truncated (FIGS. 2A-2P).

The technique of inverse polymerase chain reaction (PCR) (Innis, M. A., et al., 1990! PCR protocol, a guide to methods and applications, Academic Press, Inc. San Diego, Calif.) was used with ClaI-digested AmEPV DNA fragments which were ligated into a circle, to prepare a probe to identify clones containing a flanking sequence or to verify the absence of an intervening sequence between adjacent clones. The primers used in inverse PCR were RM82 and RM83, which were taken from the pRH512 sequence. The sequence of RM82 (SEQ ID NO. 13) was TTTCAAATTAACTGGCAACC and that of RM83 (SEQ ID NO. 14) was GGGATGGATTTTAGATTGCG.

The specific PCR reaction conditions for 34 cycles were as follows: 30 seconds at 94° C. for denaturation, 30 seconds at 37° C. for annealing, and 1.5 minutes at 72° C. for extension. Finally, the samples were incubated at 72° C. to 8.5 minutes to complete extensions. The concentration of each primer was 1 μM.

The resulting 2.2 kb inverse PCR product was digested with ClaI, and a 1.7 kb fragment was gel purified. The 1.7 kb PCR fragment was sequenced with RM83 as a primer. Additional PCR primers were made to the new sequence as it was identified. The sequencing process employed Sequenase, 5 pmol of each primer, and 10 to 50 ng of template. Prior to being sequenced, the PCR products were chloroform extracted and purified on spun columns (Sambrook et al., supra) of Sephacryl S-400. The DNA sequence was assembled and aligned, and consensus sequence was produced (Staden, R. 1982! Nucleic Acids Res. 10:4731-4751). Both strands were completely sequenced; the PCR product sequence was verified by conventional sequence.

The relevant ClaI sites of the 1.7 kb PCR fragment are at positions 3485 and 6165. This fragment was radiolabeled and used as a probe to locate additional clones, i.e., pRH827 (307 bp), pRH85 (1.88 kb), and pRH87 (1.88 kb) from the BglII fragment library. Plasmids pRH85 and pRH87 were sequenced using the same nested exonuclease II deletions and sequencing procedure, as described above for pRH512. Sequencing of the inverse PCR products with custom-designed primers confirmed that plasmids pRH85 and pRH87 represented the same 1.88 kb BglII DNA insert in opposite orientations, but also revealed a missing 80 bp between pRH827 and pRH8⁵. This 80 bp DNA fragment was identified in the DraI fragment, as extending from bases 4543 to 5128 cloned into M13.

The orientation of the spheroidin ORF on the physical map is shown in FIG. 1. It is interesting to note that the 1.7 kb inverse PCR fragment only hybridized to the AmEPV HindIII-G fragment. The amino acid sequence derived from the 8 and 9 kDa overlapping CnBr-generated polypeptides is found from nucleotide positions 4883 to 4957 (SEQ ID NO. 38). That derived from the 6.2 kDa polypeptide is found from nucleotides 3962 to 4012 (SEQ ID NO. 39), and that derived from the 15 kDa polypeptide is found from nucleotides 4628 to 4651 (SEQ ID NO. 40). Therefore, all sequences obtained from protein microsequencing were ultimately found to lie within the spheroidin ORF.

EXAMPLE 6 Spheroidin Gene Transcription

The start site for spheroidin gene transcription was determined. A primer complementary to the spheroidin gene sequence beginning 65 bp downstream of the predicted initiating methionine was prepared and used for a series of primer extensions.

A. Preparation of RNA and primer extension reactions.

Six 150 mm dishes of subconfluent cells were prepared. The culture media were aspirated, and 2 ml of viral inoculum was added to each dish. The virus concentration was about 0.1 to 1 PFU per cell. The dishes were occasionally agitated during a 3 hour adsorption period. At the end of this period, the cells were rinsed with 5 ml of modified PBS. The media were replaced, and the infected cells were incubated for 72 hours at 27° C. Total RNA from the infected cells was isolated by the guanidinium thiocyanate-cesium chloride procedure (Chirgwin, J. M., et al. 1979! Biochemistiy 18:5294-5299).

Primer extension reactions were carried out with primer RM165 (SEQ ID NO. 17), a 35-base oligonucleotide (GTTCGAAACAAGTATTTTCATCTTTT AAATAAATC) beginning and ending 100 and 65 bp downstream, respectively, of the initiating methionine codon found in the TAAATG motif. The primer was end labeled with β-³² P!ATP and T4 polynucleotide kinase and purified on a "spun column" (Sambrook et al., supra). For annealing, 40 μg of total infected-cell RNA and 10⁶ cpm of radiolabeled primer were coprecipitated with ethanol. The pellet was resuspended in 25 μl of hybridization buffer (80% formamide, 40 mM piperazine-N,N'-bis(2-ethanesulfonic acid) (pH 6.4), 400 mM NaCl, 1 mM EDTA (pH 8.0)!, denatured at 72° C. for 15 minutes, and incubated at 30° C. for 18 hours.

For primer extension, the RNA-primer hybrids were ethanol precipitated, resuspended, and used for five individual reactions. Each reaction contained 8 jig of total infected-cell RNA, 50 mM Tris-HCl, (pH 8.3), 50 mM KCI, 10 mM dithiothreitol, 10 mM MgCl₂, 4 U of avian myeloblastosis virus reverse transcriptase (Life Sciences), 8 U of RNasin (Promega), 0.25 mM each deoxynucleoside triphosphate (dNTP), and the appropriate dideoxynucleoside triphosphate (ddNTP), except for a control reaction, which contained no ddNTP. The dNTP/ddNTP ratios were 4:1, 5:1, 5:1, and 2:1, for the C, T, A, and G reactions, respectively. The reactions were carried out at 42° C. for 30 minutes.

One microliter of chase buffer (4 μl of 5 mM dNTP mixture and 1 μl of 20-U/μl reverse transcriptase) was added to each reaction mixture, which was then incubated for an additional 30 minutes at 42° C. Reaction products were separated on a sequencing gel (8% acrylamide containing 7 M urea) and visualized by autoradiography. Complementarity was observed until the AAA of the upstream TAAATG motif, indicating that transcription of the gene initiates within the TAAATG element of the proposed late promoter element. Immediately upstream is a 5' tract of noncoded poly(A) on the transcripts. The average length of the poly(A) is greater than 6 bp.

EXAMPLE 7 Analysis of Spheroidin Sequence

The spheroidin ORF (G5R) was initially identified by sequencing back through the RM58 oligonucleotide primer binding region as described above. Examination of the AmEPV spheroidin gene sequence (ORF G5R) revealed a potential ORF of 3.0 kb capable of encoding 1,003 amino acids or a protein of about 115 kDa. The ORF consists of 29% G+C, in contrast to the 18.5% reported for the entire AmEPV genome (Langridge, W. H. R., R. F. Bozarth, D. W. Roberts 1977! Virology 76:616620). Inspection of the 92 bases upstream of the initiating ATG revealed only 7 G or C residues. Also detected was the presence of known vertebrate poxvirus regulatory sequences within the 92 bp 5' of the spheroidin ORF. Included are three TTTT TNT early gene termination signals and TAAATG, which presumably represents a late transcription start signal used to initiate transcription and translation of the spheroidin gene. Several adjacent translation termination codons are also present within the 92 bp upstream of the spheroidin ORF.

Analysis of the sequence upstream of the spheroidin gene revealed four additional potential ORFs, G1L (SEQ ID NO. 25), G2R (SEQ ID NO. 23), G3L (SEQ ID NO. 26), and G4R (SEQ ID NO. 24), discussed above. The putative amino acid sequences of these ORFs are reported in FIGS. 2A-2P (SEQ ID NO. 2, 3, 4 and 5, respectively). No significant homologies were found for the small potential polypeptides encoded by ORF G2R (SEQ ID NO. 23) or G3L (SEQ ID NO. 26). ORF G1L (SEQ ID NO. 25), however, exhibited a significant degree of homology to ORF 17 found within the HindIII-I fragment of vaccinia virus, whose function is unknown. ORF G4R (SEQ ID NO. 24) showed homology to ORF HM3 of capripoxvirus. In vaccinia virus, the ORF HM3 homolog was found very near the site of an incomplete ATI gene. The partial G6L ORF (SEQ ID NO. 27) to the right of the spheroidin gene exhibited good homology to vaccinia virus NTPase I. Much better homology (78.4% identity over 162 amino acids) was found between the partial G6L ORF (SEQ ID NO. 27) and NPH I of CbEPV (Yuen, L., et al. 1991! Virol.

EXAMPLE 8 Isolation and Sequencing of the AmEPV EcoRI-Q Fragment Containing the tk Gene

Sequencing of the EcoRI-Q fragment of genomic AmEPV of Example 1 was performed using techniques described above for spheroidin. The sequencing showed 1511 bp containing two complete and one partial ORF. Analysis of the DNA sequence of ORF Q2 (SEQ ID NO. 28) indicates the sites where the identifying degenerate oligonucleotides (RM03 SEQ ID NO. 18 and RM04 SEQ ID NO. 19) might hybridize. Two oligonucleotides, RM03 and RM04, based on different but strongly conserved regions of the tk genes of several poxviruses and vertebrates (Upton, C., et al. 1986! J. Virol. 60:920-927; Boyle, D. B., et al. 1987! Virology 156:355-365) were prepared by the methods referred to above. RM03 was the 32 fold degenerate oligonucleotide (SEQ ID NO. 18) GA(T/C)GA(G/A)GG(G/A)GG (G/A)CA(G/A)TT(C/T)TT corresponding to the amino acid residues in the vaccinia tk protein from the aspartic acid at position 82 to the phenylalanine at position 87. RM04 (SEQ ID NO. 19) was (GGNCCCATGTT(C/T)TCNGG with 32-fold degeneracy and corresponded to the region from the glycine at position 11 to the glycine at position 16 in vaccinia. These probes were radiolabeled as described above for the RH58 probe.

The AmEPV thymidine kinase (tk) gene was identified by hybridization with the degenerate oligonucleotide probes RM03 and RM04 to a Southern blot of the EcoRI-digested EPV DNA. The EcoRI band of interest (EcoRI-Q) was isolated, purified, and ligated into a pUC18 vector (GIBCO), previously digested with EcoRI and treated with calf intestinal alkaline phosphatase. Recombinant clones were identified by the size of the insert and by hybridization to the radioactive labeled oligonucleotide probes.

One such clone was called pMEGtk-1. The recombinant clones containing the EcoRI-Q fragment oriented in both directions relative to the pUC18 vector sequences were used for sequencing. Sequential nested deletions were generated by the method of Henikoff, cited above, as described for pRH512. These clones were used for sequencing the entire EcoRI-Q fragment.

Subsequently, these oligonucleotides and another, RM129 is a non-degenerate oligonucleotide GGTGCAAAATCTGATATTTC (SEQ ID NO. 20) prepared from the ORF Q1, were employed as sequencing primers to confirm their positioning as indicated in ORF Q2 (SEQ ID NO. 28). ORF Q2 potentially encodes for a protein of 182 amino acids (21.2 kDa) (SEQ ID NO. 10). ORF Q3 potentially encodes a polypeptide of at least 68 amino acids but is incomplete and is transcribed in the opposite direction from ORF Q2. ORF Q1 (SEQ ID NO. 31) potentially encodes a small peptide of 66 amino acids (7.75 kDa) (SEQ ID NO. 9).

Further analysis of the EcoRI-Q fragment reveals several other points. First, the A+T content is very high (80%). For ORF Q2, the 100 nucleotides upstream of the start codon for translation are 90% A+T. Some potential poxvirus transcription signals were found between ORFs Q1 and Q2. The five bases immediately preceding the start codon for ORF Q1 are TAAATG which comprise a consensus late poxvirus promoter. A potential poxvirus early transcription termination signal sequence (TTTTTAT) is located 2 nt past the translation stop codon of Q2.

The deduced amino acid sequence for the tk encoded by the ORF Q2 of the EcoRI-Q fragment can be compared to the tk genes for the poxviruses swine pox (Schnitzlein, W. M., et al. 1991! Virol. 181:727-732; Feller, J. A., et al., 1991! Virol. 183:578-585); fowlpox (Boyle et al., supra; Binns, M. M., et al. 1988! J. Gen. Virol. 69:1275-1283); vaccinia (Weir, J. P., et al. 1983! J. Virol. 46:530-537; Hruby, D. E., et al. 1983! Proc. Natl. Acad. Sci. USA 80:3411-3415); variola and monkeypox (Esposito, J. J., et al. 1984! Virol. 135:561-567); capripoxvirus (Gershon, P. D., et al. 1989! J. Gen. Virol. 70:525-533); Shope fibroma virus (Upton et al., supra); the cellular thymidine kinases of humans (Bradshaw, H. D., et al. 1984! Mol. Cell. Biol. 4:2316-2320; Flemington, E., et al. 1987! Gene 52:267-277); the tk of mouse (Lin, P. F., et al. 1985! Mol Cell. Biol. 5:3149-3156); the tk of chicken (Kwoh, T. J., et al. 1984! Nucl. Acids Res. 12:3959-3971); ASF (Blasco, R., et al. 1990! Virol. 178:301-304; Martin Hernandez, A. M., et al. 1991! J. Virol. 65:1046-1052).

EXAMPLE 9 Expression of the AmEPV tk Gene in a Vaccinia Virus

The AmEPV tk gene was tested functionally by cloning the gene into a vaccinia virus strain tk⁻ mutant, as follows.

The EcoRI-Q fragment of AmEPV, described above, was inserted in both possible orientations into shuttle plasmid pHGN3.1 (Bloom, D. D., et al. 1991! J. Virol. 65:1530-1542) which had been isolated from bacterial cells by the alkaline lysis method. This EcoRI-Q DNA fragment contains the AmEPV tk open reading frame (ORF). The cloning was performed conventionally. The resulting plasmid was designated pHGN3.1/EcoRI-Q.

The plasmid was transfected by Lipofectin (GIBCO) as described specifically below into mammalian cells infected with vaccinia virus. The cells were either rat tk⁻, human 143 tk⁻, or CV-1 cell lines onto which the vaccinia virus VSC8 was propagated. These cells were maintained in Eagle's Minimal Essential Medium with Earle's salts (Massung et al. 1991! Virol. 180:347-354, incorporated by reference herein).

The VSC8 vaccinia strain (Dr. Bernard Moss) contains the β-galactosidase gene driven by the vaccinia P₁₁ promoter (P₁₁ -Lac Z cassette) inserted into the viral tk gene. While VSC8 contains an inactive tk gene due to the insertion of the 3galactosidase, portions of the vaccinia tk sequence remain. VSC8 is thus tk⁻ and, upon staining with X-Gal (5-bromo-4-chloro-3-indoyl-β-D-galactopyranoside), will form blue plaques (β-galactosidase positive).

Cells were grown to 80% confluence (4×10⁶ per 60 mm dish). Lipofectin solution (20 μg of Lipofectin in 50 μl of dH₂ O) was added to 10 μg plasmid DNA (pHGN3.1/AmEPV EcoRI-Q) in 50 μl of dH₂ O and incubated for 15 minutes at room temperature. After a 2 hour period of viral adsorption (m.o.i. of 2, 37° C.), the monolayers were washed three times with serum-free OptiMEM. Three milliliters of serum-free OptiMEM was then added to each 60 mm dish. The Lipofectin/DNA mixture was slowly added dropwise with gentle swirling and incubated an additional 12 to 18 hours at 37° C. Fetal bovine serum was then added (10% final) and the infected cells were harvested at 48 hours postinfection.

Recombinant viruses, containing the EcoRI-Q fragment inserted into the hemagglutinin (HA) gene of vaccinia, were identified by hybridization of AmEPV EcoRI-Q fragments, radioactively labeled by procedures described above, to replicas of nitrocellulose "lifts" of virus plaques from the infected monolayer. Potential recombinants were isolated from replica filters and plaque-purified several times before testing.

The tk of AmEPV exhibits some degree of homology with the tk of vaccinia. To confirm that insertion of the AmEPV tk gene was within the HA gene of vaccinia rather than within residual tk sequences remaining in VSC8, the recombinants were examined by a series of Southern hybridizations to HindIII digests of the various viruses. When DNA from wild-type virus was hybridized to a vaccinia virus tk probe, hybridization was observed exclusively within the ≈5 kb HindIII-J fragment of AmEPV.

When either VSC8 or either of the AmEPV tk containing recombinants was examined using the vaccinia tk probe, hybridization occurred instead to an ≈8 kb fragment consistent with insertion of the ≈3.1 kb β-galactosidase cassette into the TK gene of the HindIII-J fragment. Hybridization of the HindIII digests of the same three viruses to radiolabeled AmEPV EcoRI-Q DNA resulted in hybridization to a large-molecular-weight DNA fragment in the recombinant containing the AmEPV TK gene, which we have shown corresponds to the HindIII-A fragment. These results suggest that insertion of the AmEPV TK gene into vaccinia occurred within the HA gene contained within the large (>23 kb) HindIII-A fragment of the virus as expected. Identical results were observed for VSC8::TKII. It is also interesting to note the lack of hybridization of the vaccinia virus (VV) and AmEPV TK probes to the heterologous poxvirus TK genes under these conditions, even though there is significant sequence homology between the vaccinia and the AmEPV TK genes.

Plaque-purified vaccinia recombinants were tested for growth on human 143 TK⁻ cells in the presence of methotrexate. Under these conditions, only TK⁺ virus will grow and produce plaques. Both recombinants (VSC8::AmEPV TKI and VSC8::AmEPV TKII) representing the two orientations of the AmEPV EcoRI-Q fragment gave plaques in the presence of methotrexate. All plaques from both recombinant viruses which grew in the presence of methotrexate also stained blue upon staining with X-Gal, suggesting that the TK⁺ phenotype of these recombinants is most likely due to a functional TK gene contained within the AmEPV EcoRI-Q fragment. Since functionality is independent of the orientation of the AmEPV EcoRI-Q fragment, it is plausible that an AmEPV TK gene promoter contained within the EcoRI-Q fragment may function in vaccinia.

EXAMPLE 7 Orientation of the TK Gene Within the AmEPV Genome

In order to determine the orientation of the Q1, Q2, Q3 ORFs within the EcoRI-Q fragment relative to the genome, a DNA primer-mediated extension reaction was performed. The EcoRI-Q fragment is contained within the PstI-F fragment. An oligonucleotide identical in sequence to bases 182-163 (RM129, SEQ ID NO. 12) was prepared and hybridized to a heat-denatured PstI digest of genomic AmEPV DNA. The partial hybrid was then extended with the Klenow fragment of E. coli DNA polymerase in the presence of radiolabeled substrates. Extension will terminate at the end of the PstI-F fragment.

The radiolabeled product was then hybridized to an EcoRI digest of AmEPV DNA. If orientation of the gene is such that the tk ORF reads toward the end of the genome, hybridization would be expected to the EcoRI-E fragment; whereas if the gene is read toward the center of the genome, hybridization would be expected to the EcoRI-I fragment.

The results indicate hybridization not only to the EcoRI-E fragment, but also to the EcoRI-A fragment. These results infer that the orientation of the tk gene is with reading toward the left end of the genome. Hybridization of the run-off extension product also to the EcoRI-A fragment is consistent with the presence of an inverted terminal repetition, common in poxviruses, with identical sequences residing in both the EcoRI-A and the EcoRI-E fragments.

The optimal growth temperature for AmEPV in the laboratory is 28° C., whereas that of the vertebrate poxviruses is 37° C. As described herein, when the AmEPV DNA fragment containing the entire tk gene was cloned into the tk⁻ strain of vaccinia virus, the recombinant virus was capable of growing at 37° C. in the presence of methotrexate (Sigma), indicative of a tk⁺ phenotype. This example demonstrates that the Entomopoxvirus tk gene can be successfully transferred into mammalian expression systems, and that AmEPV tk is functionally active over a considerable temperature range.

EXAMPLE 10 Isolation and Sequencing of CbEPV and CfEPV Spheroidin Genes

Viruses and Cell Culture

Choristoneura EPVs, CbEPV and CfEPV, occlusion bodies (OBs) were obtained from Dr. Basil M. Arif, Forest Pest Management Institute, Sault Ste. Marie, Ontario, Canada, and can be obtained from other sources as well. The AmEPV OBs were the same as those used previously (Hall and Moyer, 1991). The gypsy moth cell line, IPLB-LD-652, used for AmEPV replication was maintained in EX-CELL 401 (JRH Biosciences, Lenexa, Kans.) supplemented with 10% fetal bovine serum. Wild type cowpox virus, Brighton red strain, was produced in CV-1 cells cultured in Eagle's MEM with Earle's salts.

SDS-PAGE, Occlusion Body Solubilization, and Total Cell Protein Preparation

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of proteins was with a 4% acrylamide stacking gel and a 7.5% separating gel. For sample preparation, 2× Laemrnmli sample buffer consisting of 125 mM Tris-HCI (pH 6.8), 4% SDS (wt/vol), 10% β-mercaptoethanol (vol/vol), 20% glycerol (vol/vol), and 0.05% bromphenol blue (wt/vol) was used. Quantitation of OBs was achieved by counting a diluted suspension in a hemocytometer. The OB suspension (varying from 8×10⁶ to 1×10⁸ OBs/ml) usually prepared in 1× TE (10 mM Tris-HCI, 1 mM EDTA, pH 8.0), was diluted 1:1 with the 2× Laemmli sample buffer and immediately boiled for 5 or 10 min. For studies designed to assay for spheroidin degradation, the OBs plus sample buffer were left at room temperature for various time periods before boiling. After electrophoretic separation, the proteins were visualized by Coomassie blue staining.

The preparation of total uninfected or infected cell protein for SDS-PAGE utilized a 2× lysis buffer consisting of 160 mM Tris-HCI (pH 9), 4% SDS (wt/vol), 4% β-mercaptoethanol (vol/vol), 10% glycerol (vol/vol), 5 M urea, 20 mM EDTA (pH 8), and 0.01% bromphenol blue (wt/vol). Cells were scraped from a 150 mm diameter culture dish using a rubber policeman and centrifuged at 1000× g for 5 min at 4° C. Cells were washed in appropriate cold phosphate buffered saline (PBS) and recentrifuged. Insect cells were harvested in Hank's PBS which contained 15 g glucose per liter. The cell pellets were resuspended in a final volume of 500 μl of PBS which contained 5 μl each per ml of PMSF (phenylmethyl sulfonyl fluoride, 0.1 M stock in 95% ethanol) and aprotinin (0.3 mg/ml stock). The cells were probe sonicated on ice for 15 sec., five hundred microliters of 2× lysis buffer was added, and the preparation sonicated as before. Samples were stored at -70° C. and boiled before loading on an SDS-PAGE gel.

Preparation of EPV DNAs

CfEPV DNA was obtained from Dr. Basil M. Arif, Forest Pest Management Institute, Sault Ste. Marie, Ontario, Canada. CbEPV DNA used in the polymerase chain reaction (PCR) studies was prepared directly from occlusion bodies by the agarose in situ method (Hall and Hink, 1990) and extracted by "freeze-squeeze" (Sambrook et al, 1989). AmEPV DNA was prepared from infected LD-652 cell culture by concentrating extracellular virus which was then treated with DNase I and RNase A prior to dissolution of the occlusion bodies by SDS and proteinase K digestion (Gruidl et al., 1992).

PCR Primers and Reactions

PCR, product purification, and dideoxy sequencing were done as described previously (Hall and Moyer, 1991) except that the specific reaction conditions for 34 cycles were 1 min at 94° C. for denaturation, 1 min at 37° C. for annealing, and 2 min at 72° C. for extension. Finally, samples were incubated at 72° C. for 9 min to complete extensions. Typically, 50 to 100 ng of template DNA was used in the PCRs. Custom oligonucleotide primers RM82, RM83, RM92 and RM118 were described previously (Hall and Moyer, 1991). Sequences of these and other AmEPV spheroidin specific PCR primers (5' to 3', base pair numbers from Hall and Moyer, 1991) are summarized in Table 2.

                  TABLE 2     ______________________________________     PCR reactions used in checking Choristoneura EPV DNA     for a homolog of the AmEPV spheroidin gene     AmEPV spheroidin                  Expected    Appropriate Size     specific     Product     Product Observed     primer pair.sup.1                  Size (bp)   CbEPV   CfEPV     ______________________________________     12-9         314         -       -     12-8         599         +       +     12-6         828         -       -     12-3         1047        -       -     12-4         1184        -       -     1-4          290         +       +     12-11        1444        -       +      1-11        549         +       +      2-11        307         +       +     12-15        1542        -       -      1-15        648         +       +      2-15        378         +       +     12-13        1944        -       -      1-13        1050        +       +      2-13        807         +       +      5-13        632         -       +      7-13        595         +       +     14-13        426         +       +     10-13        259         -       +     ______________________________________      .sup.1 Primer numbers correspond to those in FIG. 5 and the sequences (5'      to 3') are shown below: (SEQ ID Nos: 52-66)      1. RM58GAAGTNGATCCNGAATATGT      2. RM75GAAAATAAAATTATATTGGA      3. RM76AGACAATTCCAGATATAATG      4. RM78CCGCATCTATATTCTGCTTC      5. RM79GTTTAAAACCTAAAGTACCC      6. RM82TTTCAAATTAACTGGCAACC      7. RM83GGGATGGATTTTAGATTGCG      8. RM87GTTGCATCTGTAGTTACATC      9. RM91TCTAGCAATAATCGACTTAC      10. RM92GCCTGGTTGGGTAACAACTC      11. RM93CATTTCTATTAAGCCTAACG      12. RM95GTACCTTTAGCAACCAAAAC      13. RM118CTGCTAGATTATCTACTCCG      14. RM169AATTGCACATTATCATTGGG      15. RM170ATTACCCAATGATAATGTGC

Primer RM206 (AGATGATGATTAAAGTGTGG) (SEQ ID NO. 50) was from bases 2379 through 2398 and RM212 (GATAATGATACTCCGGTTGC) (SEQ ID NO. 51) from bases 2077 through 2096 of the CbEPV NPH I sequence (Yuen et al., 1991).

Cloning and Double Strand Plasmid Sequencing

BglII clones in both orientations (1.06 kb and 1.78 kb) covering the unsequenced 5' end of the AmEPV NPH I gene were selected from an AmEPV BglII fragment library (Hall and Moyer, 1991) by hybridization with an AmEPV 13 kb HindIII fragment probe. Plasmids were cloned in the Escherichia coli SURE strain (Stratagene, La Jolla, Calif.). Plasmids were sequenced by use of exonuclease III deletions and dideoxy sequencing as described (Hall and Moyer, 1991). Both strands were completely sequenced.

Radiolabeled Probes, Southern Blotting, and Hybridization

Random oligolabeling of DNA for probes, Southern transfer and hybridization (at 65° C. with BLOTTO) were as described previously (Hall and Moyer, 1991).

Protein Microsequencing

Lys-c endoprotease digestion of the 115 kDa protein of CbEPV OBs purified and recovered from SDS-PAGE gels was used to generate internal peptide fragments for sequencing on a gas phase sequencer.

Antibody Preparation and Immunoblotting

A preparation of total occlusion body antigens was prepared by solubilizing purified AmEPV occlusion bodies purified from infected cell cultures. Rabbits were then intradermally injected with 100-200 pg of antigen per rabbit in Freund's complete adjuvant. One month later, the rabbits were boosted with about 500 μg each of the same antigen in incomplete adjuvant.

After an additional 3 weeks, the rabbits were boosted with 200 μg of antigen in incomplete adjuvant.

Eleven days later, the immune serum was collected. This serum is referred to as occlusion body antisera. Monospecific spheroidin antibodies were prepared from this serum based on immunoaffinity of individual antibodies for purified spheroidin (Harlow and Lane, 1988). Samples of the sera were adsorbed to a nitrocellulose blot prepared from a preparative SDS-PAGE gel of solubilized AmEPV occlusion bodies. The section of the blot containing the 115 kDa AmEPV spheroidin and bound antibodies was then excised. The monospecific AmEPV spheroidin antibodies were eluted using 100 mM glycine, pH 2.5. After neutralization and dilution, the monospecific spheroidin antibodies were used to probe Western blots.

For immunoblotting, duplicate samples run on SDS-PAGE gels were prepared. One-half of the gel was stained with Coomassie blue, and the other half (containing prestained molecular mass markers) was transferred to nitrocellulose membrane in Tris-glycine buffer (Harlow and Lane, 1988) using the BioRad Trans Blot at 250 mA for 3 hours. The blot was blocked for 2 hr using BLOTTO (0.5% nonfat dry milk in TBS: 0.01 M Tris, pH8, 0.15 M NaCI). Dilutions of the antibody were prepared in BLOTTO and adsorbed to the blot overnight. The blot was washed 3 times in TBS at room temperature, and the secondary antibody (goat anti-rabbit conjugated to alkaline phosphatase) at a 1:1000 dilution was adsorbed to the blot for 11/2 hr. The blot was washed with TBS as previously. Secondary antibody reactions and color development was as described (Harlow and Lane, 1988).

SDS-PAGE of Solubilized Occlusion Bodies

When purified occlusion bodies of CbEPV, CfEPV and AmEPV are solubilized in Laemmli sample buffer, boiled immediately, and analyzed on SDS-PAGE gels, Coomassie blue staining shows the major protein to be about 115 kDa in each case. The Choristoneura EPVs show a second 47 kDa protein in lesser amounts. Other minor proteins were also observed.

The purported CbEPV spheroidin gene has a coding capacity of 47 kDa (Yuen et al., 1990) despite the fact that the observed size of the corresponding spberoidin appears to be 115 kDa, which is similar to that observed for the AmEPV spheroidin. This discrepancy has been explained by suggesting that the CbEPV spheroidin exists as relatively unstable dimers, which dissociate under a variety of conditions to monomers of 47 kDa (Yuen et al., 1990). The AmEPV spheroidin of 115 kDa, however, shows no such propensity for dissociation.

Prior to dissolution, occlusion bodies are stable and routinely stored at 4° C. in buffer. The only discernible difference in methods of occlusion body solubilization and preparation is the incubation time in SDS buffer before boiling. The relative instability of the various spheroidins was evaluated by incubating the occlusion bodies of all three EPVs at room temperature for up to two hours in SDS solubilizing buffer before boiling the samples. While some degradation of the 115 kDa protein was observed for the CfEPV OB preparation, little if any degradation of the CbEPV or AmEPV preparations was observed. The CfEPV 115 kDa protein was degraded to a variety of smaller proteins but not in a fashion suggesting a relationship to the 47 kDa protein. Whether the OB suspension was in 1× TE (10 mM Tris, 1 mM EDTA, pH8) or in deionized water prior to dissolution has no effect on the subsequent degradation CfEPV occlusion bodies.

Discovery of an AmEPV Spheroidin Gene Homolog in CbEPV and CfEPV

Selected oligonucleotide primers derived from within various regions of the AmEPV spheroidin gene were selected as appropriate primer pairs for PCR to look for the spheroidin gene in CbEPV and CfEPV. The relative positions of these primers within the spheroidin gene are shown in FIG. 5. Table 2 lists the specific primer pairs and sequences, the expected size of the PCR products based on the AmEPV spheroidin sequences, and the results when these primers were used in conjunction with CbEPV or CfEPV templates. From Table 2, for CbEPV template 10 out 19 primer pairs resulted in an appropriate size product expected if the two genes were similar. For CfEPV this was 13 out of 19 primer pairs. We chose one of the products (1 kb) generated from CfEPV DNA by primer pair 1-13 (in Table 2) for further analyses.

This PCR product was radiolabeled and used as a probe for a blot containing restriction fragments of both CfEPV and AmEPV DNAs. All hybridizations to CfEPV showed predominant, specific hybridization signals. The CfEPV derived probe also shows appropriate, discrete hybridizations to AmEPV DNA; i.e., a 13 kb HindIII fragment, a 20 kb EcoRI fragment, a 4.5 kb BglII fragment, and a 4.5 kb BstBI fragment. This pattern of hybridization to AmEPV is that expected for hybridization to the AmEPV spheroidin gene.

Partial Sequence of a Spheroidin-like Gene in CbEPV or CfEPV

Further indications of the existence for an AmEPV spheroidin gene homolog in the genome Choristoneura EPVs come from PCR product sequencing of the 1 kb Choristoneura PCR products (primer pair 1-13; Table 2). The resulting sequences derived from the CbEPV or CfEPV DNA with a comparison to the AmEPV sequence is shown in FIG. 6A. When the deduced amino acid sequence of this region is compared (FIG. 6B), a very high degree of homology is found between all three viruses.

The Spheroidin-like Gene in CbEPV and CfEPV is Expressed

Samples of the CbEPV=115 kDa protein were isolated from SDS-polyacrylamide gels, and treated with lys-c endoprotease to generate peptides for microsequencing. Three of the resulting peptides were analyzed, and the amino acid sequence was compared to the spheroidin of AmEPV. The CbEPV sequences obtained were homologous to three corresponding regions of the AmEPV spheroidin (FIG. 6C). These results demonstrate that the Choristoneura viruses not only contain a spheroidin-like gene, but that gene is expressed to yield a polypeptide within occlusion bodies of similar size and sequence to the previously-identified spheroidin protein of AmEPV.

We have also addressed the question of whether the AmEPV spheroidin homolog in CbEPV and CfEPV is expressed by a Western blot analysis of the proteins of CbEPV and CfEPV using antibody derived against either AmEPV occlusion bodies or monospecific sera against AmEPV spheroidin. Sera directed against purified AmEPV occlusion bodies recognize proteins of ≈115 kDa in both CbEPV and AmEPV. Stronger signals are observed in the AmEPV samples as expected. An AmEPV protein of 38 kDa is also recognized in the samples. Weak binding is also observed to the abundantly expressed protein of the vertebrate cowpox virus which was used as a control. When immunoaffinity purified, monospecific AmEPV spheroidin sera is used, the 115 kDa protein of CbEPV also cross-reacts. Similar results were obtained with CfEPV. These results also support the conclusion that the two Choristoneura viruses and AmEPV encode a very similar major occlusion body protein of 115 kDa which in AmEPV corresponds to the spheroidin gene.

Co-linearity of AmEPV, CbEPV, and CfEPV Maps in the Spheroidin Region

We have shown that the gene adjacent to the 3' terminus of the AmEPV spheroidin gene is NPH I (NTPase I) in polarity opposite to that of the spheroidin gene. A NPH I gene from CbEPV has been sequenced (Yuen et al., 1991).

The sequence of the NPH I (or NTPase I) gene of AmEPV is presented in FIGS. 7A-7B. The 3' end sequence of this gene is provided in FIG. 1 and the nucleotide numbering system depicted in FIGS. 7A-7B results from appending the 5 end of the sequence to the sequence provided in FIG. 1.

When the complete coding sequence and deduced amino acid sequence of the AmEPV NPH I gene was compared to the already published CbEPV NPH I gene (Yuen et al., 1991), the two genes show 89% amino acid and 86% nucleotide identity. Both proteins have a deduced 648 amino acids, with the major difference being that AmEPV has deleted amino acid number 127 and has one extra amino acid at the very end of the sequence. Both genes show the typical poxvirus late gene promoter sequence motif, TAAATG, at the beginning of the open reading frame as well as the A+T rich sequence upstream of the gene. Of the 30 bases preceding the starting ATG, only a single G differentiates the AmEPV and CbEPV. The intergenic region between the spheroidin and NPH I genes begins to diverge immediately following the NPH I open reading frame (ORF) at the downstream 3' end.

The proximity of the spheroidin and NPH I genes in both Choristoneura viruses was tested by performing a series of PCR reactions using the PCR primers shown in FIG. 8 which were designed based on the AmEPV gene arrangement and were used with either CfEPV or CbEPV. Primers RM206 and RM212 are described above in this example, RM83 and RM161 in Table 2. Primer pair RM161-RM212 failed to give a PCR product with CbEPV DNA indicating sequence differences between CbEPV and CfEPV in the RM161 primer binding region. However, the other three reactions generated PCR products ranging in size from ≈1-2.5 kb, indicating that the NPH I and spheroidin genes are adjacent and arranged similarly to AmEPV. Based on the PCR products, the intergenic distance between the Choristoneura spheroidin and NPH I genes appears to be at least about 450 bp longer than the same region in AmEPV. The increased size of this intergenic region is large enough to perhaps allow for a small ORF to be present between the two genes in the Choristoneura viruses. However, PCR product sequencing of the RM83-RM212 and the RM161-RM206 PCR products using RM206 as the primer failed to show any OR-F of significant size.

Our results suggest that the published Choristoneura EPV gene identified by Yuen et al. (1990) as the spheroidin gene, is incorrect. Our evidence shows instead that the spheroidin gene of Choristoneura EPVs is virtually identical to that of AmEPV (FIG. 6), i.e., encodes a 115 kDa protein and is expressed. Hence this protein is highly conserved amongst all three viruses.

The AmEPV spheroidin gene found in the Choristoneura EPV genomes and the NPH I genes were found to be immediately adjacent to each other and in opposite polarity in all three viruses. Although the intergenic distance between the two genes is somewhat different between the two Choristoneura viruses and AmEPV, it would appear that the genes in this region of the viral DNA are co-linear.

We have shown that the linear conserved core of genes found in vertebrate poxviruses is not maintained in AmEPV. Based on the data presented here, it appears that the entomopoxviruses have evolved and maintained a common core of co-linear genes, different from their vertebrate counterparts.

It should be understood that the examples and embodiments described herein are for illustrative purposes only. Various modifications or changes in light thereof will be suggested to persons skilled in the art by this specification. The subject invention encompasses recombinant polynucleotide sequences, plasmids, vectors, and transformed hosts which are equivalent to those which are specifically exemplified herein in that the characteristic expression features are retained in said equivalent constructs even if inconsequential modifications to the DNA sequence have been made. For example, it is within the skill of a person trained in the art to use a fragment of the spheroidin gene's non-coding region which is upstream of the structural gene in order to achieve the desired level of expression. Such fragments of the regulatory sequences fall within the scope of the current invention, so long as the desired level of expression which is characteristic of this system is retained. Furthermore, inconsequential changes to the nucleotide sequences can be made without affecting the disclosed functions of these sequences. Such modifications also fall within the scope of the current invention and are to be included within the spirit and purview of this application and the scope of the appended claims.

EXAMPLE 12 Production of a Recombinant AmEPV which Expresses an Heterologous Gene Inserted into the AmEPV Thymidine Kinase Gene

An heterologous gene was inserted into the AmEPV Tk gene via homologous recombination, and recombinant virus expressing the heterologous gene was obtained as follows. Unless otherwise noted, for plaque assays, C11-3 (Tk⁻ cells produced as described below), were used in a 50:50 mixture of Excell:TC100 medium. The overlay used for detection of LacZ expression used only TC100 medium.

A plasmid, pTk::ATI-LacZ was prepared by using PCR and primers for the Tk gene with EcoRI ends. The PCR reaction was run on the full length clone of the EcoRI-Q fragment (pMEGtk-1, ATCC No 68532) described in Example 8, using primers RM282, SEQ ID NO. 67, and RM283, SEQ ID NO. 68, in about 100 μL 10 mM Tris, pH 7.76, o.4 mM EDTA. This resulted in the amplification of a fragment from base 253 to base 780 (about 527 base pairs) of the GenBank AAVTHYKIN locus, with internal EcoRi sites at each blunt end. The fragment also has a unique internal PacI site almost exactly in the middle of the fragment such that digestion with PacI results in the production of two sub-fragments of about 250 bp each. The fragment was digested with EcoRI, and ligated into EcoRI digested pBluescript II to produce plasmid pBSTK. The pBSTK plasmid was transformed into E. coli and clones carrying the recombinant plasmid were identified using the standard IPTG/X-gal method. The Tk gene fragment was then excised from the pBSTK plasmid with BamHI and AccI. In addition, pBR322 was digested with BamHI and AccI, and the 2.5 Kb fragment containing the ampicillin resistance gene and the origin of replication was gel purified. The BamHI-AccI Tk gene fragment and the pBR322 BamHI-AccI fragments were then ligated to generate plasmid pRTK An aliquot of this plasmid was digested with BamHI and AccI to confirm the presence of the BammHI-AccI Tk gene fragment. The pRTK plasmid was then digested with PacI to linearize the plasmid and PacI ends were blunted and treated with calf intestinal phosphatase to prevent self-ligation. The plasmid construct pSC11, provided by Dr. Bernard Moss of the NIH, was digested with XhoI and PstI, the 3.1 kb fragment was isolated and ligated to the ATI promoter which was produced by PCR of cowpox virus DNA, Brighton Red Strain, using a 5'-primer which produced a KpnI site and a 3'-primer which produced an XhoI site. The ATI-LacZ cassette was then digested with KpnI and PstI and the 3.4 kb fragment was gel-purified. This fragment was blunt-ended and ligated into the blunt ended, linearized pRTK vector to produce the pTK::ATI-LacZ vector having about 250 bp of Tk sequence flanking each end of the ATI-LacZ gene cassette. Recombinant plasmids were identified by PCR with primers specific for the ATI promoter, and the recombinants were confirmed by additional PCR reactions using primers specific for the Tk and LacZ sequences.

Insect cells (LD652 gypsy moth) infected with AmEPV were then transfected with the pTK:ATI-LacZ construct. The cells were grown in the commercially available TC100 medium (GIBCO). Virus that recombined with the plasmid DNA was then selected by overlaying infected cells, plated at 10-fold serial dilutions of the transfection mixture, with agarose containing X-gal and selecting blue plaques for expansion and further characterization. Out of about 80 plaques total, we were able to select one blue plaque by this method, demonstrating that the LacZ gene presented in the context of the pTK::ATI-LacZ plasmid was taken up by the virus infected cells, and that homologous recombination of the ATI-LacZ cassette into the AmEPV had occurred. Using completely analogous methods to those described above, any expression cassette can be introduced into the Entomopoxvirus genome and expressed in insect cells. Because the ATI promoter is a mammalian (cowpox virus) vector, this experiment also demonstrates the ease with which a gene cassette constructed for mammalian expression can be adapted for expression by recombinant Entomopoxvirus in insect cells.

The construct used to produce recombinant entomopoxvirus may be modified so as to increase the efficiency with which recombinant virus is produced. This is achieved by the simple expedient of including more Tk gene as flanking sequence on either side of the heterologous gene sought to be recombined into the Entomopoxvirus genome. This increased recombination efficiency was demonstrated in the following experiment (see FIG. 9) in which 748 bp of downstream Tk flanking sequence was used on one side of the ATI-LacZ expression cassette and 664 bp of upstream Tk flanking sequence was used on the other side of the ATI-LacZ expression cassette:

The vector pYLATILacZ was produced as shown in FIG. 11 by PCR amplification of a portion of the EcoRI-Q fragment using as primers pTKI, SEQ ID NO. 69, and pTK2, SEQ ID NO. 70 as a first pair, and pTK3, SEQ ID NO. 71, and pTK4, SEQ ID NO. 72, as a second pair. In this manner, two fragments were produced. The first had SacI and BamHI ends, and the second had HindIII and HindII ends. The first fragment was cloned into pBluescript II (SK+) from Stratagene, and, in a separate step, the second fragment was then cloned into this intermediate clone to produce pTkDU. Because the Tk gene in pTkDU is interrupted, this vector encodes a non-functional Tk gene product. Therefore Cl 1.3 The cells (produced by a process of adaptation of Tk⁺ LD652 cells to increasing levels, 10 μg/ml every 5 weeks, of BuDR over one year up to 100 μg/ml BuDR) transfected with the pTkDU vector grew well in growth media supplemented with 100 μg/ml BuDR.

The ability of this vector to produce recombinant AmEPV was tested by first infecting Tk⁺ LD652 cells with Tk⁺ AmEPV. The infected cells were then transfected with the pTkDU vector and the cells were allowed to grow for 4 to 5 days in culture. The entire contents of the cell culture was then used to infect C11.3 Tk cells plated with 100 μg/ml BuDR. Multiple plaques were identified as a result of these steps, thus demonstrating the production of Tk⁻ recombinant AmEPV. To confirm that the recombinant virus was produced via recombination with the pTkDU vector, virus was isolated, viral DNA was digested with EcoRI, and the digest thus produced was probed with non-radioactively labeled (digoxigenin) EcoRI-Q fragment. Because a new EcoRI site was inserted into the middle of the Tk gene present in the pTkDU vector, if the Tk⁻ virus was produced via homologous recombination with the transfected pTkDU vector, the predicted Southern blot result is that two fragments would light up, with one fragment having a size of about 748 bp and another fragment of about 664 bp. On the other hand, spontaneous mutants would be predicted to have only one EcoRI fragment having a size of about 1.5 KB. As shown in the Southern blot provided (FIG. 10), two fragments of the predicted size were observed in the digests from several recombinant virus plaques (Lanes 1-3; Lane M=λ DNA EcoRI-HindIII molecular weight markers; lane 4=the EcoRI cut pTkDU vector used to create the recombinant viruses shown in lanes 1-3, some partial digestion is noted; lane 5=wild type AmEPV DNA cut with EcoRI-the expected 1.5. KB band is noted).

To produce pYLATILacZ with the heterologous LacZ gene acting as a marker, the pTkDU vector was then digested with EcoRV and PstI to linearize the vector. The KpnI-PstI ATI-LacZ gene cassette was then produced by first digesting with KpnI, blunt ending this end with T4 DNA polymerase and then digesting with PstI. The ATI-LacZ cassette was then ligated to the HincII-PstI linearized pTkDU vector to produce the vector pYLATILacZ. Upon transfection of this construct into AmEPV infected insect cells, blue recombinants are selected as described above.

The production of Tk⁻ Entomopoxvirus and of blue Entomopoxvirus plaques clearly demonstrates the ability to produce a recombinant Entomopoxvirus and to express an heterologous gene therefrom. It also clearly demonstrates the production of a recombinant cell in which an heterologous protein is produced from a recombinant virus having a thymidine kinase-heterologous gene fusion within its genome. This example also demonstrates the ability to screen for disruption of the thymidine kinase gene. Using exactly analogous methods, the same conclusions for the spheroidin gene are supported by this work. Palmer et al. (1995) have used analogous methods to produce recombinant Entomopoxvirus via insertion of an heterologous gene into the spheroidin locus. A further advantage of the method exemplified in this work is that while recombination into the Entomopoxvirus Tk gene disrupts the Tk gene, the spheroidin gene may be left intact and recombinant Entomopoxvirus could be environmentally stable while embedded in the occlusion body.

EXAMPLE 13 Characterization of the Entomopoxvirus Spheroidin Promoter:

To better characterize the Entomopoxvirus spheroidin promoter, the experiment outlined in FIG. 11 was conducted as follows. The end result of the experiment utlizes differential expression from different spheroidin promoter sub-fragments to drive a reporter gene (LacZ) to show the different strength of the promoter depending on the sequence utilized:

Using PCR primers pU, SEQ ID NO. 73, PU2 SEQ ID NO. 74 and pU20, SEQ ID NO. 75 two different spheroidin promoter fragments having either +2 nucleotides (pU +pU2) or +20 nucleotides (pU +pU20) were produced. In either case, these primers provide a 5'-Sac1 site and a 3'-BamH1 site. In addition, the PCR primers pD1, SEQ ID NO. 76 and pD2, SEQ ID NO. 77 were used to amplify a 1 kb downstream fragment containing the spheroidin coding sequence with a 5'-HindIII and a 3'-HincII terminus. These fragments were then separately cloned into the Sac1-BamH1 site and the HindIII-HincIl site of the commercially available vector pBluescript II (SK⁺), Stratagene, La Jolla, Calif., to produce vectors pDU2 (4984 bp) and pDU20 (5002 bp). Each of these vectors was then linearized at the BamHl site and the LacZ gene with BamH1 termini, derived by digestion of pMC1871 (1746 bp) obtained from Pharmacia Biotech., Inc. Piscataway, N.J. (Cat. No. 27-4945-01) with BamH1, was ligated into the linearized vectors to produce pDU2LacZ and pDU20LacZ. These vectors were then transfected into LD652 cells infected with wt AmEPV at an M.0.I of at least 5, and the amount of LacZ produced 54 hours postinfection was quantitated by freeze-thawing and sonicating the harvest. A chromogenic assay, in which a colored product of ONPG (O-nitrophenyl-β-D-galactoside) is quantitated at 420 nm, according to Miller, J. H., Experiments in Molecular Genetics; Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1972, p. 352-355, using chloroform in place of toluene, was used.

The results of this assay were:

a) For Recombinant AmEPV produced by pDU20LacZ:

    ______________________________________     A.sub.420     ______________________________________     0.847     0.878     Average = 0.862     ______________________________________

b) For Recombinant AmEPV produced by pDU2LacZ:

    ______________________________________     A.sub.420     ______________________________________     0.161     0.178     Average = 0.170     ______________________________________

Thus, the recombinant AmPEV with the +20 spheroidin promoter produced 5.1 times the amount of β-gal activity than did the +2 recombinant.

From this experiment, it is evident that although the spheroidin promoter up to and including the ATG is active, the spheroidin promoter extends beyond the spheroidin ATG.

EXAMPLE 14 Production and Use of a Mammalian/Insect Bi-Functional Vector

To optimize the utility of the Entomopoxvirus expression system described herein, a bi-functional vector for facile production of either recombinant Entomopoxvirus (for heterologous gene expression in insect cells) or recombinant vaccinia (for heterologous gene expression in mammalian cells) constructs is produced as shown in FIG. 12 and as described below.

Since the vaccinia ATI promoter operates in both Entomopoxvirus infected insect cells, and in vaccinia infected mammalian cells, the ATI promoter is one candidate for use in the bi-functional vector. Naturally, other promoters which similarly function in both host cell types may be utilized. On either side of the ATI promoter gene cassette, AmEPV Tk flanking sequences are provided as described above in example 12. On either side of the AmEPV Tk sequences, vaccinia virus Tk flanking sequences are inserted. Naturally, Tk sequences from Entomopoxvirus strains other than AmEPV could be used and other vertebrate virus Tk flanking sequences than vaccinia Tk sequences could be used. An heterologous gene is then separately cloned into a restriction site such that it is operatively linked to the An promoter. Specifically, these steps may be carried out as follows:

pBluescript II (KS+) is digested with BssHII to excise the multiple cloning site and linearize the vector. The linearized vector is then blunt-ended by filling in with nucleotide triphosphates and the Klenow enzyme. A blunt-ended HindIII-Xhol vaccinia DNA fragment (1.76 kb) containing the vaccinia Tk gene is ligated into the blunt-ended vector to create pVTk. pVTk is then cut with EcoRI, which cuts the vaccinia Tk gene into an upstream 786 bp and a downstream 986 bp fragment, and is then blunt-ended with Klenow. The left arm of the AmEPV Tk gene (about 664 bp) is amplified by PCR as described in Example 12, except that the primers are designed to provide Sma1 sites at the termini, with an internal HindIII and NotI site being internal to the Sma1 site at one end of the amplified fragment. The amplified fragment is cleaved with Sma1 and then ligated into the EcoRI cut pVTk vector, to produce pVTkETkO.5. pVTkETkO.5 is then linearized with HindIII, which cuts the AmEPV Tk gene left arm, and blunt-ended with Klenow. The right arm of the AmEPV Tk gene (about 748 bp) is then PCR amplified as described in Example 12, except that the primers are designed to provide Sma1 sites at the termini. The amplified fragment is cut with Sma1, and ligated into the linearized pVTkETkO.5 vector to generate pVTkETk having a contiguous segment of nucleotides as follows: 768 bp vaccinia Tk-664 bp AmEPV Tk-748 bp AmEPV Tk-986 bp Vaccinia Tk. Between the two AmEPV Tk segments, there is a unique NotI restriction site. The pVTkETk bi-functional vector is linearized with NotI and is available for insertion of any expression cassette. Thus, to produce an expression cassette, pBluescript II (KS+) is cut with NotI and any other appropriate second enzyme. The ATI promoter is PCR amplified from cowpox virus using primers that provide an NotI restriction site at one end of the promoter and a second site at the other terminus of the promoter which matches the second site used for cleaving the pBluescript vector. The ATI promoter is then ligated into the linearized pBluescript vector. A gene of interest is amplified using PCR primers such that at the downstream end of the gene, there is an NotI site internal to another restriction site, while at the other end, at the start of the sequence to be translated, a site which matches the site external to the NotI and which matches the second site placed at the terminus of the ATI promoter is provided. The fragment is ligated into the pBluescript vector carrying the ATI promoter, in-frame with the promoter, and the construct is amplified by transformation into E. coli. The ATI-gene cassette is then excised using NotI and ligated into the pVTkETk bi-functional vector linearized with NotI to produce the bi-functional vector with the ATI promoter driving the heterologous gene. A bi-functional vector produced as described above is then utilized, according to FIG. 12, to produce either entomopoxvirus or vaccinia recombinants.

For production of Entomopoxvirus recombinants which express the foreign gene, insect cells are infected with wild-type Entomopoxvirus and then transfected with the heterologous gene construct, and recombinants containing the heterologous gene are then isolated. For production of vaccinia virus recombinants, mammalian cells are infected with wild-type vaccinia virus and then transfected with the heterologous gene construct, and recombinants containing the heterologous gene are isolated.

    __________________________________________________________________________     #             SEQUENCE LISTING     - (1) GENERAL INFORMATION:     -    (iii) NUMBER OF SEQUENCES: 77     - (2) INFORMATION FOR SEQ ID NO:1:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 8457 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: Amsacta m - #oorei entomopoxvirus     -     (ix) FEATURE:               (A) NAME/KEY: CDS     #(65..1459)B) LOCATION: complement     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 1474..2151     -     (ix) FEATURE:               (A) NAME/KEY: CDS     #(2239..2475) LOCATION: complement     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 2502..2987     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 3080..6091     -     (ix) FEATURE:               (A) NAME/KEY: CDS     #(6277..6768) LOCATION: complement     #ID NO:1: (xi) SEQUENCE DESCRIPTION: SEQ     - AGATCTGATG TTCTATATAT AGTACAAATT TGTATGATTA ATTGATATTT TA - #AAATTCAA       60     - GATATTAAAT ATTAGATTCT AAACTATTCT TCTCATTATC AATATAACTA TC - #ATAATCAT      120     - TTTTTATTTT ACTACATACA TTCATAATTC TATTACTATT TTTTTTATAC AT - #ATCTATTA      180     - ATTCCATAAA CTTTTTATTT TTTATATTAA ATATTTCTAA TGTATTTTTA AA - #TTCGTCAA      240     - TACTATTAAT ATCATATCTA GAAATAAATA ATGCACCTCT ATAACTACTA GC - #CAATAAAT      300     - CACCAATAAA ACTCATAGAA TAATATAATT TTTTAAATTC AAATTTAGAT TT - #TATGTTGA      360     - AATAAACTAT ATAATATAAA AATATTATAT TAAACATACC ACAATCGGGA CT - #ATCATATT      420     - GTAATTCAAA AGTATTAAAA AAGTAATAAT TTACATTTTT AAATATATCA TT - #TAAATATT      480     - CTGATAGTAC ATCAATGTAT AAATAAGCAT AATTAGTATT AGGAGTACTA TT - #GTAGTGTT      540     - TATGGCTTTT TATAGTCATA TCAGATTCAA TAAACATATA TTTTTTATTT TG - #TTTTATAA      600     - GTTCTGGTAT ATAACCACTA CTATTAAAAA AGTATGCAGC TTTTTTATCT TT - #ATCAAAGT      660     - GTTTATCTAT TACGCAACAA GTAAAATGAT CATTATAAAT TATAGGAAAC AT - #AAAAAATC      720     - TTTTTTTATC ATTCATTAAA AAAAATTTTA CTCTATCTTC AAGTTTATAG CA - #TCTCATAG      780     - ATGAAGCTAC TGTAGCAATA TTTTTATCAG TTTTTTCAAA TAAAATCAAA TG - #AAAATAAT      840     - CATAATCTGT ATTAATCATA GTTAATGGAT ATATACAATT ATATATATCT CC - #CGAACTTA      900     - ACCATGTAGA TTTATCATGT TTTCTTGGGT AAGCTTTAGG TTTAGGATTA AA - #TCCCAAAG      960     - GCGGTATTCC TATTTGAGCA TCCAAATCAT CATAAATTGT GGCAAATGTA GA - #AAAATCTC     1020     - TTGTTTTGGA TAATTCTGAT TTTAGAAAAG ACTTTCTCAT ATATACTAAT GG - #AATGCCTT     1080     - TATATTTTTT AGATGTAATA AAAGTATTAA TATTTATATT TTTATCTTGT AA - #ATATTTTT     1140     - TTATAGTCCA AAATAGAAAA AATTTTCTTT TAATATTATT TTCAAAATTA AT - #ATTATTAA     1200     - TATGATTTGG ATCTAAAACT AATTCATTAT ATAATATTTC CAAGTATTTT AT - #AGGTATAA     1260     - ATGTTACTTT ACCTCTTGTT TCATCATCAT CATCTATTTT TTCTAATATA GC - #TATATTTG     1320     - CATTAGTATT ATATTTAATA GGATTTATAA AATATACCAT ATTATCTATT TT - #ACTAAAAA     1380     - ATAACATAGA CATAAAATTA ATACCAGATT CTGGCATTTT TAAATTTTTA TT - #TGGAAATC     1440     - TTCTAATTTT ATTATTCATT ATTTATTTAA TAA ATG TTT CTA GT - #T TAT TTC AAT     1494     # Met Phe Leu Val Tyr Phe Asn     #5  1     - ACA TTT TTA ATA ATA ATT TTA TTA TTT GGT AT - #T ATA GGT ATT TAT ATA     1542     Thr Phe Leu Ile Ile Ile Leu Leu Phe Gly Il - #e Ile Gly Ile Tyr Ile     #         20     - TTA ACA TTT GTG TTT AAT ATA GAT TTT TTA AT - #A AAT AAT AAT AAA ATA     1590     Leu Thr Phe Val Phe Asn Ile Asp Phe Leu Il - #e Asn Asn Asn Lys Ile     #     35     - TAT ATA TTA TCA TAT AAC GCA ACT AAT ATA AA - #C AAT ATA AAT AAT TTA     1638     Tyr Ile Leu Ser Tyr Asn Ala Thr Asn Ile As - #n Asn Ile Asn Asn Leu     # 55     - AAT TTA TAC GAT TAT TCA GAT ATT ATA TTT TT - #G ACA AAT TTT AAC ATA     1686     Asn Leu Tyr Asp Tyr Ser Asp Ile Ile Phe Le - #u Thr Asn Phe Asn Ile     #                 70     - AAT AAT AAT CTT TTA GTA ACA CAA GCT AAT AA - #T TTA CAA GAT ATA CCA     1734     Asn Asn Asn Leu Leu Val Thr Gln Ala Asn As - #n Leu Gln Asp Ile Pro     #             85     - ATA TTT AAT GTA AAT AAT ATT ATA TCT AAT CA - #A TAT AAT TTT TAT TCA     1782     Ile Phe Asn Val Asn Asn Ile Ile Ser Asn Gl - #n Tyr Asn Phe Tyr Ser     #        100     - GCG TCT AGT AAT AAT GTA AAT ATA TTA TTA GG - #A TTA AGA AAA ACA TTA     1830     Ala Ser Ser Asn Asn Val Asn Ile Leu Leu Gl - #y Leu Arg Lys Thr Leu     #   115     - AAT ATA AAT AGA AAT CCA TTT TTA TTA TTT AG - #A AAT ACA TCT CTA GCT     1878     Asn Ile Asn Arg Asn Pro Phe Leu Leu Phe Ar - #g Asn Thr Ser Leu Ala     120                 1 - #25                 1 - #30                 1 -     #35     - ATA GTT TTC AAT AAT AAT GAA ACT TTT CAC TG - #T TAT ATA AGT TCA AAT     1926     Ile Val Phe Asn Asn Asn Glu Thr Phe His Cy - #s Tyr Ile Ser Ser Asn     #               150     - CAA AAT AGT GAT GTA TTA GAT ATA GTA TCA CA - #T ATA GAA TTT ATG AAA     1974     Gln Asn Ser Asp Val Leu Asp Ile Val Ser Hi - #s Ile Glu Phe Met Lys     #           165     - TCT AGA TAT AAT AAA TAT GTA ATT ATA GGA GA - #A ATA CCC GTA AAT AAT     2022     Ser Arg Tyr Asn Lys Tyr Val Ile Ile Gly Gl - #u Ile Pro Val Asn Asn     #       180     - AAT ATA TCT ATT AAT AAT ATA TTA AAT AAT TT - #T GCT ATT ATA ACT AAT     2070     Asn Ile Ser Ile Asn Asn Ile Leu Asn Asn Ph - #e Ala Ile Ile Thr Asn     #   195     - GTG AGA TTA ATA GAT AAA TAT AAC TCT ATA AT - #A TCA TTT TTA AAT ATC     2118     Val Arg Leu Ile Asp Lys Tyr Asn Ser Ile Il - #e Ser Phe Leu Asn Ile     200                 2 - #05                 2 - #10                 2 -     #15     - AAC GTA GGA ACA CTT TTT GTC ATA AAT CCA TA - #ATATTTAG TAATAATCAC     2168     Asn Val Gly Thr Leu Phe Val Ile Asn Pro     #               225     - TAACATATTT TTTATTAAAA TGAATAAAAT ATATATTGTT ATTGTCAATA TT - #TTATATCA     2228     - TTTTACAGTC TTATTTTTTT TTTTTGCTTT TAGGTATAAT TTTACCTTCT AA - #ACGTTTAT     2288     - CTCCCCAAAC ATCTACAGTA GATGGTTTAT TAGATTCTGT GTTATACACA TC - #TGCTGGAT     2348     - TTGCGGCATT TGTATCCAAA CCATAATATC CAGGTCTATA ATTATCTTTA AA - #AACTTGGG     2408     - ATTGAGATAC TTCTTCAGTT TTTAAATTAT TAAAATATCC AAGATTATTT TT - #TTTTGATG     2468     - AAGACATAAT TGATATTATA ATACTTTATA GAT ATG TCA ATA TT - #T ATC TAC TAT     2522     # Met Ser Ile Phe Ile Tyr Tyr     #5  1     - ATT TTC AAC AAT AGA TTT TAT ATA TAT AAA AG - #A ATG AAT ACT GTA CAA     2570     Ile Phe Asn Asn Arg Phe Tyr Ile Tyr Lys Ar - #g Met Asn Thr Val Gln     #         20     - ATT TTA GTT GTC ATA TTA ATA ACA ACA GCA TT - #A TCT TTT CTA GTT TTT     2618     Ile Leu Val Val Ile Leu Ile Thr Thr Ala Le - #u Ser Phe Leu Val Phe     #     35     - CAA TTA TGG TAT TAT GCC GAA AAT TAC GAA TA - #T ATA TTA AGA TAT AAT     2666     Gln Leu Trp Tyr Tyr Ala Glu Asn Tyr Glu Ty - #r Ile Leu Arg Tyr Asn     # 55     - GAT ACA TAT TCA AAT TTA CAA TTT GCG AGA AG - #C GCA AAT ATA AAT TTT     2714     Asp Thr Tyr Ser Asn Leu Gln Phe Ala Arg Se - #r Ala Asn Ile Asn Phe     #                 70     - GAT GAT TTA ACT GTT TTT GAT CCC AAC GAT AA - #T GTT TTT AAT GTT GAA     2762     Asp Asp Leu Thr Val Phe Asp Pro Asn Asp As - #n Val Phe Asn Val Glu     #             85     - GAA AAA TGG CGC TGT GCT TCA ACT AAT AAT AA - #T ATA TTT TAT GCA GTT     2810     Glu Lys Trp Arg Cys Ala Ser Thr Asn Asn As - #n Ile Phe Tyr Ala Val     #        100     - TCA ACT TTT GGA TTT TTA AGT ACA GAA AGT AC - #T GGT ATT AAT TTA ACA     2858     Ser Thr Phe Gly Phe Leu Ser Thr Glu Ser Th - #r Gly Ile Asn Leu Thr     #   115     - TAT ACA AAT TCT AGA GAT TGT ATT ATA GAT TT - #A TTT TCT AGA ATT ATA     2906     Tyr Thr Asn Ser Arg Asp Cys Ile Ile Asp Le - #u Phe Ser Arg Ile Ile     120                 1 - #25                 1 - #30                 1 -     #35     - AAA ATA GTA TAT GAT CCT TGT ACT GTC GAA AC - #A TCT AAC GAT TGT AGA     2954     Lys Ile Val Tyr Asp Pro Cys Thr Val Glu Th - #r Ser Asn Asp Cys Arg     #               150     - TTA TTA AGA TTA TTG ATG GCC AAT ACA TCA TA - #AATACATT ATAATATTAT     3004     Leu Leu Arg Leu Leu Met Ala Asn Thr Ser     #           160     - TATAATATCA ATCATAATTT TTATATATAT TTTATCTAAA AGGACTTTTT AT - #TTTTTATA     3064     #ACC AAA ACA ATA AGA    3115AC GTA CCT TTA GCA     #Ser Asn Val Pro Leu Ala Thr Lys Thr Ile A - #rg     #                10     - AAA TTA TCA AAT CGA AAA TAT GAA ATA AAG AT - #T TAT TTA AAA GAT GAA     3163     Lys Leu Ser Asn Arg Lys Tyr Glu Ile Lys Il - #e Tyr Leu Lys Asp Glu     #         25     - AAT ACT TGT TTC GAA CGT GTA GTA GAT ATG GT - #A GTT CCA TTA TAT GAT     3211     Asn Thr Cys Phe Glu Arg Val Val Asp Met Va - #l Val Pro Leu Tyr Asp     #     40     - GTG TGT AAT GAA ACT TCT GGT GTT ACT TTA GA - #A TCA TGT AGT CCA AAT     3259     Val Cys Asn Glu Thr Ser Gly Val Thr Leu Gl - #u Ser Cys Ser Pro Asn     # 60     - ATA GAA GTA ATT GAA TTA GAC AAT ACT CAT GT - #T AGA ATC AAA GTT CAC     3307     Ile Glu Val Ile Glu Leu Asp Asn Thr His Va - #l Arg Ile Lys Val His     #                 75     - GGC GAT ACA TTA AAA GAA ATG TGT TTT GAA TT - #A TTG TTC CCG TGT AAT     3355     Gly Asp Thr Leu Lys Glu Met Cys Phe Glu Le - #u Leu Phe Pro Cys Asn     #             90     - GTA AAC GAA GCC CAA GTA TGG AAA TAT GTA AG - #T CGA TTA TTG CTA GAT     3403     Val Asn Glu Ala Gln Val Trp Lys Tyr Val Se - #r Arg Leu Leu Leu Asp     #        105     - AAT GTA TCA CAT AAT GAC GTA AAA TAT AAA TT - #A GCT AAT TTT AGA CTG     3451     Asn Val Ser His Asn Asp Val Lys Tyr Lys Le - #u Ala Asn Phe Arg Leu     #   120     - ACT CTT AAT GGA AAA CAT TTA AAA TTA AAA GA - #A ATC GAT CAA CCG CTA     3499     Thr Leu Asn Gly Lys His Leu Lys Leu Lys Gl - #u Ile Asp Gln Pro Leu     125                 1 - #30                 1 - #35                 1 -     #40     - TTT ATT TAT TTT GTC GAT GAT TTG GGA AAT TA - #T GGA TTA ATT ACT AAG     3547     Phe Ile Tyr Phe Val Asp Asp Leu Gly Asn Ty - #r Gly Leu Ile Thr Lys     #               155     - GAA AAT ATT CAA AAT AAT AAT TTA CAA GTT AA - #C AAA GAT GCA TCA TTT     3595     Glu Asn Ile Gln Asn Asn Asn Leu Gln Val As - #n Lys Asp Ala Ser Phe     #           170     - ATT ACT ATA TTT CCA CAA TAT GCG TAT ATT TG - #T TTA GGT AGA AAA GTA     3643     Ile Thr Ile Phe Pro Gln Tyr Ala Tyr Ile Cy - #s Leu Gly Arg Lys Val     #       185     - TAT TTA AAT GAA AAA GTA ACT TTT GAT GTA AC - #T ACA GAT GCA ACT AAT     3691     Tyr Leu Asn Glu Lys Val Thr Phe Asp Val Th - #r Thr Asp Ala Thr Asn     #   200     - ATT ACT TTA GAT TTT AAT AAA TCT GTT AAT AT - #C GCA GTA TCA TTC CTT     3739     Ile Thr Leu Asp Phe Asn Lys Ser Val Asn Il - #e Ala Val Ser Phe Leu     205                 2 - #10                 2 - #15                 2 -     #20     - GAT ATA TAT TAC GAA GTT AAT AAT AAT GAA CA - #A AAA GAT TTA TTA AAA     3787     Asp Ile Tyr Tyr Glu Val Asn Asn Asn Glu Gl - #n Lys Asp Leu Leu Lys     #               235     - GAT TTA CTT AAG AGA TAC GGT GAA TTT GAA GT - #C TAT AAC GCA GAT ACT     3835     Asp Leu Leu Lys Arg Tyr Gly Glu Phe Glu Va - #l Tyr Asn Ala Asp Thr     #           250     - GGA TTA ATT TAT GCT AAA AAT CTA AGT ATT AA - #A AAT TAT GAT ACT GTG     3883     Gly Leu Ile Tyr Ala Lys Asn Leu Ser Ile Ly - #s Asn Tyr Asp Thr Val     #       265     - ATT CAA GTA GAA AGG TTG CCA GTT AAT TTG AA - #A GTT AGA GCA TAT ACT     3931     Ile Gln Val Glu Arg Leu Pro Val Asn Leu Ly - #s Val Arg Ala Tyr Thr     #   280     - AAG GAT GAA AAT GGT CGC AAT CTA TGT TTG AT - #G AAA ATA ACA TCT AGT     3979     Lys Asp Glu Asn Gly Arg Asn Leu Cys Leu Me - #t Lys Ile Thr Ser Ser     285                 2 - #90                 2 - #95                 3 -     #00     - ACA GAA GTA GAC CCC GAG TAT GTA ACT AGT AA - #T AAT GCT TTA TTG GGT     4027     Thr Glu Val Asp Pro Glu Tyr Val Thr Ser As - #n Asn Ala Leu Leu Gly     #               315     - ACG CTC AGA GTA TAT AAA AAG TTT GAT AAA TC - #T CAT TTA AAA ATT GTA     4075     Thr Leu Arg Val Tyr Lys Lys Phe Asp Lys Se - #r His Leu Lys Ile Val     #           330     - ATG CAT AAC AGA GGA AGT GGT AAT GTA TTT CC - #A TTA AGA TCA TTA TAT     4123     Met His Asn Arg Gly Ser Gly Asn Val Phe Pr - #o Leu Arg Ser Leu Tyr     #       345     - CTG GAA TTG TCT AAT GTA AAA GGA TAT CCA GT - #T AAA GCA TCT GAT ACT     4171     Leu Glu Leu Ser Asn Val Lys Gly Tyr Pro Va - #l Lys Ala Ser Asp Thr     #   360     - TCG AGA TTA GAT GTT GGT ATT TAC AAA TTA AA - #T AAA ATT TAT GTA GAT     4219     Ser Arg Leu Asp Val Gly Ile Tyr Lys Leu As - #n Lys Ile Tyr Val Asp     365                 3 - #70                 3 - #75                 3 -     #80     - AAC GAC GAA AAT AAA ATT ATA TTG GAA GAA AT - #T GAA GCA GAA TAT AGA     4267     Asn Asp Glu Asn Lys Ile Ile Leu Glu Glu Il - #e Glu Ala Glu Tyr Arg     #               395     - TGC GGA AGA CAA GTA TTC CAC GAA CGT GTA AA - #A CTT AAT AAA CAC CAA     4315     Cys Gly Arg Gln Val Phe His Glu Arg Val Ly - #s Leu Asn Lys His Gln     #           410     - TGT AAA TAT ACT CCC AAA TGT CCA TTC CAA TT - #T GTT GTA AAC AGC CCA     4363     Cys Lys Tyr Thr Pro Lys Cys Pro Phe Gln Ph - #e Val Val Asn Ser Pro     #       425     - GAT ACT ACG ATT CAC TTA TAT GGT ATT TCT AA - #T GTT TGT TTA AAA CCT     4411     Asp Thr Thr Ile His Leu Tyr Gly Ile Ser As - #n Val Cys Leu Lys Pro     #   440     - AAA GTA CCC AAA AAT TTA AGA CTT TGG GGA TG - #G ATT TTA GAT TGC GAT     4459     Lys Val Pro Lys Asn Leu Arg Leu Trp Gly Tr - #p Ile Leu Asp Cys Asp     445                 4 - #50                 4 - #55                 4 -     #60     - ACT TCT AGA TTT ATT AAA CAT ATG GCT GAT GG - #A TCT GAT GAT TTA GAT     4507     Thr Ser Arg Phe Ile Lys His Met Ala Asp Gl - #y Ser Asp Asp Leu Asp     #               475     - CTT GAC GTT AGG CTT AAT AGA AAT GAT ATA TG - #T TTA AAA CAA GCC ATA     4555     Leu Asp Val Arg Leu Asn Arg Asn Asp Ile Cy - #s Leu Lys Gln Ala Ile     #           490     - AAA CAA CAT TAT ACT AAT GTA ATT ATA TTA GA - #G TAC GCA AAT ACA TAT     4603     Lys Gln His Tyr Thr Asn Val Ile Ile Leu Gl - #u Tyr Ala Asn Thr Tyr     #       505     - CCA AAT TGC ACA TTA TCA TTG GGT AAT AAT AG - #A TTT AAT AAT GTA TTT     4651     Pro Asn Cys Thr Leu Ser Leu Gly Asn Asn Ar - #g Phe Asn Asn Val Phe     #   520     - GAT ATG AAT GAT AAC AAA ACT ATA TCT GAG TA - #T ACT AAC TTT ACA AAA     4699     Asp Met Asn Asp Asn Lys Thr Ile Ser Glu Ty - #r Thr Asn Phe Thr Lys     525                 5 - #30                 5 - #35                 5 -     #40     - AGT AGA CAA GAC CTT AAT AAC ATG TCA TGT AT - #A TTA GGA ATA AAC ATA     4747     Ser Arg Gln Asp Leu Asn Asn Met Ser Cys Il - #e Leu Gly Ile Asn Ile     #               555     - GGT AAT TCC GTA AAT ATT AGT AGT TTG CCT GG - #T TGG GTA ACA CCT CAC     4795     Gly Asn Ser Val Asn Ile Ser Ser Leu Pro Gl - #y Trp Val Thr Pro His     #           570     - GAA GCT AAA ATT CTA AGA TCT GGT TGT GCT AG - #A GTT AGA GAA TTT TGT     4843     Glu Ala Lys Ile Leu Arg Ser Gly Cys Ala Ar - #g Val Arg Glu Phe Cys     #       585     - AAA TCA TTC TGT GAT CTT TCT AAT AAG AGA TT - #C TAT GCT ATG GCT AGA     4891     Lys Ser Phe Cys Asp Leu Ser Asn Lys Arg Ph - #e Tyr Ala Met Ala Arg     #   600     - GAT CTC GTA AGT TTA CTA TTT ATG TGT AAC TA - #T GTT AAT ATT GAA ATT     4939     Asp Leu Val Ser Leu Leu Phe Met Cys Asn Ty - #r Val Asn Ile Glu Ile     605                 6 - #10                 6 - #15                 6 -     #20     - AAC GAA GCA GTA TGC GAA TAT CCT GGA TAT GT - #C ATA TTA TTC GCA AGA     4987     Asn Glu Ala Val Cys Glu Tyr Pro Gly Tyr Va - #l Ile Leu Phe Ala Arg     #               635     - GCT ATT AAA GTA ATT AAT GAT TTA TTA TTA AT - #T AAC GGA GTA GAT AAT     5035     Ala Ile Lys Val Ile Asn Asp Leu Leu Leu Il - #e Asn Gly Val Asp Asn     #           650     - CTA GCA GGA TAT TCA ATT TCC TTA CCT ATA CA - #T TAT GGA TCT ACT GAA     5083     Leu Ala Gly Tyr Ser Ile Ser Leu Pro Ile Hi - #s Tyr Gly Ser Thr Glu     #       665     - AAG ACT CTA CCA AAT GAA AAG TAT GGT GGT GT - #T GAT AAG AAA TTT AAA     5131     Lys Thr Leu Pro Asn Glu Lys Tyr Gly Gly Va - #l Asp Lys Lys Phe Lys     #   680     - TAT CTA TTC TTA AAG AAT AAA CTA AAA GAT TT - #A ATG CGT GAT GCT GAT     5179     Tyr Leu Phe Leu Lys Asn Lys Leu Lys Asp Le - #u Met Arg Asp Ala Asp     685                 6 - #90                 6 - #95                 7 -     #00     - TTT GTC CAA CCT CCA TTA TAT ATT TCT ACT TA - #C TTT AGA ACT TTA TTG     5227     Phe Val Gln Pro Pro Leu Tyr Ile Ser Thr Ty - #r Phe Arg Thr Leu Leu     #               715     - GAT GCT CCA CCA ACT GAT AAT TAT GAA AAA TA - #T TTG GTT GAT TCG TCC     5275     Asp Ala Pro Pro Thr Asp Asn Tyr Glu Lys Ty - #r Leu Val Asp Ser Ser     #           730     - GTA CAA TCA CAA GAT GTT CTA CAG GGT CTG TT - #G AAT ACA TGT AAT ACT     5323     Val Gln Ser Gln Asp Val Leu Gln Gly Leu Le - #u Asn Thr Cys Asn Thr     #       745     - ATT GAT ACT AAT GCT AGA GTT GCA TCA AGT GT - #T ATT GGA TAT GTT TAT     5371     Ile Asp Thr Asn Ala Arg Val Ala Ser Ser Va - #l Ile Gly Tyr Val Tyr     #   760     - GAA CCA TGC GGA ACA TCA GAA CAT AAA ATT GG - #T TCA GAA GCA TTG TGT     5419     Glu Pro Cys Gly Thr Ser Glu His Lys Ile Gl - #y Ser Glu Ala Leu Cys     765                 7 - #70                 7 - #75                 7 -     #80     - AAA ATG GCT AAA GAA GCA TCT AGA TTA GGA AA - #T CTA GGT TTA GTA AAT     5467     Lys Met Ala Lys Glu Ala Ser Arg Leu Gly As - #n Leu Gly Leu Val Asn     #               795     - CGT ATT AAT GAA AGT AAT TAC AAC AAA TGT AA - #T AAA TAT GGT TAT AGA     5515     Arg Ile Asn Glu Ser Asn Tyr Asn Lys Cys As - #n Lys Tyr Gly Tyr Arg     #           810     - GGA GTA TAC GAA AAT AAC AAA CTA AAA ACA AA - #A TAT TAT AGA GAA ATA     5563     Gly Val Tyr Glu Asn Asn Lys Leu Lys Thr Ly - #s Tyr Tyr Arg Glu Ile     #       825     - TTT GAT TGT AAT CCT AAT AAT AAT AAT GAA TT - #A ATA TCC AGA TAT GGA     5611     Phe Asp Cys Asn Pro Asn Asn Asn Asn Glu Le - #u Ile Ser Arg Tyr Gly     #   840     - TAT AGA ATA ATG GAT TTA CAT AAA ATT GGA GA - #A ATT TTT GCA AAT TAC     5659     Tyr Arg Ile Met Asp Leu His Lys Ile Gly Gl - #u Ile Phe Ala Asn Tyr     845                 8 - #50                 8 - #55                 8 -     #60     - GAT GAA AGT GAA TCT CCT TGC GAA CGA AGA TG - #T CAT TAC TTG GAA GAT     5707     Asp Glu Ser Glu Ser Pro Cys Glu Arg Arg Cy - #s His Tyr Leu Glu Asp     #               875     - AGA GGT CTT TTA TAT GGT CCT GAA TAT GTA CA - #T CAC AGA TAT CAA GAA     5755     Arg Gly Leu Leu Tyr Gly Pro Glu Tyr Val Hi - #s His Arg Tyr Gln Glu     #           890     - TCA TGT ACG CCT AAT ACG TTT GGA AAT AAC AC - #A AAT TGT GTA ACA AGA     5803     Ser Cys Thr Pro Asn Thr Phe Gly Asn Asn Th - #r Asn Cys Val Thr Arg     #       905     - AAT GGT GAA CAA CAC GTA TAC GAA AAT AGT TG - #T GGA GAT AAT GCA ACA     5851     Asn Gly Glu Gln His Val Tyr Glu Asn Ser Cy - #s Gly Asp Asn Ala Thr     #   920     - TGT GGA AGA AGA ACA GGA TAT GGA AGA AGA AG - #T AGG GAT GAA TGG AAT     5899     Cys Gly Arg Arg Thr Gly Tyr Gly Arg Arg Se - #r Arg Asp Glu Trp Asn     925                 9 - #30                 9 - #35                 9 -     #40     - GAC TAT AGA AAA CCC CAC GTT TAT GAC AAT TG - #T GCC GAT GCA AAT AGT     5947     Asp Tyr Arg Lys Pro His Val Tyr Asp Asn Cy - #s Ala Asp Ala Asn Ser     #               955     - TCA TCT TCA GAT AGC TGT TCA GAC AGT AGT AG - #T AGT AGT GAA TCT GAA     5995     Ser Ser Ser Asp Ser Cys Ser Asp Ser Ser Se - #r Ser Ser Glu Ser Glu     #           970     - TCT GAT TCA GAT GGA TGT TGC GAC ACA GAT GC - #T AGT TTA GAT TCT GAT     6043     Ser Asp Ser Asp Gly Cys Cys Asp Thr Asp Al - #a Ser Leu Asp Ser Asp     #       985     - ATT GAA AAT TGT TAT CAA AAT CCA TCA AAA TG - #T GAT GCA GGA TGC     TAAATGAA6098     Ile Glu Asn Cys Tyr Gln Asn Pro Ser Lys Cy - #s Asp Ala Gly Cys     #   1000     - TTAATATTAT ATAATATTAA CTTACAAGTT ATAAAAATCA TTAAAATGAT TT - #TTTAAAAT     6158     - GATATTATCG ATAGTTGTGA TAATGTGCTC TTTTATTTTA TTAATTGCGA TG - #ATTATAAT     6218     - ATTATCTTTT AGATATATTT AATATTAATT ATAAATCGAC TGACAATAAT AT - #TTATTCCT     6278     - ATTCATAATA ATCATCTGCT ATATATATTA ATGTATCATT CTCTATTATA AA - #TATAGGTA     6338     - TATTGTCTTT ATCAATCATT AATTTTGCTA CAGCTGTATT ATCTTTATAT AC - #TATATTTG     6398     - TGTCTTTGTT TAATAAACCT TTTAATATAG TGGCTCTATC ATAATCTTTA CA - #ATATGATA     6458     - TGGGATATAA TTTTATATTA ATAATAACAT TAGATACGTT CATTTCTTTC AT - #TCTAGTTT     6518     - TACGTATTGT GTCAAAAATT ATTTCATTTT CTGCTGGTTC TATATATTTA TA - #TGTGTTAT     6578     - GAATAGATTC GATAGATGAT GATTTTAATA AATCAAATAT AACATTTATT TT - #ACCTTGTT     6638     - TATCTTTTAT AATATCTAAT ATTTCTTTAT CTACAGATTT TCTGTTGTTG GT - #ATATGATA     6698     - TTAAAAAATG AACGTTAACA TATCTATATT CTTGTGGTAA ATCTTTATGA GA - #ATTTAATC     6758     - TTATAGATCT TCCTATTATT TGTTTTAATT CTGATTCATT CCACGGCATA TC - #TAATATAA     6818     - TTATATCATT AATACATTTG AATGATATGC CTTCAGATCC AGCGTAAGAA AA - #TATGCAAA     6878     - CTTTTACTTT TTTACCATTA TTATTTTCAT AATTATTATA TTCGTTTAAT TC - #ATTATCTC     6938     - TAGTTTTTAA AGTTTTGCTA GAATATTCAA TATAAGAAAT ATTAAAACAA TT - #AAAATAAC     6998     - ATTTTAAACT TGATATTCCT TCAAAATTAA CTAAAGGTTC AAATATTAAT AC - #TTTTCCTC     7058     - TCGAATTTAA AATTATTTTA CAAGTTTCTA TATATTTACA CGAATATTGA TA - #TAATATAT     7118     - TATAATTATT TATATCAGTG ATTGGTAAAT TAGTTTTTAT TTTTATATTA TC - #ATTTTTAA     7178     - AACTTTCAAT AAAAGATTCA GAGAAATTAA TATTTTTTGT AAACTCGGAA AA - #TTCAGCAA     7238     - GTTTTCTTTT AATCATATCA TTATATTCTA TATTATCTAA ATCTCCTTTT AT - #TTTAAGAT     7298     - CATAAAAAGC AAATGAAGAT ATTAATCTTC TCATAGTTTT TAAACCACCT AA - #TTCAGTTT     7358     - TATAATCATA TTTTTCTGCC ATATTATATA ATTTAGATTG CTCATCTGAC AT - #AATTATAT     7418     - TATGATAAAA TATATTTTTT TTTGCATATC CATCTATATA ATTTGTTTCT GT - #TAAACTAT     7478     - CTGCTTCTAT TAATCTTTTA TAAGAACATA TAGCTAATAA TGTTTCTCTT AA - #TTCCTTAA     7538     - AATTAATTAA CTTTCCATTA TTTATATATT CTTCTTTTAT ATTCATAACA TT - #TGGTCTAA     7598     - GTAAACCTAT TAAATTATTA AATTCAGAAA TATTATTAGT TACTGGAGTA GC - #GGACATAC     7658     - ATAATATTTT ATTATTTTCG AAATTTGCTA ATTTTATTAA TTTTTTATAA AT - #AGGAGTAA     7718     - AATTTCTTTC GTTATTATCT TTTTTAACAG TTCTTGATAT TAATTTATGA AC - #TTCGTCTA     7778     - TTATTATTAG TAATCTACTT TTTTTATTAA GAGAACTTTC TATAGATCTA TA - #TATATTAT     7838     - TAAATTTATC TAAACTAGAT GACGAATCAT AATATATAAA TTTTATATTA CT - #GGTATCTG     7898     - ATATATATGA TCTTATAGTA TTTAACCAAG GATCTATGTA TAATGATTTT TT - #AATAAATA     7958     - TTAAAATTAT CCATCTTGGA AATAATTCTT TTATATATTT TATAATATAC AC - #AGCAGTTA     8018     - ATGTTTTTCC CATACCAGTA TCCCAAAATA ATAACATACT ATTCAAATTT TT - #TAATCCTA     8078     - TGAATATTCT ACTTACAAAA TATTGATAAT CTTGTAATGT AATTTCAGTA TT - #TGTAATAT     8138     - TATTCATAAT TTTATTAGGC AAATGTTGTG TTTTATCAAG TGCATAATTT AT - #ATGTTTAC     8198     - CAACAATAGA ATCTAATGCA AACATTTAGT TATATAAAAA ATAATATTTA TA - #TTAACTTA     8258     - AGATGTTTCA TTAATTTTAT GTCTGTGATG TGGAGTTAAA ACCCAAGATA TT - #GATATATC     8318     - TATATCATTA ATTCTTCTTT TGAATCTATG TCTATCAATC GCAAATTTAT CC - #CAGTATAA     8378     - TTTTCGAGTT TGTTTTGCAG CATATAACCA AACATACATA ATGTGGAGTT TT - #GGTGGTTC     8438     #                 845 - #7     - (2) INFORMATION FOR SEQ ID NO:2:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 464 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:2:     - Met Asn Asn Lys Ile Arg Arg Phe Pro Asn Ly - #s Asn Leu Lys Met Pro     #                 15     - Glu Ser Gly Ile Asn Phe Met Ser Met Leu Ph - #e Phe Ser Lys Ile Asp     #             30     - Asn Met Val Tyr Phe Ile Asn Pro Ile Lys Ty - #r Asn Thr Asn Ala Asn     #         45     - Ile Ala Ile Leu Glu Lys Ile Asp Asp Asp As - #p Glu Thr Arg Gly Lys     #     60     - Val Thr Phe Ile Pro Ile Lys Tyr Leu Glu Il - #e Leu Tyr Asn Glu Leu     # 80     - Val Leu Asp Pro Asn His Ile Asn Asn Ile As - #n Phe Glu Asn Asn Ile     #                 95     - Lys Arg Lys Phe Phe Leu Phe Trp Thr Ile Ly - #s Lys Tyr Leu Gln Asp     #           110     - Lys Asn Ile Asn Ile Asn Thr Phe Ile Thr Se - #r Lys Lys Tyr Lys Gly     #       125     - Ile Pro Leu Val Tyr Met Arg Lys Ser Phe Le - #u Lys Ser Glu Leu Ser     #   140     - Lys Thr Arg Asp Phe Ser Thr Phe Ala Thr Il - #e Tyr Asp Asp Leu Asp     145                 1 - #50                 1 - #55                 1 -     #60     - Ala Gln Ile Gly Ile Pro Pro Leu Gly Phe As - #n Pro Lys Pro Lys Ala     #               175     - Tyr Pro Arg Lys His Asp Lys Ser Thr Trp Le - #u Ser Ser Gly Asp Ile     #           190     - Tyr Asn Cys Ile Tyr Pro Leu Thr Met Ile As - #n Thr Asp Tyr Asp Tyr     #       205     - Phe His Leu Ile Leu Phe Glu Lys Thr Asp Ly - #s Asn Ile Ala Thr Val     #   220     - Ala Ser Ser Met Arg Cys Tyr Lys Leu Glu As - #p Arg Val Lys Phe Phe     225                 2 - #30                 2 - #35                 2 -     #40     - Leu Met Asn Asp Lys Lys Arg Phe Phe Met Ph - #e Pro Ile Ile Tyr Asn     #               255     - Asp His Phe Thr Cys Cys Val Ile Asp Lys Hi - #s Phe Asp Lys Asp Lys     #           270     - Lys Ala Ala Tyr Phe Phe Asn Ser Ser Gly Ty - #r Ile Pro Glu Leu Ile     #       285     - Lys Gln Asn Lys Lys Tyr Met Phe Ile Glu Se - #r Asp Met Thr Ile Lys     #   300     - Ser His Lys His Tyr Asn Ser Thr Pro Asn Th - #r Asn Tyr Ala Tyr Leu     305                 3 - #10                 3 - #15                 3 -     #20     - Tyr Ile Asp Val Leu Ser Glu Tyr Leu Asn As - #p Ile Phe Lys Asn Val     #               335     - Asn Tyr Tyr Phe Phe Asn Thr Phe Glu Leu Gl - #n Tyr Asp Ser Pro Asp     #           350     - Cys Gly Met Phe Asn Ile Ile Phe Leu Tyr Ty - #r Ile Val Tyr Phe Asn     #       365     - Ile Lys Ser Lys Phe Glu Phe Lys Lys Leu Ty - #r Tyr Ser Met Ser Phe     #   380     - Ile Gly Asp Leu Leu Ala Ser Ser Tyr Arg Gl - #y Ala Leu Phe Ile Ser     385                 3 - #90                 3 - #95                 4 -     #00     - Arg Tyr Asp Ile Asn Ser Ile Asp Glu Phe Ly - #s Asn Thr Leu Glu Ile     #               415     - Phe Asn Ile Lys Asn Lys Lys Phe Met Glu Le - #u Ile Asp Met Tyr Lys     #           430     - Lys Asn Ser Asn Arg Ile Met Asn Val Cys Se - #r Lys Ile Lys Asn Asp     #       445     - Tyr Asp Ser Tyr Ile Asp Asn Glu Lys Asn Se - #r Leu Glu Ser Asn Ile     #   460     - (2) INFORMATION FOR SEQ ID NO:3:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 225 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:3:     - Met Phe Leu Val Tyr Phe Asn Thr Phe Leu Il - #e Ile Ile Leu Leu Phe     #                 15     - Gly Ile Ile Gly Ile Tyr Ile Leu Thr Phe Va - #l Phe Asn Ile Asp Phe     #             30     - Leu Ile Asn Asn Asn Lys Ile Tyr Ile Leu Se - #r Tyr Asn Ala Thr Asn     #         45     - Ile Asn Asn Ile Asn Asn Leu Asn Leu Tyr As - #p Tyr Ser Asp Ile Ile     #     60     - Phe Leu Thr Asn Phe Asn Ile Asn Asn Asn Le - #u Leu Val Thr Gln Ala     # 80     - Asn Asn Leu Gln Asp Ile Pro Ile Phe Asn Va - #l Asn Asn Ile Ile Ser     #                 95     - Asn Gln Tyr Asn Phe Tyr Ser Ala Ser Ser As - #n Asn Val Asn Ile Leu     #           110     - Leu Gly Leu Arg Lys Thr Leu Asn Ile Asn Ar - #g Asn Pro Phe Leu Leu     #       125     - Phe Arg Asn Thr Ser Leu Ala Ile Val Phe As - #n Asn Asn Glu Thr Phe     #   140     - His Cys Tyr Ile Ser Ser Asn Gln Asn Ser As - #p Val Leu Asp Ile Val     145                 1 - #50                 1 - #55                 1 -     #60     - Ser His Ile Glu Phe Met Lys Ser Arg Tyr As - #n Lys Tyr Val Ile Ile     #               175     - Gly Glu Ile Pro Val Asn Asn Asn Ile Ser Il - #e Asn Asn Ile Leu Asn     #           190     - Asn Phe Ala Ile Ile Thr Asn Val Arg Leu Il - #e Asp Lys Tyr Asn Ser     #       205     - Ile Ile Ser Phe Leu Asn Ile Asn Val Gly Th - #r Leu Phe Val Ile Asn     #   220     - Pro     - 225     - (2) INFORMATION FOR SEQ ID NO:4:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 78 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:4:     - Met Ser Ser Ser Lys Lys Asn Asn Leu Gly Ty - #r Phe Asn Asn Leu Lys     #                 15     - Thr Glu Glu Val Ser Gln Ser Gln Val Phe Ly - #s Asp Asn Tyr Arg Pro     #             30     - Gly Tyr Tyr Gly Leu Asp Thr Asn Ala Ala As - #n Pro Ala Asp Val Tyr     #         45     - Asn Thr Glu Ser Asn Lys Pro Ser Thr Val As - #p Val Trp Gly Asp Lys     #     60     - Arg Leu Glu Gly Lys Ile Ile Pro Lys Ser Ly - #s Lys Lys Lys     # 75     - (2) INFORMATION FOR SEQ ID NO:5:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 161 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:5:     - Met Ser Ile Phe Ile Tyr Tyr Ile Phe Asn As - #n Arg Phe Tyr Ile Tyr     #                 15     - Lys Arg Met Asn Thr Val Gln Ile Leu Val Va - #l Ile Leu Ile Thr Thr     #             30     - Ala Leu Ser Phe Leu Val Phe Gln Leu Trp Ty - #r Tyr Ala Glu Asn Tyr     #         45     - Glu Tyr Ile Leu Arg Tyr Asn Asp Thr Tyr Se - #r Asn Leu Gln Phe Ala     #     60     - Arg Ser Ala Asn Ile Asn Phe Asp Asp Leu Th - #r Val Phe Asp Pro Asn     # 80     - Asp Asn Val Phe Asn Val Glu Glu Lys Trp Ar - #g Cys Ala Ser Thr Asn     #                 95     - Asn Asn Ile Phe Tyr Ala Val Ser Thr Phe Gl - #y Phe Leu Ser Thr Glu     #           110     - Ser Thr Gly Ile Asn Leu Thr Tyr Thr Asn Se - #r Arg Asp Cys Ile Ile     #       125     - Asp Leu Phe Ser Arg Ile Ile Lys Ile Val Ty - #r Asp Pro Cys Thr Val     #   140     - Glu Thr Ser Asn Asp Cys Arg Leu Leu Arg Le - #u Leu Met Ala Asn Thr     145                 1 - #50                 1 - #55                 1 -     #60     - Ser     - (2) INFORMATION FOR SEQ ID NO:6:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 1003 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:6:     - Met Ser Asn Val Pro Leu Ala Thr Lys Thr Il - #e Arg Lys Leu Ser Asn     #                 15     - Arg Lys Tyr Glu Ile Lys Ile Tyr Leu Lys As - #p Glu Asn Thr Cys Phe     #             30     - Glu Arg Val Val Asp Met Val Val Pro Leu Ty - #r Asp Val Cys Asn Glu     #         45     - Thr Ser Gly Val Thr Leu Glu Ser Cys Ser Pr - #o Asn Ile Glu Val Ile     #     60     - Glu Leu Asp Asn Thr His Val Arg Ile Lys Va - #l His Gly Asp Thr Leu     # 80     - Lys Glu Met Cys Phe Glu Leu Leu Phe Pro Cy - #s Asn Val Asn Glu Ala     #                 95     - Gln Val Trp Lys Tyr Val Ser Arg Leu Leu Le - #u Asp Asn Val Ser His     #           110     - Asn Asp Val Lys Tyr Lys Leu Ala Asn Phe Ar - #g Leu Thr Leu Asn Gly     #       125     - Lys His Leu Lys Leu Lys Glu Ile Asp Gln Pr - #o Leu Phe Ile Tyr Phe     #   140     - Val Asp Asp Leu Gly Asn Tyr Gly Leu Ile Th - #r Lys Glu Asn Ile Gln     145                 1 - #50                 1 - #55                 1 -     #60     - Asn Asn Asn Leu Gln Val Asn Lys Asp Ala Se - #r Phe Ile Thr Ile Phe     #               175     - Pro Gln Tyr Ala Tyr Ile Cys Leu Gly Arg Ly - #s Val Tyr Leu Asn Glu     #           190     - Lys Val Thr Phe Asp Val Thr Thr Asp Ala Th - #r Asn Ile Thr Leu Asp     #       205     - Phe Asn Lys Ser Val Asn Ile Ala Val Ser Ph - #e Leu Asp Ile Tyr Tyr     #   220     - Glu Val Asn Asn Asn Glu Gln Lys Asp Leu Le - #u Lys Asp Leu Leu Lys     225                 2 - #30                 2 - #35                 2 -     #40     - Arg Tyr Gly Glu Phe Glu Val Tyr Asn Ala As - #p Thr Gly Leu Ile Tyr     #               255     - Ala Lys Asn Leu Ser Ile Lys Asn Tyr Asp Th - #r Val Ile Gln Val Glu     #           270     - Arg Leu Pro Val Asn Leu Lys Val Arg Ala Ty - #r Thr Lys Asp Glu Asn     #       285     - Gly Arg Asn Leu Cys Leu Met Lys Ile Thr Se - #r Ser Thr Glu Val Asp     #   300     - Pro Glu Tyr Val Thr Ser Asn Asn Ala Leu Le - #u Gly Thr Leu Arg Val     305                 3 - #10                 3 - #15                 3 -     #20     - Tyr Lys Lys Phe Asp Lys Ser His Leu Lys Il - #e Val Met His Asn Arg     #               335     - Gly Ser Gly Asn Val Phe Pro Leu Arg Ser Le - #u Tyr Leu Glu Leu Ser     #           350     - Asn Val Lys Gly Tyr Pro Val Lys Ala Ser As - #p Thr Ser Arg Leu Asp     #       365     - Val Gly Ile Tyr Lys Leu Asn Lys Ile Tyr Va - #l Asp Asn Asp Glu Asn     #   380     - Lys Ile Ile Leu Glu Glu Ile Glu Ala Glu Ty - #r Arg Cys Gly Arg Gln     385                 3 - #90                 3 - #95                 4 -     #00     - Val Phe His Glu Arg Val Lys Leu Asn Lys Hi - #s Gln Cys Lys Tyr Thr     #               415     - Pro Lys Cys Pro Phe Gln Phe Val Val Asn Se - #r Pro Asp Thr Thr Ile     #           430     - His Leu Tyr Gly Ile Ser Asn Val Cys Leu Ly - #s Pro Lys Val Pro Lys     #       445     - Asn Leu Arg Leu Trp Gly Trp Ile Leu Asp Cy - #s Asp Thr Ser Arg Phe     #   460     - Ile Lys His Met Ala Asp Gly Ser Asp Asp Le - #u Asp Leu Asp Val Arg     465                 4 - #70                 4 - #75                 4 -     #80     - Leu Asn Arg Asn Asp Ile Cys Leu Lys Gln Al - #a Ile Lys Gln His Tyr     #               495     - Thr Asn Val Ile Ile Leu Glu Tyr Ala Asn Th - #r Tyr Pro Asn Cys Thr     #           510     - Leu Ser Leu Gly Asn Asn Arg Phe Asn Asn Va - #l Phe Asp Met Asn Asp     #       525     - Asn Lys Thr Ile Ser Glu Tyr Thr Asn Phe Th - #r Lys Ser Arg Gln Asp     #   540     - Leu Asn Asn Met Ser Cys Ile Leu Gly Ile As - #n Ile Gly Asn Ser Val     545                 5 - #50                 5 - #55                 5 -     #60     - Asn Ile Ser Ser Leu Pro Gly Trp Val Thr Pr - #o His Glu Ala Lys Ile     #               575     - Leu Arg Ser Gly Cys Ala Arg Val Arg Glu Ph - #e Cys Lys Ser Phe Cys     #           590     - Asp Leu Ser Asn Lys Arg Phe Tyr Ala Met Al - #a Arg Asp Leu Val Ser     #       605     - Leu Leu Phe Met Cys Asn Tyr Val Asn Ile Gl - #u Ile Asn Glu Ala Val     #   620     - Cys Glu Tyr Pro Gly Tyr Val Ile Leu Phe Al - #a Arg Ala Ile Lys Val     625                 6 - #30                 6 - #35                 6 -     #40     - Ile Asn Asp Leu Leu Leu Ile Asn Gly Val As - #p Asn Leu Ala Gly Tyr     #               655     - Ser Ile Ser Leu Pro Ile His Tyr Gly Ser Th - #r Glu Lys Thr Leu Pro     #           670     - Asn Glu Lys Tyr Gly Gly Val Asp Lys Lys Ph - #e Lys Tyr Leu Phe Leu     #       685     - Lys Asn Lys Leu Lys Asp Leu Met Arg Asp Al - #a Asp Phe Val Gln Pro     #   700     - Pro Leu Tyr Ile Ser Thr Tyr Phe Arg Thr Le - #u Leu Asp Ala Pro Pro     705                 7 - #10                 7 - #15                 7 -     #20     - Thr Asp Asn Tyr Glu Lys Tyr Leu Val Asp Se - #r Ser Val Gln Ser Gln     #               735     - Asp Val Leu Gln Gly Leu Leu Asn Thr Cys As - #n Thr Ile Asp Thr Asn     #           750     - Ala Arg Val Ala Ser Ser Val Ile Gly Tyr Va - #l Tyr Glu Pro Cys Gly     #       765     - Thr Ser Glu His Lys Ile Gly Ser Glu Ala Le - #u Cys Lys Met Ala Lys     #   780     - Glu Ala Ser Arg Leu Gly Asn Leu Gly Leu Va - #l Asn Arg Ile Asn Glu     785                 7 - #90                 7 - #95                 8 -     #00     - Ser Asn Tyr Asn Lys Cys Asn Lys Tyr Gly Ty - #r Arg Gly Val Tyr Glu     #               815     - Asn Asn Lys Leu Lys Thr Lys Tyr Tyr Arg Gl - #u Ile Phe Asp Cys Asn     #           830     - Pro Asn Asn Asn Asn Glu Leu Ile Ser Arg Ty - #r Gly Tyr Arg Ile Met     #       845     - Asp Leu His Lys Ile Gly Glu Ile Phe Ala As - #n Tyr Asp Glu Ser Glu     #   860     - Ser Pro Cys Glu Arg Arg Cys His Tyr Leu Gl - #u Asp Arg Gly Leu Leu     865                 8 - #70                 8 - #75                 8 -     #80     - Tyr Gly Pro Glu Tyr Val His His Arg Tyr Gl - #n Glu Ser Cys Thr Pro     #               895     - Asn Thr Phe Gly Asn Asn Thr Asn Cys Val Th - #r Arg Asn Gly Glu Gln     #           910     - His Val Tyr Glu Asn Ser Cys Gly Asp Asn Al - #a Thr Cys Gly Arg Arg     #       925     - Thr Gly Tyr Gly Arg Arg Ser Arg Asp Glu Tr - #p Asn Asp Tyr Arg Lys     #   940     - Pro His Val Tyr Asp Asn Cys Ala Asp Ala As - #n Ser Ser Ser Ser Asp     945                 9 - #50                 9 - #55                 9 -     #60     - Ser Cys Ser Asp Ser Ser Ser Ser Ser Glu Se - #r Glu Ser Asp Ser Asp     #               975     - Gly Cys Cys Asp Thr Asp Ala Ser Leu Asp Se - #r Asp Ile Glu Asn Cys     #           990     - Tyr Gln Asn Pro Ser Lys Cys Asp Ala Gly Cy - #s     #       1000     - (2) INFORMATION FOR SEQ ID NO:7:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 163 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:7:     - Arg Ser Ile Arg Leu Asn Ser His Lys Asp Le - #u Pro Gln Glu Tyr Arg     #                 15     - Tyr Val Asn Val His Phe Leu Ile Ser Tyr Th - #r Asn Asn Arg Lys Ser     #             30     - Val Asp Lys Glu Ile Leu Asp Ile Ile Lys As - #p Lys Gln Gly Lys Ile     #         45     - Asn Val Ile Phe Asp Leu Leu Lys Ser Ser Se - #r Ile Glu Ser Ile His     #     60     - Asn Thr Tyr Lys Tyr Ile Glu Pro Ala Glu As - #n Glu Ile Ile Phe Asp     # 80     - Thr Ile Arg Lys Thr Arg Met Lys Glu Met As - #n Val Ser Asn Val Ile     #                 95     - Ile Asn Ile Lys Leu Tyr Pro Ile Ser Tyr Cy - #s Lys Asp Tyr Asp Arg     #           110     - Ala Thr Ile Leu Lys Gly Leu Leu Asn Lys As - #p Thr Asn Ile Val Tyr     #       125     - Lys Asp Asn Thr Ala Val Ala Lys Leu Met Il - #e Asp Lys Asp Asn Ile     #   140     - Pro Ile Phe Ile Ile Glu Asn Asp Thr Leu Il - #e Tyr Ile Ala Asp Asp     145                 1 - #50                 1 - #55                 1 -     #60     - Tyr Tyr Glu     - (2) INFORMATION FOR SEQ ID NO:8:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 1511 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     -     (vi) ORIGINAL SOURCE:               (A) ORGANISM: Amsacta m - #oorei entemopoxvirus     -     (ix) FEATURE:               (A) NAME/KEY: CDS     #(18..218)(B) LOCATION: complement     -     (ix) FEATURE:               (A) NAME/KEY: CDS     #(234..782)B) LOCATION: complement     -     (ix) FEATURE:               (A) NAME/KEY: CDS               (B) LOCATION: 852..1511     #ID NO:8: (xi) SEQUENCE DESCRIPTION: SEQ     - GAATTCAAGT TAAATATTTA TAAACAACAA TCATATTTTT TTAAAGAATC TA - #ATAAATTT       60     - TTTAACATTT TATTATTATT TGATAATTGT TTATTTAATT CGTTATTGAT AT - #TAACAATA      120     - TTATTTATCA TTTTACCTAT TTTTTTTTTT CTATCTACTA ACGAAATATC AG - #ATTTTGCA      180     - CCTTCAATAT CAGAATAATA ATTATCATTA TTTTGCATTT ATGAATAAAA AT - #ATTAATAT      240     - GAATTATTAT AACATAATCT ACACACAGGA ACATATAAAT CTTGTCCACC TA - #TTTCAATT      300     - ATTTGATTTT TATTATGTTT TTTAATTGTA AAAGAAGCAT CTTTATAACA AA - #ATTGACAT      360     - ATAGCTTGTA ATTTTTTTAT TTTTTCTACT TTAGGAATTA ATTTTGATAT AG - #AATTAAAT      420     - ATATTTCTGT TAAAGTCACA ATTTAATCCA GCAACAATAA CTTTTTTTTT AT - #TATTAGCC      480     - ATTTTATCAC AAAATTGTTC TAAATCATTT TCTTCAAAAA ATTGACACTC AT - #CTATGCCA      540     - ATAATATCAT AATTATCTAC GATATTGATT TCATTAATTA AATTATTTGT TT - #TAATGTAT      600     - AAATATTCTT TATTTAATAT ATTTCCGTCA TGATTTATTA TATTTTTATT TA - #TAAATCTA      660     - TTATCTATAT TATGAGTTAT AATTACACAT TTTTGATTAG ATAAAATATA TC - #TATTAATT      720     - TTTCGCATCA ATTCTGTTGT TTTGCCAGAA AACATAGGAC CAATTATTAA TT - #CTATCGAC      780     - ATTTTTTTTT ATTATTTGAT ATATTTTTTC AAAAAAAAAT TAATCAATGA AA - #AAAAAATA      840     #ATT TTA ATA AAT ATT     890TA AAT TCT GAT ATA     #Leu Asn Ser Asp Ile Ile Leu Ile Asn Ile     #            10     - TTA AAA TAT TAT AAT TTA AAA AAA ATA ATA AT - #A AAC AGA GAT AAT GTT      938     Leu Lys Tyr Tyr Asn Leu Lys Lys Ile Ile Il - #e Asn Arg Asp Asn Val     #     25     - ATT AAT ATT AAT ATA TTA AAA AAA TTA GTT AA - #T TTA GAA GAA TTG CAT      986     Ile Asn Ile Asn Ile Leu Lys Lys Leu Val As - #n Leu Glu Glu Leu His     # 45     - ATA ATA TAT TAT GAT AAT AAT ATT TTA AAT AA - #T ATT CCA GAA AAT ATT     1034     Ile Ile Tyr Tyr Asp Asn Asn Ile Leu Asn As - #n Ile Pro Glu Asn Ile     #                 60     - AAA AGT TTA TAT ATT TCA AAT TTA AAT ATT AT - #T AAT TTA AAT TTT ATA     1082     Lys Ser Leu Tyr Ile Ser Asn Leu Asn Ile Il - #e Asn Leu Asn Phe Ile     #             75     - ACA AAA TTA AAA AAT ATA ACA TAT TTA GAT AT - #A TCT TAT AAC AAA AAT     1130     Thr Lys Leu Lys Asn Ile Thr Tyr Leu Asp Il - #e Ser Tyr Asn Lys Asn     #         90     - AGC AAT ATA AGT AAT ATT ATA CTA CCA CAT TC - #T ATA GAA TTT TTA AAT     1178     Ser Asn Ile Ser Asn Ile Ile Leu Pro His Se - #r Ile Glu Phe Leu Asn     #    105     - TGT GAA TCA TGT AAT ATA AAT GAC TAT AAT TT - #T ATT AAT AAT TTA GTA     1226     Cys Glu Ser Cys Asn Ile Asn Asp Tyr Asn Ph - #e Ile Asn Asn Leu Val     110                 1 - #15                 1 - #20                 1 -     #25     - AAT TTA AAA AAA TTA ATA ATA TCT AAA AAT AA - #A TTT GGT AAC TTT AAT     1274     Asn Leu Lys Lys Leu Ile Ile Ser Lys Asn Ly - #s Phe Gly Asn Phe Asn     #               140     - AAT GTT TTT CCT ATT AGT ATA GTT GAG TTA AA - #T ATG GAA TCA ATA CAA     1322     Asn Val Phe Pro Ile Ser Ile Val Glu Leu As - #n Met Glu Ser Ile Gln     #           155     - ATA AAA GAT TAT AAA TTT ATA GAA AAA TTA AT - #T AAT TTA AAA AAA TTA     1370     Ile Lys Asp Tyr Lys Phe Ile Glu Lys Leu Il - #e Asn Leu Lys Lys Leu     #       170     - GAT ATA TCT TTC AAT GTT AAA AAA AAT AAT AT - #A CAT TTG ATA AAA TTT     1418     Asp Ile Ser Phe Asn Val Lys Lys Asn Asn Il - #e His Leu Ile Lys Phe     #   185     - CCA AAA AGT ATA ACT CAT TTA TGT GAT TAT CA - #A TCA TAT AAA GAA AAT     1466     Pro Lys Ser Ile Thr His Leu Cys Asp Tyr Gl - #n Ser Tyr Lys Glu Asn     190                 1 - #95                 2 - #00                 2 -     #05     - TAT AAT TAT TTA AAA AAT TTA TCA AAT ATA AT - #T GAA TAT GAA TTC     1511     Tyr Asn Tyr Leu Lys Asn Leu Ser Asn Ile Il - #e Glu Tyr Glu Phe     #               220     - (2) INFORMATION FOR SEQ ID NO:9:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 66 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:9:     - Met Gln Asn Asn Asp Asn Tyr Tyr Ser Asp Il - #e Glu Gly Ala Lys Ser     #                 15     - Asp Ile Ser Leu Val Asp Arg Lys Lys Lys Il - #e Gly Lys Met Ile Asn     #             30     - Asn Ile Val Asn Ile Asn Asn Glu Leu Asn Ly - #s Gln Leu Ser Asn Asn     #         45     - Asn Lys Met Leu Lys Asn Leu Leu Asp Ser Le - #u Lys Lys Tyr Asp Cys     #     60     - Cys Leu      65     - (2) INFORMATION FOR SEQ ID NO:10:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 182 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:10:     - Met Ser Ile Glu Leu Ile Ile Gly Pro Met Ph - #e Ser Gly Lys Thr Thr     #                 15     - Glu Leu Met Arg Lys Ile Asn Arg Tyr Ile Le - #u Ser Asn Gln Lys Cys     #             30     - Val Ile Ile Thr His Asn Ile Asp Asn Arg Ph - #e Ile Asn Lys Asn Ile     #         45     - Ile Asn His Asp Gly Asn Ile Leu Asn Lys Gl - #u Tyr Leu Tyr Ile Lys     #     60     - Thr Asn Asn Leu Ile Asn Glu Ile Asn Ile Va - #l Asp Asn Tyr Asp Ile     # 80     - Ile Gly Ile Asp Glu Cys Gln Phe Phe Glu Gl - #u Asn Asp Leu Glu Gln     #                 95     - Phe Cys Asp Lys Met Ala Asn Asn Lys Lys Ly - #s Val Ile Val Ala Gly     #           110     - Leu Asn Cys Asp Phe Asn Arg Asn Ile Phe As - #n Ser Ile Ser Lys Leu     #       125     - Ile Pro Lys Val Glu Lys Ile Lys Lys Leu Gl - #n Ala Ile Cys Gln Phe     #   140     - Cys Tyr Lys Asp Ala Ser Phe Thr Ile Lys Ly - #s His Asn Lys Asn Gln     145                 1 - #50                 1 - #55                 1 -     #60     - Ile Ile Glu Ile Gly Gly Gln Asp Leu Tyr Va - #l Pro Val Cys Arg Leu     #               175     - Cys Tyr Asn Asn Ser Tyr                 180     - (2) INFORMATION FOR SEQ ID NO:11:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 220 amino               (B) TYPE: amino acid               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     -           (xi) SEQUENCE DESCRIPTION: - # SEQ ID NO:11:     - Met Asp Leu Leu Asn Ser Asp Ile Ile Leu Il - #e Asn Ile Leu Lys Tyr     #                 15     - Tyr Asn Leu Lys Lys Ile Ile Ile Asn Arg As - #p Asn Val Ile Asn Ile     #             30     - Asn Ile Leu Lys Lys Leu Val Asn Leu Glu Gl - #u Leu His Ile Ile Tyr     #         45     - Tyr Asp Asn Asn Ile Leu Asn Asn Ile Pro Gl - #u Asn Ile Lys Ser Leu     #     60     - Tyr Ile Ser Asn Leu Asn Ile Ile Asn Leu As - #n Phe Ile Thr Lys Leu     # 80     - Lys Asn Ile Thr Tyr Leu Asp Ile Ser Tyr As - #n Lys Asn Ser Asn Ile     #                 95     - Ser Asn Ile Ile Leu Pro His Ser Ile Glu Ph - #e Leu Asn Cys Glu Ser     #           110     - Cys Asn Ile Asn Asp Tyr Asn Phe Ile Asn As - #n Leu Val Asn Leu Lys     #       125     - Lys Leu Ile Ile Ser Lys Asn Lys Phe Gly As - #n Phe Asn Asn Val Phe     #   140     - Pro Ile Ser Ile Val Glu Leu Asn Met Glu Se - #r Ile Gln Ile Lys Asp     145                 1 - #50                 1 - #55                 1 -     #60     - Tyr Lys Phe Ile Glu Lys Leu Ile Asn Leu Ly - #s Lys Leu Asp Ile Ser     #               175     - Phe Asn Val Lys Lys Asn Asn Ile His Leu Il - #e Lys Phe Pro Lys Ser     #           190     - Ile Thr His Leu Cys Asp Tyr Gln Ser Tyr Ly - #s Glu Asn Tyr Asn Tyr     #       205     - Leu Lys Asn Leu Ser Asn Ile Ile Glu Tyr Gl - #u Phe     #   220     - (2) INFORMATION FOR SEQ ID NO:12:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:12:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               ATGT     - (2) INFORMATION FOR SEQ ID NO:13:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:13:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               AACC     - (2) INFORMATION FOR SEQ ID NO:14:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:14:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TGCG     - (2) INFORMATION FOR SEQ ID NO:15:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:15:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               CCTC     - (2) INFORMATION FOR SEQ ID NO:16:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:16:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TCCG     - (2) INFORMATION FOR SEQ ID NO:17:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 35 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:17:(xi) SEQUENCE DESCRIPTION: SEQ     #       35         TTCA TCTTTTAAAT AAATC     - (2) INFORMATION FOR SEQ ID NO:18:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:18:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TYTT     - (2) INFORMATION FOR SEQ ID NO:19:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 17 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:19:(xi) SEQUENCE DESCRIPTION: SEQ     #   17             G     - (2) INFORMATION FOR SEQ ID NO:20:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:20:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TTTC     - (2) INFORMATION FOR SEQ ID NO:21:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 3012 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:21:(xi) SEQUENCE DESCRIPTION: SEQ     - ATGAGTAACG TACCTTTAGC AACCAAAACA ATAAGAAAAT TATCAAATCG AA - #AATATGAA       60     - ATAAAGATTT ATTTAAAAGA TGAAAATACT TGTTTCGAAC GTGTAGTAGA TA - #TGGTAGTT      120     - CCATTATATG ATGTGTGTAA TGAAACTTCT GGTGTTACTT TAGAATCATG TA - #GTCCAAAT      180     - ATAGAAGTAA TTGAATTAGA CAATACTCAT GTTAGAATCA AAGTTCACGG CG - #ATACATTA      240     - AAAGAAATGT GTTTTGAATT ATTGTTCCCG TGTAATGTAA ACGAAGCCCA AG - #TATGGAAA      300     - TATGTAAGTC GATTATTGCT AGATAATGTA TCACATAATG ACGTAAAATA TA - #AATTAGCT      360     - AATTTTAGAC TGACTCTTAA TGGAAAACAT TTAAAATTAA AAGAAATCGA TC - #AACCGCTA      420     - TTTATTTATT TTGTCGATGA TTTGGGAAAT TATGGATTAA TTACTAAGGA AA - #ATATTCAA      480     - AATAATAATT TACAAGTTAA CAAAGATGCA TCATTTATTA CTATATTTCC AC - #AATATGCG      540     - TATATTTGTT TAGGTAGAAA AGTATATTTA AATGAAAAAG TAACTTTTGA TG - #TAACTACA      600     - GATGCAACTA ATATTACTTT AGATTTTAAT AAATCTGTTA ATATCGCAGT AT - #CATTCCTT      660     - GATATATATT ACGAAGTTAA TAATAATGAA CAAAAAGATT TATTAAAAGA TT - #TACTTAAG      720     - AGATACGGTG AATTTGAAGT CTATAACGCA GATACTGGAT TAATTTATGC TA - #AAAATCTA      780     - AGTATTAAAA ATTATGATAC TGTGATTCAA GTAGAAAGGT TGCCAGTTAA TT - #TGAAAGTT      840     - AGAGCATATA CTAAGGATGA AAATGGTCGC AATCTATGTT TGATGAAAAT AA - #CATCTAGT      900     - ACAGAAGTAG ACCCCGAGTA TGTAACTAGT AATAATGCTT TATTGGGTAC GC - #TCAGAGTA      960     - TATAAAAAGT TTGATAAATC TCATTTAAAA ATTGTAATGC ATAACAGAGG AA - #GTGGTAAT     1020     - GTATTTCCAT TAAGATCATT ATATCTGGAA TTGTCTAATG TAAAAGGATA TC - #CAGTTAAA     1080     - GCATCTGATA CTTCGAGATT AGATGTTGGT ATTTACAAAT TAAATAAAAT TT - #ATGTAGAT     1140     - AACGACGAAA ATAAAATTAT ATTGGAAGAA ATTGAAGCAG AATATAGATG CG - #GAAGACAA     1200     - GTATTCCACG AACGTGTAAA ACTTAATAAA CACCAATGTA AATATACTCC CA - #AATGTCCA     1260     - TTCCAATTTG TTGTAAACAG CCCAGATACT ACGATTCACT TATATGGTAT TT - #CTAATGTT     1320     - TGTTTAAAAC CTAAAGTACC CAAAAATTTA AGACTTTGGG GATGGATTTT AG - #ATTGCGAT     1380     - ACTTCTAGAT TTATTAAACA TATGGCTGAT GGATCTGATG ATTTAGATCT TG - #ACGTTAGG     1440     - CTTAATAGAA ATGATATATG TTTAAAACAA GCCATAAAAC AACATTATAC TA - #ATGTAATT     1500     - ATATTAGAGT ACGCAAATAC ATATCCAAAT TGCACATTAT CATTGGGTAA TA - #ATAGATTT     1560     - AATAATGTAT TTGATATGAA TGATAACAAA ACTATATCTG AGTATACTAA CT - #TTACAAAA     1620     - AGTAGACAAG ACCTTAATAA CATGTCATGT ATATTAGGAA TAAACATAGG TA - #ATTCCGTA     1680     - AATATTAGTA GTTTGCCTGG TTGGGTAACA CCTCACGAAG CTAAAATTCT AA - #GATCTGGT     1740     - TGTGCTAGAG TTAGAGAATT TTGTAAATCA TTCTGTGATC TTTCTAATAA GA - #GATTCTAT     1800     - GCTATGGCTA GAGATCTCGT AAGTTTACTA TTTATGTGTA ACTATGTTAA TA - #TTGAAATT     1860     - AACGAAGCAG TATGCGAATA TCCTGGATAT GTCATATTAT TCGCAAGAGC TA - #TTAAAGTA     1920     - ATTAATGATT TATTATTAAT TAACGGAGTA GATAATCTAG CAGGATATTC AA - #TTTCCTTA     1980     - CCTATACATT ATGGATCTAC TGAAAAGACT CTACCAAATG AAAAGTATGG TG - #GTGTTGAT     2040     - AAGAAATTTA AATATCTATT CTTAAAGAAT AAACTAAAAG ATTTAATGCG TG - #ATGCTGAT     2100     - TTTGTCCAAC CTCCATTATA TATTTCTACT TACTTTAGAA CTTTATTGGA TG - #CTCCACCA     2160     - ACTGATAATT ATGAAAAATA TTTGGTTGAT TCGTCCGTAC AATCACAAGA TG - #TTCTACAG     2220     - GGTCTGTTGA ATACATGTAA TACTATTGAT ACTAATGCTA GAGTTGCATC AA - #GTGTTATT     2280     - GGATATGTTT ATGAACCATG CGGAACATCA GAACATAAAA TTGGTTCAGA AG - #CATTGTGT     2340     - AAAATGGCTA AAGAAGCATC TAGATTAGGA AATCTAGGTT TAGTAAATCG TA - #TTAATGAA     2400     - AGTAATTACA ACAAATGTAA TAAATATGGT TATAGAGGAG TATACGAAAA TA - #ACAAACTA     2460     - AAAACAAAAT ATTATAGAGA AATATTTGAT TGTAATCCTA ATAATAATAA TG - #AATTAATA     2520     - TCCAGATATG GATATAGAAT AATGGATTTA CATAAAATTG GAGAAATTTT TG - #CAAATTAC     2580     - GATGAAAGTG AATCTCCTTG CGAACGAAGA TGTCATTACT TGGAAGATAG AG - #GTCTTTTA     2640     - TATGGTCCTG AATATGTACA TCACAGATAT CAAGAATCAT GTACGCCTAA TA - #CGTTTGGA     2700     - AATAACACAA ATTGTGTAAC AAGAAATGGT GAACAACACG TATACGAAAA TA - #GTTGTGGA     2760     - GATAATGCAA CATGTGGAAG AAGAACAGGA TATGGAAGAA GAAGTAGGGA TG - #AATGGAAT     2820     - GACTATAGAA AACCCCACGT TTATGACAAT TGTGCCGATG CAAATAGTTC AT - #CTTCAGAT     2880     - AGCTGTTCAG ACAGTAGTAG TAGTAGTGAA TCTGAATCTG ATTCAGATGG AT - #GTTGCGAC     2940     - ACAGATGCTA GTTTAGATTC TGATATTGAA AATTGTTATC AAAATCCATC AA - #AATGTGAT     3000     #     3012     - (2) INFORMATION FOR SEQ ID NO:22:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 419 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:22:(xi) SEQUENCE DESCRIPTION: SEQ     - TCAACTAATA ATAATATATT TTATGCAGTT TCAACTTTTG GATTTTTAAG TA - #CAGAAAGT       60     - ACTGGTATTA ATTTAACATA TACAAATTCT AGAGATTGTA TTATAGATTT AT - #TTTCTAGA      120     - ATTATAAAAA TAGTATATGA TCCTTGTACT GTCGAAACAT CTAACGATTG TA - #GATTATTA      180     - AGATTATTGA TGGCCAATAC ATCATAAATA CATTATAATA TTATTATAAT AT - #CAATCATA      240     - ATTTTTATAT ATATTTTATC TAAAAGGACT TTTTATTTTT TATATATTAA TA - #ATAATAAA      300     - TGAGTAACGT ACCTTTAGCA ACCAAAACAA TAAGAAAATT ATCAAATCGA AA - #ATATGAAA      360     - TAAAGATTTA TTTAAAAGAT GAAAATACTT GTTTCGAACG TGTAGTAGAT AT - #GGTAGTT      419     - (2) INFORMATION FOR SEQ ID NO:23:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 678 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:23:(xi) SEQUENCE DESCRIPTION: SEQ     - ATGTTTCTAG TTTATTTCAA TACATTTTTA ATAATAATTT TATTATTTGG TA - #TTATAGGT       60     - ATTTATATAT TAACATTTGT GTTTAATATA GATTTTTTAA TAAATAATAA TA - #AAATATAT      120     - ATATTATCAT ATAACGCAAC TAATATAAAC AATATAAATA ATTTAAATTT AT - #ACGATTAT      180     - TCAGATATTA TATTTTTGAC AAATTTTAAC ATAAATAATA ATCTTTTAGT AA - #CACAAGCT      240     - AATAATTTAC AAGATATACC AATATTTAAT GTAAATAATA TTATATCTAA TC - #AATATAAT      300     - TTTTATTCAG CGTCTAGTAA TAATGTAAAT ATATTATTAG GATTAAGAAA AA - #CATTAAAT      360     - ATAAATAGAA ATCCATTTTT ATTATTTAGA AATACATCTC TAGCTATAGT TT - #TCAATAAT      420     - AATGAAACTT TTCACTGTTA TATAAGTTCA AATCAAAATA GTGATGTATT AG - #ATATAGTA      480     - TCACATATAG AATTTATGAA ATCTAGATAT AATAAATATG TAATTATAGG AG - #AAATACCC      540     - GTAAATAATA ATATATCTAT TAATAATATA TTAAATAATT TTGCTATTAT AA - #CTAATGTG      600     - AGATTAATAG ATAAATATAA CTCTATAATA TCATTTTTAA ATATCAACGT AG - #GAACACTT      660     # 678              AA     - (2) INFORMATION FOR SEQ ID NO:24:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 486 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:24:(xi) SEQUENCE DESCRIPTION: SEQ     - ATGTCAATAT TTATCTACTA TATTTTCAAC AATAGATTTT ATATATATAA AA - #GAATGAAT       60     - ACTGTACAAA TTTTAGTTGT CATATTAATA ACAACAGCAT TATCTTTTCT AG - #TTTTTCAA      120     - TTATGGTATT ATGCCGAAAA TTACGAATAT ATATTAAGAT ATAATGATAC AT - #ATTCAAAT      180     - TTACAATTTG CGAGAAGCGC AAATATAAAT TTTGATGATT TAACTGTTTT TG - #ATCCCAAC      240     - GATAATGTTT TTAATGTTGA AGAAAAATGG CGCTGTGCTT CAACTAATAA TA - #ATATATTT      300     - TATGCAGTTT CAACTTTTGG ATTTTTAAGT ACAGAAAGTA CTGGTATTAA TT - #TAACATAT      360     - ACAAATTCTA GAGATTGTAT TATAGATTTA TTTTCTAGAA TTATAAAAAT AG - #TATATGAT      420     - CCTTGTACTG TCGAAACATC TAACGATTGT AGATTATTAA GATTATTGAT GG - #CCAATACA      480     #          486     - (2) INFORMATION FOR SEQ ID NO:25:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 1395 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:25:(xi) SEQUENCE DESCRIPTION: SEQ     - TTAAATATTA GATTCTAAAC TATTCTTCTC ATTATCAATA TAACTATCAT AA - #TCATTTTT       60     - TATTTTACTA CATACATTCA TAATTCTATT ACTATTTTTT TTATACATAT CT - #ATTAATTC      120     - CATAAACTTT TTATTTTTTA TATTAAATAT TTCTAATGTA TTTTTAAATT CG - #TCAATACT      180     - ATTAATATCA TATCTAGAAA TAAATAATGC ACCTCTATAA CTACTAGCCA AT - #AAATCACC      240     - AATAAAACTC ATAGAATAAT ATAATTTTTT AAATTCAAAT TTAGATTTTA TG - #TTGAAATA      300     - AACTATATAA TATAAAAATA TTATATTAAA CATACCACAA TCGGGACTAT CA - #TATTGTAA      360     - TTCAAAAGTA TTAAAAAAGT AATAATTTAC ATTTTTAAAT ATATCATTTA AA - #TATTCTGA      420     - TAGTACATCA ATGTATAAAT AAGCATAATT AGTATTAGGA GTACTATTGT AG - #TGTTTATG      480     - GCTTTTTATA GTCATATCAG ATTCAATAAA CATATATTTT TTATTTTGTT TT - #ATAAGTTC      540     - TGGTATATAA CCACTACTAT TAAAAAAGTA TGCAGCTTTT TTATCTTTAT CA - #AAGTGTTT      600     - ATCTATTACG CAACAAGTAA AATGATCATT ATAAATTATA GGAAACATAA AA - #AATCTTTT      660     - TTTATCATTC ATTAAAAAAA ATTTTACTCT ATCTTCAAGT TTATAGCATC TC - #ATAGATGA      720     - AGCTACTGTA GCAATATTTT TATCAGTTTT TTCAAATAAA ATCAAATGAA AA - #TAATCATA      780     - ATCTGTATTA ATCATAGTTA ATGGATATAT ACAATTATAT ATATCTCCCG AA - #CTTAACCA      840     - TGTAGATTTA TCATGTTTTC TTGGGTAAGC TTTAGGTTTA GGATTAAATC CC - #AAAGGCGG      900     - TATTCCTATT TGAGCATCCA AATCATCATA AATTGTGGCA AATGTAGAAA AA - #TCTCTTGT      960     - TTTGGATAAT TCTGATTTTA GAAAAGACTT TCTCATATAT ACTAATGGAA TG - #CCTTTATA     1020     - TTTTTTAGAT GTAATAAAAG TATTAATATT TATATTTTTA TCTTGTAAAT AT - #TTTTTTAT     1080     - AGTCCAAAAT AGAAAAAATT TTCTTTTAAT ATTATTTTCA AAATTAATAT TA - #TTAATATG     1140     - ATTTGGATCT AAAACTAATT CATTATATAA TATTTCCAAG TATTTTATAG GT - #ATAAATGT     1200     - TACTTTACCT CTTGTTTCAT CATCATCATC TATTTTTTCT AATATAGCTA TA - #TTTGCATT     1260     - AGTATTATAT TTAATAGGAT TTATAAAATA TACCATATTA TCTATTTTAC TA - #AAAAATAA     1320     - CATAGACATA AAATTAATAC CAGATTCTGG CATTTTTAAA TTTTTATTTG GA - #AATCTTCT     1380     #  1395     - (2) INFORMATION FOR SEQ ID NO:26:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 237 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:26:(xi) SEQUENCE DESCRIPTION: SEQ     - TTATTTTTTT TTTTTGCTTT TAGGTATAAT TTTACCTTCT AAACGTTTAT CT - #CCCCAAAC       60     - ATCTACAGTA GATGGTTTAT TAGATTCTGT GTTATACACA TCTGCTGGAT TT - #GCGGCATT      120     - TGTATCCAAA CCATAATATC CAGGTCTATA ATTATCTTTA AAAACTTGGG AT - #TGAGATAC      180     - TTCTTCAGTT TTTAAATTAT TAAAATATCC AAGATTATTT TTTTTTGATG AA - #GACAT      237     - (2) INFORMATION FOR SEQ ID NO:27:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 492 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:27:(xi) SEQUENCE DESCRIPTION: SEQ     - CTATTCATAA TAATCATCTG CTATATATAT TAATGTATCA TTCTCTATTA TA - #AATATAGG       60     - TATATTGTCT TTATCAATCA TTAATTTTGC TACAGCTGTA TTATCTTTAT AT - #ACTATATT      120     - TGTGTCTTTG TTTAATAAAC CTTTTAATAT AGTGGCTCTA TCATAATCTT TA - #CAATATGA      180     - TATGGGATAT AATTTTATAT TAATAATAAC ATTAGATACG TTCATTTCTT TC - #ATTCTAGT      240     - TTTACGTATT GTGTCAAAAA TTATTTCATT TTCTGCTGGT TCTATATATT TA - #TATGTGTT      300     - ATGAATAGAT TCGATAGATG ATGATTTTAA TAAATCAAAT ATAACATTTA TT - #TTACCTTG      360     - TTTATCTTTT ATAATATCTA ATATTTCTTT ATCTACAGAT TTTCTGTTGT TG - #GTATATGA      420     - TATTAAAAAA TGAACGTTAA CATATCTATA TTCTTGTGGT AAATCTTTAT GA - #GAATTTAA      480     #      492     - (2) INFORMATION FOR SEQ ID NO:28:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 549 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:28:(xi) SEQUENCE DESCRIPTION: SEQ     - TTAATATGAA TTATTATAAC ATAATCTACA CACAGGAACA TATAAATCTT GT - #CCACCTAT       60     - TTCAATTATT TGATTTTTAT TATGTTTTTT AATTGTAAAA GAAGCATCTT TA - #TAACAAAA      120     - TTGACATATA GCTTGTAATT TTTTTATTTT TTCTACTTTA GGAATTAATT TT - #GATATAGA      180     - ATTAAATATA TTTCTGTTAA AGTCACAATT TAATCCAGCA ACAATAACTT TT - #TTTTTATT      240     - ATTAGCCATT TTATCACAAA ATTGTTCTAA ATCATTTTCT TCAAAAAATT GA - #CACTCATC      300     - TATGCCAATA ATATCATAAT TATCTACGAT ATTGATTTCA TTAATTAAAT TA - #TTTGTTTT      360     - AATGTATAAA TATTCTTTAT TTAATATATT TCCGTCATGA TTTATTATAT TT - #TTATTTAT      420     - AAATCTATTA TCTATATTAT GAGTTATAAT TACACATTTT TGATTAGATA AA - #ATATATCT      480     - ATTAATTTTT CGCATCAATT CTGTTGTTTT GCCAGAAAAC ATAGGACCAA TT - #ATTAATTC      540     #        549     - (2) INFORMATION FOR SEQ ID NO:29:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 69 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:29:(xi) SEQUENCE DESCRIPTION: SEQ     - TTTTTTTTAT TATTTGATAT ATTTTTTCAA AAAAAAATTA ATCAATGAAA AA - #AAAATAAA       60     #         69     - (2) INFORMATION FOR SEQ ID NO:30:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 141 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:30:(xi) SEQUENCE DESCRIPTION: SEQ     - AAACATAGGA CCAATTATTA ATTCTATCGA CATTTTTTTT TATTATTTGA TA - #TATTTTTT       60     - CAAAAAAAAA TTAATCAATG AAAAAAAAAT AAAATTATCA AAATGGATTT AC - #TAAATTCT      120     #                 141AT T     - (2) INFORMATION FOR SEQ ID NO:31:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 201 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:31:(xi) SEQUENCE DESCRIPTION: SEQ     - TTATAAACAA CAATCATATT TTTTTAAAGA ATCTAATAAA TTTTTTAACA TT - #TTATTATT       60     - ATTTGATAAT TGTTTATTTA ATTCGTTATT GATATTAACA ATATTATTTA TC - #ATTTTACC      120     - TATTTTTTTT TTTCTATCTA CTAACGAAAT ATCAGATTTT GCACCTTCAA TA - #TCAGAATA      180     #                 201CA T     - (2) INFORMATION FOR SEQ ID NO:32:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 660 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:32:(xi) SEQUENCE DESCRIPTION: SEQ     - ATGGATTTAC TAAATTCTGA TATAATTTTA ATAAATATTT TAAAATATTA TA - #ATTTAAAA       60     - AAAATAATAA TAAACAGAGA TAATGTTATT AATATTAATA TATTAAAAAA AT - #TAGTTAAT      120     - TTAGAAGAAT TGCATATAAT ATATTATGAT AATAATATTT TAAATAATAT TC - #CAGAAAAT      180     - ATTAAAAGTT TATATATTTC AAATTTAAAT ATTATTAATT TAAATTTTAT AA - #CAAAATTA      240     - AAAAATATAA CATATTTAGA TATATCTTAT AACAAAAATA GCAATATAAG TA - #ATATTATA      300     - CTACCACATT CTATAGAATT TTTAAATTGT GAATCATGTA ATATAAATGA CT - #ATAATTTT      360     - ATTAATAATT TAGTAAATTT AAAAAAATTA ATAATATCTA AAAATAAATT TG - #GTAACTTT      420     - AATAATGTTT TTCCTATTAG TATAGTTGAG TTAAATATGG AATCAATACA AA - #TAAAAGAT      480     - TATAAATTTA TAGAAAAATT AATTAATTTA AAAAAATTAG ATATATCTTT CA - #ATGTTAAA      540     - AAAAATAATA TACATTTGAT AAAATTTCCA AAAAGTATAA CTCATTTATG TG - #ATTATCAA      600     - TCATATAAAG AAAATTATAA TTATTTAAAA AATTTATCAA ATATAATTGA AT - #ATGAATTC      660     - (2) INFORMATION FOR SEQ ID NO:33:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 3907 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:33:(xi) SEQUENCE DESCRIPTION: SEQ     - TTCTAAACGT TTATCTCCCC AAACATCTAC AGTAGATGGT TTATTAGATT CT - #GTGTTATA       60     - CACATCTGCT GGATTTGCGG CATTTGTATC CAAACCATAA TATCCAGGTC TA - #TAATTATC      120     - TTTAAAAACT TGGGATTGAG ATACTTCTTC AGTTTTTAAA TTATTAAAAT AT - #CCAAGATT      180     - ATTTTTTTTT GATGAAGACA TAATTGATAT TATAATACTT TATAGATATG TC - #AATATTTA      240     - TCTACTATAT TTTCAACAAT AGATTTTATA TATATAAAAG AATGAATACT GT - #ACAAATTT      300     - TAGTTGTCAT ATTAATAACA ACAGCATTAT CTTTTCTAGT TTTTCAATTA TG - #GTATTATG      360     - CCGAAAATTA CGAATATATA TTAAGATATA ATGATACATA TTCAAATTTA CA - #ATTTGCGA      420     - GAAGCGCAAA TATAAATTTT GATGATTTAA CTGTTTTTGA TCCCAACGAT AA - #TGTTTTTA      480     - ATGTTGAAGA AAAATGGCGC TGTGCTTCAA CTAATAATAA TATATTTTAT GC - #AGTTTCAA      540     - CTTTTGGATT TTTAAGTACA GAAAGTACTG GTATTAATTT AACATATACA AA - #TTCTAGAG      600     - ATTGTATTAT AGATTTATTT TCTAGAATTA TAAAAATAGT ATATGATCCT TG - #TACTGTCG      660     - AAACATCTAA CGATTGTAGA TTATTAAGAT TATTGATGGC CAATACATCA TA - #AATACATT      720     - ATAATATTAT TATAATATCA ATCATAATTT TTATATATAT TTTATCTAAA AG - #GACTTTTT      780     - ATTTTTTATA TATTAATAAT AATAAATGAG TAACGTACCT TTAGCAACCA AA - #ACAATAAG      840     - AAAATTATCA AATCGAAAAT ATGAAATAAA GATTTATTTA AAAGATGAAA AT - #ACTTGTTT      900     - CGAACGTGTA GTAGATATGG TAGTTCCATT ATATGATGTG TGTAATGAAA CT - #TCTGGTGT      960     - TACTTTAGAA TCATGTAGTC CAAATATAGA AGTAATTGAA TTAGACAATA CT - #CATGTTAG     1020     - AATCAAAGTT CACGGCGATA CATTAAAAGA AATGTGTTTT GAATTATTGT TC - #CCGTGTAA     1080     - TGTAAACGAA GCCCAAGTAT GGAAATATGT AAGTCGATTA TTGCTAGATA AT - #GTATCACA     1140     - TAATGACGTA AAATATAAAT TAGCTAATTT TAGACTGACT CTTAATGGAA AA - #CATTTAAA     1200     - ATTAAAAGAA ATCGATCAAC CGCTATTTAT TTATTTTGTC GATGATTTGG GA - #AATTATGG     1260     - ATTAATTACT AAGGAAAATA TTCAAAATAA TAATTTACAA GTTAACAAAG AT - #GCATCATT     1320     - TATTACTATA TTTCCACAAT ATGCGTATAT TTGTTTAGGT AGAAAAGTAT AT - #TTAAATGA     1380     - AAAAGTAACT TTTGATGTAA CTACAGATGC AACTAATATT ACTTTAGATT TT - #AATAAATC     1440     - TGTTAATATC GCAGTATCAT TCCTTGATAT ATATTACGAA GTTAATAATA AT - #GAACAAAA     1500     - AGATTTATTA AAAGATTTAC TTAAGAGATA CGGTGAATTT GAAGTCTATA AC - #GCAGATAC     1560     - TGGATTAATT TATGCTAAAA ATCTAAGTAT TAAAAATTAT GATACTGTGA TT - #CAAGTAGA     1620     - AAGGTTGCCA GTTAATTTGA AAGTTAGAGC ATATACTAAG GATGAAAATG GT - #CGCAATCT     1680     - ATGTTTGATG AAAATAACAT CTAGTACAGA AGTAGACCCC GAGTATGTAA CT - #AGTAATAA     1740     - TGCTTTATTG GGTACGCTCA GAGTATATAA AAAGTTTGAT AAATCTCATT TA - #AAAATTGT     1800     - AATGCATAAC AGAGGAAGTG GTAATGTATT TCCATTAAGA TCATTATATC TG - #GAATTGTC     1860     - TAATGTAAAA GGATATCCAG TTAAAGCATC TGATACTTCG AGATTAGATG TT - #GGTATTTA     1920     - CAAATTAAAT AAAATTTATG TAGATAACGA CGAAAATAAA ATTATATTGG AA - #GAAATTGA     1980     - AGCAGAATAT AGATGCGGAA GACAAGTATT CCACGAACGT GTAAAACTTA AT - #AAACACCA     2040     - ATGTAAATAT ACTCCCAAAT GTCCATTCCA ATTTGTTGTA AACAGCCCAG AT - #ACTACGAT     2100     - TCACTTATAT GGTATTTCTA ATGTTTGTTT AAAACCTAAA GTACCCAAAA AT - #TTAAGACT     2160     - TTGGGGATGG ATTTTAGATT GCGATACTTC TAGATTTATT AAACATATGG CT - #GATGGATC     2220     - TGATGATTTA GATCTTGACG TTAGGCTTAA TAGAAATGAT ATATGTTTAA AA - #CAAGCCAT     2280     - AAAACAACAT TATACTAATG TAATTATATT AGAGTACGCA AATACATATC CA - #AATTGCAC     2340     - ATTATCATTG GGTAATAATA GATTTAATAA TGTATTTGAT ATGAATGATA AC - #AAAACTAT     2400     - ATCTGAGTAT ACTAACTTTA CAAAAAGTAG ACAAGACCTT AATAACATGT CA - #TGTATATT     2460     - AGGAATAAAC ATAGGTAATT CCGTAAATAT TAGTAGTTTG CCTGGTTGGG TA - #ACACCTCA     2520     - CGAAGCTAAA ATTCTAAGAT CTGGTTGTGC TAGAGTTAGA GAATTTTGTA AA - #TCATTCTG     2580     - TGATCTTTCT AATAAGAGAT TCTATGCTAT GGCTAGAGAT CTCGTAAGTT TA - #CTATTTAT     2640     - GTGTAACTAT GTTAATATTG AAATTAACGA AGCAGTATGC GAATATCCTG GA - #TATGTCAT     2700     - ATTATTCGCA AGAGCTATTA AAGTAATTAA TGATTTATTA TTAATTAACG GA - #GTAGATAA     2760     - TCTAGCAGGA TATTCAATTT CCTTACCTAT ACATTATGGA TCTACTGAAA AG - #ACTCTACC     2820     - AAATGAAAAG TATGGTGGTG TTGATAAGAA ATTTAAATAT CTATTCTTAA AG - #AATAAACT     2880     - AAAAGATTTA ATGCGTGATG CTGATTTTGT CCAACCTCCA TTATATATTT CT - #ACTTACTT     2940     - TAGAACTTTA TTGGATGCTC CACCAACTGA TAATTATGAA AAATATTTGG TT - #GATTCGTC     3000     - CGTACAATCA CAAGATGTTC TACAGGGTCT GTTGAATACA TGTAATACTA TT - #GATACTAA     3060     - TGCTAGAGTT GCATCAAGTG TTATTGGATA TGTTTATGAA CCATGCGGAA CA - #TCAGAACA     3120     - TAAAATTGGT TCAGAAGCAT TGTGTAAAAT GGCTAAAGAA GCATCTAGAT TA - #GGAAATCT     3180     - AGGTTTAGTA AATCGTATTA ATGAAAGTAA TTACAACAAA TGTAATAAAT AT - #GGTTATAG     3240     - AGGAGTATAC GAAAATAACA AACTAAAAAC AAAATATTAT AGAGAAATAT TT - #GATTGTAA     3300     - TCCTAATAAT AATAATGAAT TAATATCCAG ATATGGATAT AGAATAATGG AT - #TTACATAA     3360     - AATTGGAGAA ATTTTTGCAA ATTACGATGA AAGTGAATCT CCTTGCGAAC GA - #AGATGTCA     3420     - TTACTTGGAA GATAGAGGTC TTTTATATGG TCCTGAATAT GTACATCACA GA - #TATCAAGA     3480     - ATCATGTACG CCTAATACGT TTGGAAATAA CACAAATTGT GTAACAAGAA AT - #GGTGAACA     3540     - ACACGTATAC GAAAATAGTT GTGGAGATAA TGCAACATGT GGAAGAAGAA CA - #GGATATGG     3600     - AAGAAGAAGT AGGGATGAAT GGAATGACTA TAGAAAACCC CACGTTTATG AC - #AATTGTGC     3660     - CGATGCAAAT AGTTCATCTT CAGATAGCTG TTCAGACAGT AGTAGTAGTA GT - #GAATCTGA     3720     - ATCTGATTCA GATGGATGTT GCGACACAGA TGCTAGTTTA GATTCTGATA TT - #GAAAATTG     3780     - TTATCAAAAT CCATCAAAAT GTGATGCAGG ATGCTAAATG AAATTTAATA TT - #ATATAATA     3840     - TTAACTTACA AGTTATAAAA ATCATTAAAA TGATTTTTTA AAATGATATT AT - #CGATAGTT     3900     #        3907     - (2) INFORMATION FOR SEQ ID NO:34:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 25 amino               (B) TYPE: amino acid               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: protein     -     (ix) FEATURE:               (A) NAME/KEY: Region               (B) LOCATION: 3     #/note= "This amino acid may be:                    either As - #n or Arg."     -     (ix) FEATURE:               (A) NAME/KEY: Region               (B) LOCATION: 12     #/note= "This amino acid may be:                    either As - #n or Arg."     #ID NO:34:(xi) SEQUENCE DESCRIPTION: SEQ     -      Met Ala Xaa Asp Leu Val Ser Leu - # Leu Phe Met Xaa Xaa Tyr Val     Asn     #   15     -      Ile Glu Ile Asn Glu Ala Val Xaa - # Glu     #                 25     - (2) INFORMATION FOR SEQ ID NO:35:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 17 amino               (B) TYPE: amino acid               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: peptide     -     (ix) FEATURE:               (A) NAME/KEY: Region               (B) LOCATION: 15     #/note= "This amino acid may be:                    either Th - #r or Ile."     #ID NO:35:(xi) SEQUENCE DESCRIPTION: SEQ     -      Met Lys Ile Thr Ser Ser Thr Glu - # Val Asp Pro Glu Tyr Val Xaa     Ser     #   15     -      Asn     - (2) INFORMATION FOR SEQ ID NO:36:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 8 amino               (B) TYPE: amino acid               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: protein     #ID NO:36:(xi) SEQUENCE DESCRIPTION: SEQ     -      Asn Ala Leu Phe Phe Asn Val Phe     #  5 1     - (2) INFORMATION FOR SEQ ID NO:37:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 7 amino               (B) TYPE: amino acid               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: peptide     #ID NO:37:(xi) SEQUENCE DESCRIPTION: SEQ     -      Glu Val Asp Pro Glu Tyr Val     #  5 1     - (2) INFORMATION FOR SEQ ID NO:38:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 66 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:38:(xi) SEQUENCE DESCRIPTION: SEQ     - ATGGCTAGAG ATCTCGTAAG TTTACTATTT ATGTGTAACT ATGTTAATAT TG - #AAATTAAC       60     #           66     - (2) INFORMATION FOR SEQ ID NO:39:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 51 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:39:(xi) SEQUENCE DESCRIPTION: SEQ     #             51CTAGTAC AGAAGTAGAC CCCGAGTATG TAACTAGTAA T     - (2) INFORMATION FOR SEQ ID NO:40:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 24 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: double               (D) TOPOLOGY: unknown     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:40:(xi) SEQUENCE DESCRIPTION: SEQ     #                24ATGT ATTT     - (2) INFORMATION FOR SEQ ID NO:41:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 1689 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:41:(xi) SEQUENCE DESCRIPTION: SEQ     - TCCTATTATT TGTTTTAATT CTGATTCATT CCACGGCATA TCTAATATAA TT - #ATATCATT       60     - AATACATTTG AATGATATGC CTTCAGATCC AGCGTAAGAA AATATGCAAA CT - #TTTACTTT      120     - TTTACCATTA TTATTTTCAT AATTATTATA TTCGTTTAAT TCATTATCTC TA - #GTTTTTAA      180     - AGTTTTGCTA GAATATTCAA TATAAGAAAT ATTAAAACAA TTAAAATAAC AT - #TTTAAACT      240     - TGATATTCCT TCAAAATTAA CTAAAGGTTC AAATATTAAT ACTTTTCCTC TC - #GAATTTAA      300     - AATTATTTTA CAAGTTTCTA TATATTTACA CGAATATTGA TATAATATAT TA - #TAATTATT      360     - TATATCAGTG ATTGGTAAAT TAGTTTTTAT TTTTATATTA TCATTTTTAA AA - #CTTTCAAT      420     - AAAAGATTCA GAGAAATTAA TATTTTTTGT AAACTCGGAA AATTCAGCAA GT - #TTTCTTTT      480     - AATCATATCA TTATATTCTA TATTATCTAA ATCTCCTTTT ATTTTAAGAT CA - #TAAAAAGC      540     - AAATGAAGAT ATTAATCTTC TCATAGTTTT TAAACCACCT AATTCAGTTT TA - #TAATCATA      600     - TTTTTCTGCC ATATTATATA ATTTAGATTG CTCATCTGAC ATAATTATAT TA - #TGATAAAA      660     - TATATTTTTT TTTGCATATC CATCTATATA ATTTGTTTCT GTTAAACTAT CT - #GCTTCTAT      720     - TAATCTTTTA TAAGAACATA TAGCTAATAA TGTTTCTCTT AATTCCTTAA AA - #TTAATTAA      780     - CTTTCCATTA TTTATATATT CTTCTTTTAT ATTCATAACA TTTGGTCTAA GT - #AAACCTAT      840     - TAAATTATTA AATTCAGAAA TATTATTAGT TACTGGAGTA GCGGACATAC AT - #AATATTTT      900     - ATTATTTTCG AAATTTGCTA ATTTTATTAA TTTTTTATAA ATAGGAGTAA AA - #TTTCTTTC      960     - GTTATTATCT TTTTTAACAG TTCTTGATAT TAATTTATGA ACTTCGTCTA TT - #ATTATTAG     1020     - TAATCTACTT TTTTTATTAA GAGAACTTTC TATAGATCTA TATATATTAT TA - #AATTTATC     1080     - TAAACTAGAT GACGAATCAT AATATATAAA TTTTATATTA CTGGTATCTG AT - #ATATATGA     1140     - TCTTATAGTA TTTAACCAAG GATCTATGTA TAATGATTTT TTAATAAATA TT - #AAAATTAT     1200     - CCATCTTGGA AATAATTCTT TTATATATTT TATAATATAC ACAGCAGTTA AT - #GTTTTTCC     1260     - CATACCAGTA TCCCAAAATA ATAACATACT ATTCAAATTT TTTAATCCTA TG - #AATATTCT     1320     - ACTTACAAAA TATTGATAAT CTTGTAATGT AATTTCAGTA TTTGTAATAT TA - #TTCATAAT     1380     - TTTATTAGGC AAATGTTGTG TTTTATCAAG TGCATAATTT ATATGTTTAC CA - #ACAATAGA     1440     - ATCTAATGCA AACATTTAGT TATATAAAAA ATAATATTTA TATTAACTTA AG - #ATGTTTCA     1500     - TTAATTTTAT GTCTGTGATG TGGAGTTAAA ACCCAAGATA TTGATATATC TA - #TATCATTA     1560     - ATTCTTCTTT TGAATCTATG TCTATCAATC GCAAATTTAT CCCAGTATAA TT - #TTCGAGTT     1620     - TGTTTTGCAG CATATAACCA AACATACATA ATGTGGAGTT TTGGTGGTTC GG - #ATGAAAAG     1680     #       1689     - (2) INFORMATION FOR SEQ ID NO:42:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 485 amino               (B) TYPE: amino acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     #ID NO:42:(xi) SEQUENCE DESCRIPTION: SEQ     -      Met Phe Ala Leu Asp Ser Ile Val - # Gly Lys His Ile Asn Tyr Ala     Leu     #   15     -      Asp Lys Thr Gln His Leu Pro Asn - # Lys Ile Met Asn Asn Ile Thr     Asn     #                 30     -      Thr Glu Ile Thr Leu Gln Asp Tyr - # Gln Tyr Phe Val Ser Arg Ile     Phe     #             45     -      Ile Gly Leu Lys Asn Leu Asn Ser - # Met Leu Leu Phe Trp Asp Thr     Gly     #         60     -      Met Gly Lys Thr Leu Thr Ala Val - # Tyr Ile Ile Lys Tyr Ile Lys     Glu     #     80     -      Leu Phe Pro Arg Trp Ile Ile Leu - # Ile Phe Ile Lys Lys Ser Leu     Tyr     #   95     -      Ile Asp Pro Trp Leu Asn Thr Ile - # Arg Ser Tyr Ile Ser Asp Thr     Ser     #                110     -      Asn Ile Lys Phe Ile Tyr Tyr Asp - # Ser Ser Ser Ser Leu Asp Lys     Phe     #            125     -      Asn Asn Ile Tyr Arg Ser Ile Glu - # Ser Ser Leu Asn Lys Lys Ser     Arg     #        140     -      Leu Leu Ile Ile Ile Asp Glu Val - # His Lys Leu Ile Ser Arg Thr     Val     #    160     -      Lys Lys Asp Asn Asn Glu Arg Asn - # Phe Thr Pro Ile Tyr Lys Lys     Leu     #   175     -      Ile Lys Leu Ala Asn Phe Glu Asn - # Asn Lys Ile Leu Cys Met Ser     Ala     #                190     -      Thr Pro Val Thr Asn Asn Ile Ser - # Glu Phe Asn Asn Leu Ile Gly     Leu     #            205     -      Leu Arg Pro Asn Val Met Asn Ile - # Lys Glu Glu Tyr Ile Asn Asn     Gly     #        220     -      Lys Leu Ile Asn Phe Lys Glu Leu - # Arg Glu Thr Leu Leu Ala Ile     Cys     #    240     -      Ser Tyr Lys Arg Leu Ile Glu Ala - # Asp Ser Leu Thr Glu Thr Asn     Tyr     #   255     -      Ile Asp Gly Tyr Ala Lys Lys Asn - # Ile Phe Tyr His Asn Ile Ile     Met     #                270     -      Ser Asp Glu Gln Ser Lys Leu Tyr - # Asn Met Ala Glu Lys Tyr Asp     Tyr     #            285     -      Lys Thr Glu Leu Gly Gly Leu Lys - # Thr Met Arg Arg Leu Ile Ser     Ser     #        300     -      Phe Ala Phe Tyr Asp Leu Lys Ile - # Lys Gly Asp Leu Asp Asn Ile     Glu     #    320     -      Tyr Asn Asp Met Ile Lys Arg Lys - # Leu Ala Glu Phe Ser Glu Phe     Thr     #   335     -      Lys Asn Ile Asn Phe Ser Glu Ser - # Phe Ile Glu Ser Phe Lys Asn     Asp     #                350     -      Asn Ile Lys Ile Lys Thr Asn Leu - # Pro Ile Thr Asp Ile Asn Asn     Tyr     #            365     -      Asn Ile Leu Tyr Gln Tyr Ser Cys - # Lys Tyr Ile Glu Thr Cys Lys     Ile     #        380     -      Ile Leu Asn Ser Arg Gly Lys Val - # Leu Ile Phe Glu Pro Leu Val     Asn     #    400     -      Phe Glu Gly Ile Ser Ser Leu Lys - # Cys Tyr Phe Asn Cys Phe Asn     Ile     #   415     -      Ser Tyr Ile Glu Tyr Ser Ser Lys - # Thr Leu Lys Thr Arg Asp Asn     Glu     #                430     -      Leu Asn Glu Tyr Asn Asn Tyr Glu - # Asn Asn Asn Gly Lys Lys Val     Lys     #            445     -      Val Cys Ile Phe Ser Tyr Ala Gly - # Ser Glu Gly Ile Ser Phe Lys     Cys     #        460     -      Ile Asn Asp Ile Ile Ile Leu Asp - # Met Pro Trp Asn Glu Ser Glu     Leu     #    480     -      Lys Gln Ile Ile Gly     #   485     - (2) INFORMATION FOR SEQ ID NO:43:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 235 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:43:(xi) SEQUENCE DESCRIPTION: SEQ     - AAAAGTTTGA TAAATCACAT TTAAAAATTG TTATGCATAA TAGAGGAAGT GG - #TAATGTAT       60     - TCCCTATTAG ATCACTATAT TTGGAATTAT TGAACGTCAA AGGTTATCCT GT - #AAAAGCAT      120     - CCGATACGTC TAGGTTAGAT GTTGGTGTTT ATAAACTAAA TAAAATATAT AT - #TGATAATG      180     - ATGAAAATAA AATAATTTTA GAAGAAATTG AAACCGATTA TAGATGTGGA AG - #AGA      235     - (2) INFORMATION FOR SEQ ID NO:44:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 77 amino               (B) TYPE: amino acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     #ID NO:44:(xi) SEQUENCE DESCRIPTION: SEQ     -      Lys Phe Asp Lys Ser His Leu Lys - # Ile Val Met His Asn Arg Gly     Ser     #   15     -      Gly Asn Val Phe Pro Ile Arg Ser - # Leu Tyr Leu Glu Leu Leu Asn     Val     #                 30     -      Lys Gly Tyr Pro Val Lys Ala Ser - # Asp Thr Ser Arg Leu Asp Val     Gly     #             45     -      Val Tyr Lys Leu Asn Lys Ile Tyr - # Ile Asp Asn Asp Glu Asn Lys     Ile     #         60     -      Ile Leu Glu Glu Ile Glu Thr Asp - # Tyr Arg Cys Gly Arg     #     75     - (2) INFORMATION FOR SEQ ID NO:45:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 235 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:45:(xi) SEQUENCE DESCRIPTION: SEQ     - AAAAGTTTGA TAAATCACAT TTAAAAATCG TTATGCACAA TAGAGGAAGC GG - #TAATGTAT       60     - TCCCTATTAG ATCACTATAT TTGGAATTAT TGAACGTCAA AGGTTATCCT GT - #TAAAGCAT      120     - CCGATACGTC TAGGTTAGAC GTTGGTGTTT ATAAACTAAA TAAAATATAT AT - #TGATAATG      180     - ATGAAAATAA AATAATTTTA GAAGAAATCG AAACCGATTA TAGATGTGGA AG - #AGA      235     - (2) INFORMATION FOR SEQ ID NO:46:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 77 amino               (B) TYPE: amino acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: protein     #ID NO:46:(xi) SEQUENCE DESCRIPTION: SEQ     -      Lys Phe Asp Lys Ser His Leu Lys - # Ile Val Met His Asn Arg Gly     Ser     #   15     -      Gly Asn Val Phe Pro Ile Arg Ser - # Leu Tyr Leu Glu Leu Leu Asn     Val     #                 30     -      Lys Gly Tyr Pro Val Lys Ala Ser - # Asp Thr Ser Arg Leu Asp Val     Gly     #             45     -      Val Tyr Lys Leu Asn Lys Ile Tyr - # Ile Asp Asn Asp Glu Asn Lys     Ile     #         60     -      Ile Leu Glu Glu Ile Glu Thr Asp - # Tyr Arg Cys Gly Arg     #     75     - (2) INFORMATION FOR SEQ ID NO:47:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 10 amino               (B) TYPE: amino acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: peptide     #ID NO:47:(xi) SEQUENCE DESCRIPTION: SEQ     -      Lys Phe Lys Tyr Leu Phe Leu Lys - # Asn Lys     #   10     - (2) INFORMATION FOR SEQ ID NO:48:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 11 amino               (B) TYPE: amino acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: peptide     #ID NO:48:(xi) SEQUENCE DESCRIPTION: SEQ     -      Lys Ser Val Asn Ile Ala Val Ser - # Phe Leu Asp     #   10     - (2) INFORMATION FOR SEQ ID NO:49:     -      (i) SEQUENCE CHARACTERISTICS:     #acids    (A) LENGTH: 11 amino               (B) TYPE: amino acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: peptide     #ID NO:49:(xi) SEQUENCE DESCRIPTION: SEQ     -      Lys Tyr Leu Val Asp Ser Ser Val - # Gln Ser Gln     #   10     - (2) INFORMATION FOR SEQ ID NO:50:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:50:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               GTGG     - (2) INFORMATION FOR SEQ ID NO:51:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:51:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TTGC     - (2) INFORMATION FOR SEQ ID NO:52:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:52:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               ATGT     - (2) INFORMATION FOR SEQ ID NO:53:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:53:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TGGA     - (2) INFORMATION FOR SEQ ID NO:54:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:54:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               AATG     - (2) INFORMATION FOR SEQ ID NO:55:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:55:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               CTTC     - (2) INFORMATION FOR SEQ ID NO:56:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:56:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               ACCC     - (2) INFORMATION FOR SEQ ID NO:57:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:57:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               AACC     - (2) INFORMATION FOR SEQ ID NO:58:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:58:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TGCG     - (2) INFORMATION FOR SEQ ID NO:59:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:59:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               CATC     - (2) INFORMATION FOR SEQ ID NO:60:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:60:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TTAC     - (2) INFORMATION FOR SEQ ID NO:61:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:61:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               ACTC     - (2) INFORMATION FOR SEQ ID NO:62:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:62:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               AACG     - (2) INFORMATION FOR SEQ ID NO:63:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:63:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               AAAC     - (2) INFORMATION FOR SEQ ID NO:64:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:64:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TCCG     - (2) INFORMATION FOR SEQ ID NO:65:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:65:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               TGGG     - (2) INFORMATION FOR SEQ ID NO:66:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 20 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:66:(xi) SEQUENCE DESCRIPTION: SEQ     # 20               GTGC     - (2) INFORMATION FOR SEQ ID NO:67:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 29 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:67:(xi) SEQUENCE DESCRIPTION: SEQ     #            29    TACA CACAGGAAC     - (2) INFORMATION FOR SEQ ID NO:68:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 29 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:68:(xi) SEQUENCE DESCRIPTION: SEQ     #            29    GAAT TAATAATTG     - (2) INFORMATION FOR SEQ ID NO:69:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:69:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     AAGT TAAATATTTA     - (2) INFORMATION FOR SEQ ID NO:70:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:70:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     AAAC AACAGAATTG     - (2) INFORMATION FOR SEQ ID NO:71:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 31 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:71:(xi) SEQUENCE DESCRIPTION: SEQ     #          31      GGAT TTACTAAATT C     - (2) INFORMATION FOR SEQ ID NO:72:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:72:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     ATAT TCAATTATAT     - (2) INFORMATION FOR SEQ ID NO:73:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:73:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     ATAA CTAATGTGAG     - (2) INFORMATION FOR SEQ ID NO:74:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:74:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     TATT ATTATTAATA     - (2) INFORMATION FOR SEQ ID NO:75:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:75:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     AAAG GTACGTTACT     - (2) INFORMATION FOR SEQ ID NO:76:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:76:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     AGAT ACTACGATTC     - (2) INFORMATION FOR SEQ ID NO:77:     -      (i) SEQUENCE CHARACTERISTICS:     #pairs    (A) LENGTH: 30 base               (B) TYPE: nucleic acid               (C) STRANDEDNESS: single               (D) TOPOLOGY: linear     -     (ii) MOLECULE TYPE: DNA (genomic)     #ID NO:77:(xi) SEQUENCE DESCRIPTION: SEQ     #           30     GATG CAACTCTAGC     __________________________________________________________________________ 

We claim:
 1. A method for producing a selected polypeptide comprising culturing a selected host cell infected with a recombinant virus comprising a polynucleotide sequence encoding an Entomopoxvirus thymidine kinase promoter sequence, an allelic variant, or a fragment thereof, wherein said polynucleotide sequence is operably inked to a selected heterologous gene sequence, said polynucleotide sequence being capable of direction the replication and expression of said gene in a selected host cell.
 2. A method for producing a selected polypeptide comprising culturing a selected host cell infected with a recombinant virus comprising a polynucleotide sequence encoding an Entomopoxvirus spheroidin promoter sequence, an allelic variant, or a fragment thereof, wherein said polynucleotide sequence is operably linked to a selected heterologous gene sequence, said polynucleotide sequence being capable of directing the replication and expression of said gene in a selected host cell.
 3. A method for screening recombinant Entomopoxvirus for insertion of an heterologous gene comprising transforming Entomopoxvirus infected cells with a polynucleotide molecule comprising the heterologous gene sequence inserted into a polynucleotide sequence encoding Entomopox virus spheroidin, wherein the absence of occlusion bodies normally formed by the expression of the spheroidin protein indicates the integration of the heterologous gene.
 4. A method for screening recombinant Entomopoxvirus for insertion of an heterologous gene comprising infecting said cells with an Entomopoxvirus and transfecting the thus infected cells with a polynucleotide molecule comprising the heterologous gene sequence inserted into a polynucleotide sequence encoding Entomopoxvirus thymidine kinase, wherein the absence of thymidine kinase function indicates the insertion of the heterologous gene.
 5. A polynucleotide molecule capable of producing recombinant Entomopoxvirus in insect cells or recombinant vaccinia virus in mammalian cells which comprises contiguous sequences comprising both Entomopoxvirus coding sequences and vaccinia virus coding sequences surrounding an insertion site for an heterologous gene or expression cassette. 